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Parkinson’s disease (PD) is the most common neurodegenerative
movement disorder and second most common neurodegenerative disorder. PD
is characterized by the selective loss of dopaminergic neurons and dopamine
neurotransmitter within the substantia nigra and termini in the striatum.
Progressive loss of dopaminergic neurons occurs over many years in PD, and by
the time movement disorder symptoms manifest, up to 50-70% of dopaminergic
neurons have been lost. Several aspects of PD pathology have been described
in detail, but a better understanding of PD progression is needed to develop
more efficient treatments.
Motor symptoms associated with PD do not manifest until significant
numbers

of

dopaminergic

neurons

are

lost,

suggesting

compensatory

mechanisms play a role in maintaining normal motor function. However, little is
known about these mechanisms and the role they play in delaying PD symptom
onset.
Only palliative treatment is now available for PD. This consists of
principally of dopamine replacement therapy and L-DOPA considered the gold

treatment standard. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
model of PD, chronic administration of dopamine replacement drugs, L-DOPA or
BL-1023 in the absence of further degeneration, resulted in improved motor
function and consistent increases in the number of TH+ neurons in the substantia
nigra. The increase in TH+ neurons was not associated with dopaminergic
neurogenic activity, but rather a phenotypic shift of GAD67+ GABAergic neurons
to express TH. These data represent a novel effect of dopamine replacement
therapy as triggering putative compensatory mechanisms, presumably to restore
dopamine levels in a dopamine depleted environment.
An interleukin-23 (IL-23) knock-out mouse strain proven to have
significantly reduced dopaminergic neuron population was used to test motor
control and behavior. No significant differences were observed between knockout and wild-type in any of the forced or unforced motor tests. These data
suggest either insufficient dopaminergic loss to afford functional alterations or
that compensation to the dopaminergic signaling pathway allowed for normal
functioning.
Taken together, compensatory mechanisms represent a novel pathway for
PD treatment that include symptomatic benefits as well as potential regenerative
strategies. Targeting such pathways may provide more effective therapeutics by
avoiding the secondary toxicities of current pharmaceuticals.
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CHAPTER ONE
INTRODUCTION

Parkinson’s disease overview
Parkinson’s disease (PD) is a chronic progressive disease, the most common
neurodegenerative

movement

disorder

and

second

most

common

neurodegenerative disorder. Currently, there is no cure for PD, and therapies are
purely palliative (Mosley et al., 2012). Pathologically, PD is characterized by the
progressive loss of tyrosine hydroxylase (TH) expressing dopaminergic neurons
in the substantia nigra pars compacta (SNpc) and striatal dopaminergic termini
(Dauer and Przedborski, 2003). The loss of the neurotransmitter dopamine
accounts for characteristic motor dysfunction presented in PD (Dauer and
Przedborski, 2003). Arvid Carlsson played an instrumental role in arguing for
dopamine’s role in controlling motor function and playing a part in PD (Rubin,
2007; Murrin, 2012): first, large amounts of dopamine are present in the corpus
striatum. Second, depletion of dopamine from the striatum results in hypokinesis.
Lastly, L-DOPA administration can counteract reserpine-induced hypokinesis
(Carlsson et al., 1957; Bertler and Rosengren, 1959a, b; Carlsson, 1959; Murrin,
2012). Another, hallmark of PD neuropathology is the presence of Lewy bodies
(LB); neuronal inclusions composed primarily of ubiquitin and misfolded and
modified α-synuclein (Zhang et al., 2005). The slow, insidious nature of disease
progression in PD determines that by the time motor disturbances first appear,
more than 50-70% of dopaminergic neurons in the substantia nigra and 60-80%
of striatal termini have been lost (Dauer and Przedborski, 2003). The selective
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vulnerability of dopaminergic neurons in the substantia nigra is believed to be
due to their sensitivity to combinations of oxidative stress, low levels of
antioxidants, and high iron content (Chinta and Andersen, 2005). While the
initiating factor in PD development is still unknown, several risk factors are
proposed to play a role – age, rural residence, herbicide/pesticide exposure, high
intake of dietary fats, heavy metal exposure, head trauma, and a history of
neuroinflammation (Siderowf and Stern, 2003; Singh et al., 2007; Thomas, 2009;
Mosley et al., 2012; Blesa et al., 2015). Physical symptoms manifest in the form
of bradykinesia, resting tremor, muscular rigidity, and gait disturbances
(Bernheimer et al., 1973; Hornykiewicz and Kish, 1987; Dauer and Przedborski,
2003; Olanow et al., 2009).
In 1982, Dr. William Langston described the “The Case of the Frozen
Addicts” (Langston et al., 1983) - young men and women who after selfadministering what was thought to be heroin, were found conscious, but unable
to move or speak (Langston, 2014). It was later discovered that the patients had
unknowingly administered 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP),
a contaminant of illicit meperidine synthesis (Langston et al., 1983). The ability of
MPTP to cause PD-like motor symptoms is due to its ability to cross the blood
brain barrier (BBB), where it is taken up by resident glial cells of the CNS, and
converted into the active metabolite MPP+ (Schneider, 2008). MPP+ has a
strikingly similar molecular structure to dopamine and can therefore be
selectively transported by the dopamine transporter. Once inside the neuron,
MPP+ is transported by the organic cation transporter-1 (OCT1) across the
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mitochondria membrane and reversibly binds complex I of the electron transport
chain, interfering with ATP synthesis, depleting the neuron of energy, and
resulting in injury and cell death. Since the discovery of MPTP and its ability to
selectively destroy nigrostriatal dopaminergic neurons and induce PD-like
neurodegeneration, it has become one of the most widely used animal models of
PD (Schneider, 2008). While MPTP is able to recapitulate the loss of
dopaminergic neurons and striatal termini and microglial activation seen in PD, it
does not result in the formation of Lewy bodies as seen in PD patients
(Przedborski et al., 2001; Dauer and Przedborski, 2003; Schneider, 2008).
However, the model provides an important system in which to test new
therapeutic strategies for dopaminergic neurodegeneration and replacement
therapies for PD (Schneider, 2008).
Immunity and neurodegeneration
The barrier between the brain and peripheral immune system presents a unique
scenario as to the mechanisms by which pathogenic agents are cleared from the
brain. It is believed that during early PD, misfolded and modified proteins are not
adequately cleared from the neurons and accumulate intracellularly (Thomas,
2009; Blesa et al., 2015). Upon release from the neurons, extraneuronal modified
self-proteins lead to breakage of or deviation from immunological tolerance
resulting in an immune response (Mosley et al., 2012). Although the initiating
event of PD is not known, our laboratory has shown that modification or
aggregation of alpha synuclein (α-syn) breaks immunological tolerance and
triggers the initial immune response. (Benner et al., 2004; Olanow et al., 2009).
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Nitration of the self-protein, α-syn (N-α-syn), is believed to initiate an immune
response following its release from injured or dying neurons and drainage into
the cervical lymph nodes where it is taken up by antigen presenting cells (APCs)
and presented to naïve T cells through major histocompatibility complex II (MHC
II) (Benner et al., 2008; Reynolds et al., 2008; Mosley et al., 2012). The T cells
now specific for N-α-syn circulate throughout the body and cross the BBB at sites
of inflammatory foci where they encounter cognate antigen and induce proinflammatory and neurotoxic effector functions. These perpetuate dopaminergic
cell death either directly or through indirect mechanisms involving microglia and
alternative states of activation (Guadagno et al., 2013).
The roles of the peripheral immune system in patients are supported by
initial studies of peripheral lymphocyte populations from PD patients showing
decreased frequencies and total numbers of CD4+ T lymphocytes compared to
controls (Shalit et al., 1995; Richartz-Salzburger et al., 2007; Bonotis et al., 2008;
Larbi et al., 2009). More detailed studies reporting changes in T cell populations
in PD patients are sparse and do not reach a consensus on the specific CD4+ T
cell populations altered in patients with PD. For instance, in one study the
diminution of CD4+ T cell numbers in PD patients was found chiefly from
decreased numbers of CD4+CD45RA+ naïve T cells and to a lesser extent from
CD4+CD29+ memory subsets (Shalit et al., 1995); whereas, Stevens and
colleagues reported decreased numbers of CD4+CD45RO+ memory T cells
(Bonotis et al., 2008). A recent study by Saunders and colleagues showed slight,
but significant increases in frequencies of CD4+CD45RO+ memory/effector T
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cells with concomitant diminution of CD4+CD45RA+ resting/naïve T cell levels
(Richartz-Salzburger et al., 2007; Saunders et al., 2012). Additionally,
frequencies of peripheral CD4+ T cells with effector-associated phenotypes such
as FAS+ were increased in patients, whereas those expressing α4β7 integrins
and CD31 (PECAM1) were diminished. Notably, these changes in CD4+ T cell
phenotypes were correlated with severity of motor function as scored by Unified
Parkinson’s Disease Rating Scale, part III (UPDRS III). Differences in these
immunological profiles among the few reports may range from the heterogeneity
of disease to individual laboratory methodologies, but clearly will require further
investigation to attain consensus profiles.
Post-mortem studies of PD patient brain tissues showed both CD4+ T
cells and CD8+ T cells in close proximity to dopaminergic neurons within the
substantia nigra at levels exceeding 10-fold those found in control brains
(Speciale et al., 2007; Brochard et al., 2009). Moreover, these increased levels of
T cells were specific to leisoned brain areas. Microarray analysis of peripheral
blood leukocytes and substantia nigra brain tissue showed many genes
expressed were in common with those expressed by TH17-mediated immune
reactions and suggested that idiopathic Parkinsonism is a TH17 dominant
autoimmune disease (Saresella et al., 2011). However, whether T cell infiltration
is primary or secondary to PD progression is still unclear.
Our laboratories have substantial experience with the MPTP model,
indicating that neuroinflammation is enhanced by the adoptive transfer of effector
T cells, particularly those specific for N-α-syn, (Benner et al., 2004; Reynolds et
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al., 2007; Benner et al., 2008; Reynolds et al., 2008; Reynolds et al., 2009;
Reynolds et al., 2010). Adoptive transfer studies demonstrated that following
MPTP-intoxication, T cells exacerbate both the level of neurodegeneration and
neuroinflammation as well as prolong cell death and microglial activation with the
lesion (Benner et al., 2004; Benner et al., 2008; Reynolds et al., 2008; Reynolds
et al., 2009; Mosley et al., 2012; Kosloski et al., 2013). Recent evidence from
clinical studies indicated that T cells with an activated or memory/effector
phenotype are present in greater frequencies in PD patients compared to ageand environment-matched caregiver controls (Saunders et al., 2012). Increased
proportions of those T cell subsets were directly correlated with diminished motor
function and associated with diminished Treg function in PD patients (Saunders
et al., 2012). Taken together, the detection of CD4+ and CD8+ T cells within the
substantia nigra of mice treated with MPTP and in PD patients, the proximity of
infiltrating T cells to MHC expressing microglia/macrophages, and CD4/CD8
ratios of infiltrating T cells that are reversed from those expected in peripheral
circulation (Kurkowska-Jastrzebska et al., 1999; Ozaki et al., 2000; Benner et al.,
2004; Benner et al., 2008; Brochard et al., 2009) provide strong evidence for the
directed extravasation and migration of activated T cells to sites of inflammation
and for the association of increased disease or lesion progression with increased
T cell infiltration (Brochard et al., 2009). However, whether extravasation and
migration of T cells is necessary and the mechanism(s) associated with T cell
migration in Parkinsonism have not been adequately evaluated.
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A newly described T cell lineage, TH17, has shed new light on PD
pathology. TH17 cells are characterized by their proinflammatory functions and
the secretion of interleukin-17 (IL-17) and are thought important in defense of
extracellular pathogens and parasites. Differentiation of TH17 cells from a naïve
T cell is dependent on multiple cytokines including IL-6, TGF-β, and IL-23
(Benwell and Lee, 2010). IL-23 plays a dual role in both driving the TH17 cell
phenotype and also stabilizing TH17 cells whilst inhibiting the formation of TH1
cells. TH17 cells were first described in the experimental autoimmune
encephalomyelitis (EAE) model of multiple sclerosis (MS) (Rostami and Ciric,
2013; Robinson et al., 2014; Sie et al., 2014). They have also been shown to
play an important role in disease progression in rat models of Alzheimer’s
disease (AD), and human amyotrophic lateral sclerosis (ALS) (Chen and
Shannon, 2013; Rostami and Ciric, 2013; Luchtman et al., 2014; Robinson et al.,
2014; Sie et al., 2014).
When specifically evaluating the role the adaptive immune system plays in
PD, our laboratory and others have shown T cells specific for N-α-syn of the
TH17 cell phenotype have an increased ability to exacerbate neurodegeneration
compared to TH1 cells (Benner et al., 2004; Benner et al., 2008; Brochard et al.,
2009; Reynolds et al., 2010; Mosley et al., 2012) even though both cell types are
classically defined as pro-inflammatory T cells. Unlike TH1 cells, TH17 cells rely
on IL-23 for survival and maintenance of their phenotype (Damsker et al., 2010).
In the absence of IL-23, TH17 cells are not long lived and are unable to carry out
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their effector function (Langrish et al., 2005; Chen et al., 2006; Gaffen et al.,
2014).
The discovery of TH17 cells, their detrimental effects in neurodegenerative
diseases and their respective models, has led to the development of multiple
therapies targeting IL-23 expressing/responsive T cells that show significant
efficacy (Chen et al., 2006; Gaffen et al., 2014). These include phase I and II
clinical trials in immune-mediated inflammatory diseases (Gaffen et al., 2014)
such as psoriasis, rheumatoid arthritis, Crohn’s disease, and ankylosing
spondylitis (Gaffen et al., 2014). In the murine model of MS, mice that are unable
to develop antigen specific TH17 cells are resistant to disease development
(Sutton et al., 2006). Additionally, experiments using mice that are deficient in
expression of IL-17 or p19 (an IL-23 component), or IL-23 receptor demonstrated
a requirement for these cytokines and receptors in various inflammatory TH17mediated diseases, such as EAE, psoriasis, inflammatory bowel disease, and
collagen antibody-induced arthritis (Murphy et al., 2003; Langrish et al., 2005;
Chan et al., 2006; Chen et al., 2006; Sherlock et al., 2012).Taken together, these
results suggest that TH17 targeted therapy has the potential to improve therapy
and quality of life for patients with inflammatory diseases. They also provide the
basis for targeting TH17 cells in PD and animal models of PD.
Dopaminergic neurons and tyrosine hydroxylase in the developing
midbrain
Dopaminergic neurons within the ventral midbrain make up almost 75% of all
dopaminergic neurons in the CNS (German et al., 1983; Pakkenberg et al., 1991;
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Blum, 1998; Wallen and Perlmann, 2003). Dopaminergic neurons in the ventral
midbrain ultimately give rise to three clusters of neurons, termed A8, A9, and
A10, that will develop into anatomically and functionally distinct populations. A8
and A10 populations will ultimately develop into the retrorubral field and ventral
tegmental area, respectively (Hegarty et al., 2013). The A9 group of neurons,
which give rise to the those in the substantia nigra, are particularly vulnerable to
cell death compared to the other two groups and loss of A9 dopaminergic
neurons is a driving force behind motor deficiencies in PD (Hornykiewicz and
Kish, 1987; Hegarty et al., 2013).
Innervation of dopaminergic neurons into the striatum is critical during the
establishment of the nigrostriatal pathway due to its role in motor function and
control (Bourdy et al., 2014; Tremblay et al., 2015). Axons from midbrain
dopaminergic neurons, which begin to appear at embryonic day 11 in mice, are
guided by extrinsic cues in the dorsal midbrain and repulsive cues in the caudal
brain stem (Gates et al., 2004). Dopaminergic axons from the substantia nigra
run via the medial forebrain bundle where they terminate in the striatum, guided
by

additional

chemoattractant factors

released

from

the

striatum

and

chemorepulsion factors released from the cortex (Specht et al., 1981b, a; Gates
et al., 2004; Zhao et al., 2004). Loss of dopaminergic neurons and their axons
during PD progression leads to significant reductions in the levels of striatal
dopamine, resulting in the hallmark symptoms of PD – resting tremor, muscle
rigidity, gait abnormalities, and slowness of movement (Antony et al., 2013).
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Therefore, re-establishment of dopaminergic axons into the striatum would
provide a novel approach in the treatment of PD.
Tyrosine hydroxylase is used to identify dopaminergic neurons (Chinta
and Andersen, 2005). TH, the rate-limiting enzyme in catecholamine synthesis, is
responsible for the conversion of L-tyrosine into L-DOPA, the precursor to
dopamine (Haavik and Toska, 1998). The discovery of TH, and the description in
its role in synthesis and metabolic fate of catecholamines, is due to the work of
Julius Axelrod (Axelrod, 1971{Rubin, 2007 #418)} and Ulf von Euler (Von Euler,
1946b, a; Rubin, 2007) which ultimately led to the 1970 Nobel Prize in
Physiology or Medicine with Bernard Katz (Shafrir, 1994{Rubin, 2007 #418)}. The
physical symptoms associated with PD are largely a consequence of the death of
TH expressing dopaminergic neurons and the ensuing decline in dopamine
production. Early studies demonstrating the efficacious outcome of L-DOPA
administration in combating akinesias in PD (Birkmayer and Hornykiewicz, 1961,
1962) proved restoration of dopamine levels in PD patients could alleviate
symptoms of disease and initiated today’s gold standard of PD treatment (Murrin,
2012). The study of dopaminergic neurons was aided and advanced upon
generation of a transgenic mouse line that expresses green fluorescent protein
(GFP) under control of the rat TH promoter. Use of the TH-GFP mouse, has led
to extensive characterization of the expression pattern of TH within the
developing midbrain of mice. Such studies have shown that expression of TH
begins in the early embryonic stages of development with sharp decreases in
expression in the later stages of embryonic development. Researchers have
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hypothesized that the decrease in TH expression coincides with the timeframe of
lateral and rostral migration of dopaminergic neurons. The expression of TH is
then increased in the very late stages of embryonic development and continues
to increase into the period of postnatal development until approximately postnatal
day 14 (p14) when the levels are similar to those seen in the adult mouse
(Matsushita et al., 2002).
In the TH-GFP mouse model, in addition to the expression of TH as
indicated by expression of GFP, the intensity of GFP expression varies during
development in the midbrain. As development progresses the number of neurons
that express both TH and GFP increase, as does the intensity of GFP by TH
immunoreactive neurons. This leads to the possibility that the expression pattern
of GFP could be an indicator of not only a dopaminergic neuronal phenotype, but
also the developmental stage of the neuron relative to the intensity of the GFP
signal. Furthermore, the intensity of GFP expression could indicate how active
and functional the neuron may be. In other words, a neuron expressing high GFP
intensity may indicate a more active neuron compared to lowly expressing GFP+
neurons,, capable of producing more dopamine than a neuron with low GFP

expression in the same region.
Several theories have been proposed to explain the sharp rise in GFP
expression between embryonic days 12 and 14, including an overlap in
transcription factor activation. Alternatively, others have postulated that an
increase in the stability of TH mRNA helps to regulate the level of TH expression
(Tank et al., 2008). Still others have stated that during development, a silencer
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gene is switched on and off and directs the increase and decrease in TH
expression. It is thought that the level of dopamine metabolism may play a role in
the expression of TH, and that as dopamine metabolism increases, the gene
silencer involved in TH expression is itself silenced, leading to increased TH
expression. This increase in dopamine metabolism occurs as dopaminergic
neurons are closer to a more mature state and more synapses are made as a
result (Schimmel et al., 1999; Kim et al., 2006; Calcagno et al., 2013). A better
understanding of the regulation and expression pattern of TH during
development will help develop therapeutics that target increased TH expression
or activity by surviving neurons.
GABAergic Neurons
GABAergic neurons are an inhibitory class of neurons that utilize gammaaminobutyric acid (GABA) as their primary neurotransmitter. GABAergic neurons
also referred to as medium spiny neurons and, as their name suggests, are
medium sized compared to other neuron populations and have extensive
dendritic projections (Nair-Roberts et al., 2008; Tepper, 2010; Brown et al.,
2012). Expression of glutamic-acid decarboxylase (GAD) is the most commonly
used marker for GABAergic neurons. In mammals, GAD exists in two isoforms
with molecular weights of 65 kDa (GAD65) or 67 kDa (GAD67), with neurons of
the CNS expressing GAD67 most commonly (Soghomonian and Chesselet,
1992; Pinal et al., 1997).
As a result of the developmental patterning in the embryonic midbrain, the
midbrain is divided into dorsoventral subdivisions termed m1 – m7 which are
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characterized by specific homeodomain transcription codes and the specific
neuronal subtypes to which these regions give rise (Nakatani et al., 2007; Kala et
al., 2009). GAD67 expressing GABAergic neurons originate from the m1, m2,
m3, and m5 regions. GABAergic neurons of the midbrain show unique
characteristics compared to GABAergic neurons in other brain regions. First,
GABAergic neurons originate from multiple regions (m1, m2, m3, and m5) and
show little tangential migration. This is in stark contrast to GABAergic neurons of
the forebrain, for example, which have a propensity to migrate from their region
of origin to their target location (Anderson et al., 1997; Tamamaki et al., 1997).
Additionally, midbrain GABAergic neurons tend to function as projection neurons,
whereas GABAergic neurons of the forebrain are local interneurons, controlling
the action of other neurons in the immediate vicinity (Lahti et al., 2013).
Putative therapies for the treatment of PD have focused, in large part, on
restoring the levels of dopamine within the midbrain (Haavik and Toska, 1998;
Siderowf and Stern, 2003; Hutter-Saunders et al., 2011). Studies showing
reduced levels of GABA and GABAA receptor density in PD patients suggest that
GABA deficiency may be associated with dyskinesia, and therefore may a
secondary deficit in PD patients. Within the basal ganglia of PD patients,
GABAergic neuronal dysfunction has been described and this reduction in
signaling may contribute to the altered motor function associated with PD. Using
this knowledge, studies have shown that GABA therapy reduce motor asymmetry
in rats, and that GABA receptor agonists suppress limb tremor in PD patients
(Bartholini et al., 1987; Levy et al., 2001). Taken together, this provides strong
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evidence for GABA therapy as a promising target to relieve motor symptoms in
PD patients.
Dopaminergic-GABAergic interactions
Within the substantia nigra of mice, GABAergic neurons intermingle with
dopaminergic neurons, making these two neuronal populations highly interactive
and connected. Proper migration and connectivity into the substantia nigra
depends on intact dopaminergic and GABAergic systems. Mice birth-dating
studies showed at embryonic day 13, the ventral mesencephalon containing the
anlages for the substantia nigra, ventral tegmental area, and retrorubral field, is
completely devoid of GABAergic neurons, but rich in dopaminergic neurons.
Shortly after embryonic day 17, GABAergic neurons enter to reside along with
the dopaminergic neurons (Vasudevan et al., 2012). Furthermore, in the absence
of complete dopaminergic architecture, GABAergic neurons fail to migrate and
form the correct neuronal networks within the ventral mesencephalon
(Vasudevan et al., 2012). These essential interactions within the ventral
mesencephelon

will

be

useful

in

furthering

our

understanding

of

neurodegenerative diseases and may provide novel insight into treatments for
brain disorders.
GABAergic neurons are widely co-distributed with other types of neurons
in the midbrain, but are enriched in specific regions of the mature midbrain.
Within the substantia nigra, populations of GABAergic neurons are intimately
associated with dopaminergic neurons (Lahti et al., 2013). Within the ventral
tegmental area (VTA), 20-35% of neurons are of the GABAergic lineage and are
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thought to regulate the activity of dopaminergic neurons (Fields et al., 2007; NairRoberts et al., 2008; Omelchenko and Sesack, 2009; Brown et al., 2012). The
GABAergic neurons of the substantia nigra project to the thalamus, superior
colliculus, and basal ganglia where they play a part in regulating voluntary
movements (Zhou and Lee, 2011). Because of the unique and intimate
association that GABAergic neurons in the midbrain (substantia nigra and VTA)
share with dopaminergic neurons in this region, they are frequently referred to as
D-GABAergic neurons (Lahti et al., 2013). Fate mapping experiments in mice
showed the majority of D-GABAergic neurons originate outside of the midbrain,
specifically in rhombomere 1, at approximately embryonic day 12.5 (Achim et al.,
2012) and migrate to the midbrain mid-gestation (Lahti et al., 2013). The exact
migratory pattern of midbrain GABAergic neurons and timing of their appearance
has yet to be described.
In addition to identifying the origin of D-GABAergic neurons, experiments
showed that within the substantia nigra are two developmentally different
subgroups of D-GABAergic neurons: anterior and posterior rhombomere 1derived neurons, aD-GABAergic and pD-GABAergic, respectively (Lahti et al.,
2013); however their phenotypic expression as to neuronal subsets have not
been defined. This distinction between populations of GABAergic neurons in
adjacent regions may prove to be invaluable in future studies that attempt to
target a specific region of GABAergic neurons for therapeutic approaches.
Furthermore, additional studies will help to build the knowledge as to how
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GABAergic neurons control behaviors and the behaviors in which they play a
particularly important role.
Dopaminergic

neurons

in

the

nigrostriatal

pathway

interact

with

GABAergic neurons both at their cell body and termini regions, and loss of
dopaminergic neurons in PD leads to dysregulation of GABAergic neurons,
resulting in symptoms associated with PD (Chesselet and Delfs, 1996;
Chesselet, 2002). Additional evidence on the effects of dopamine on GABAergic
neurons comes from studies of leisoned rodents. Lesions to the nigrostriatal
dopaminergic pathway leads to an increase in GAD immunoreactivity in the
striatum, elevated levels of GAD67 mRNA, and increased GAD activity (Segovia
et al., 1990; Soghomonian and Chesselet, 1992; Soghomonian et al., 1992).
Furthermore, transplants of dopamine producing cells in the striatum reverse the
increase in GAD activity induced by dopaminergic loss (Segovia et al., 1989).
The presence of D1 receptors on GABAergic afferent from the striatum points to
a facilitory effect of dopamine on GABA release in the substantia nigra through a
D1-mediated action (Floran et al., 1990; Cameron and Williams, 1993). Taken
together, these data suggest dopaminergic neurons exert complex modulatory
effects along the nigrostriatal pathway and changes on GABAergic transmission
due to effects of dopaminergic lesion play a critical role in PD symptoms (Sesak,
2002).
Within the striatum, dopamine concentrations appear to regulate the
numerical density of TH+ neurons in a dose-dependent manner. Separate
studies examining the number of TH+ neurons within the striatum showed clear
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discrepancies between the effects of dopamine replacement therapy in the form
of L-DOPA, one demonstrating decreases in the number of TH+ striatal neurons
(Lloyd et al., 1975; Huot and Parent, 2007) and the other demonstrated an
overall increase in striatal TH+ neurons (Jollivet et al., 2004; Tande et al., 2006).
Ultimately these contradictory findings may be explained through a dual effect
hypothesis wherein at higher levels, dopamine is proposed to act in conjunction
with growth factors to up-regulate TH expressing neurons within the striatum
(Huot and Parent, 2007). At lower levels, dopamine may control TH expression
by means of a more conventional and straightforward feedback mechanism.
Regardless, it is apparent that local dopamine concentration appears to regulate
the numerical density of TH expressing neurons within the striatum. In the
absence of dopamine, due to PD progression or neurotoxin-induced neuronal
death, the increase in TH+ neurons is likely the result of a phenotypic shift of
striatal interneurons so that they may act as a local source of dopamine, and as
such be part of a compensatory mechanism for dopaminergic neuronal death
(Jollivet et al., 2004; Abe et al., 2010; Busceti et al., 2012).
The most common marker for dopaminergic neurons is TH; however TH
expression also occurs transiently in some neurons derived from the neural crest
(Jaeger and Joh, 1983). While cells that retain TH expression may signify the
establishment of these cells developing into a mature dopaminergic neuron
(Black, 1982), the following findings suggest the mere presence of TH may not
be sufficient to determine if a neuron is dopaminergic. Several reports provide
significant evidence that TH and GAD67 co-localize (TH+GAD67+) naturally in
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the brain of mammals, birds, and reptiles (Kosaka et al., 1987a; Kosaka et al.,
1987b; Kosaka et al., 1988; Wulle and Wagner, 1990). While the exact number
or percentage of neurons in mouse or primate brains that are positive for both TH
and GAD67 expression has not yet been reported, Abe and colleagues
successfully used double immunofluorescent labeling of neurons to show coexpression of these two markers in neurons at postnatal day 8 (Abe et al., 2010).
While the presence of TH+GAD67+ neurons have been demonstrated by
multiple investigations, this neuronal population does not appear to be stable or
long lived. However, the exact timeline for when these neurons begin to decline
in number is an area of debate as later studies reported their existence as late as
postnatal day 18 (p18) (Masuda et al., 2011), in stark contrast to p8 reported by
Abe and colleagues. Regardless of the temporal appearance and disappearance
of the neurons, there is a consensus that these neurons begin to wane during
development and their presence in the brain of adult mice could signify a
previously unreported phenomenon.
Two independent studies reported seeing an increase in TH+ neurons in
the substantia nigra following MPTP assault (Mao et al., 2001; Tande et al.,
2006), contradictory to the previously described actions of MPTP. Initially this
increase was explained by neurogenesis from cells originating in the
subventricular zone or progenitors within the striatal parenchyma (Bjorklund and
Dunnett, 2007). This theory was later disproved by the studies due to a lack of
bromodeoxyuridine (BrdU) incorporation to label newly formed cells (Mao et al.,
2001; Tande et al., 2006; Bjorklund and Dunnett, 2007). This led to the theory
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described and tested herein that pre-existing neurons in the substantia nigra
begin expressing TH, possibly as a compensatory mechanism for MPTP-induced
neuronal loss and reduction in dopamine.
GABAergic neurons immunoreactive for TH represent a unique and novel
type of neuron that has yet to be further characterized and explained. Several
lines of evidence suggest that these neurons exist naturally, but are normally
eliminated by the action of extracellular dopamine between postnatal day 4 and
postnatal day 8 (Masuda et al., 2011). The olfactory bulb is an area where this
unique population of TH+GAD67+ neurons is especially plentiful; at least for a
short period of time. In reptiles, it has been reported that in the glomerular layer
and external plexiform layer/mitral cell layer approximately 91% of TH
immunoreactive cells were also GAD67 immunoreactive (Kosaka et al., 1991),
but this number has not been validated in rodents or primates.
GABAergic neurons immunoreactive for TH were originally described in
the striatum of adult monkeys (Dubach et al., 1987) and have since been
reported in other species including rat (Tepper, 2010). The description of TH+
neurons within the striatum are shockingly variable, ranging from tens of
thousands as described by Dubach et al. to only 1 neuron per section in humans
(Huot and Parent, 2007). TH+ neurons present in the striatum are often reported
to also be immunoreactive for the dopamine transporter (DAT), GABA, or GAD67
suggesting that not all TH+ neurons are purely dopaminergic in nature, but rather
could be of the GABAergic lineage (Betarbet et al., 1997; Cossette et al., 2005b;
Cossette et al., 2005a; Mazloom and Smith, 2006; Tande et al., 2006; Huot and
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Parent, 2007; Tepper et al., 2010). Still, some investigators find these cases
unconvincing and argue that TH+ neurons do not naturally occur in the striatum
of animals, but are only seen after MPTP or 6-OHDA lesion (Tepper, 2010).
While others argue that TH+ GABAergic neurons are not present in control or
leisoned rodent models, but only are detected in the striatum of primates
(Dubach et al., 1987; Betarbet et al., 1997; Tepper, 2010).
GABAergic neurons of the midbrain are a highly heterogeneous group of
neurons in terms of their location, morphology, connections, functions,
developmental origins, and molecular regulatory mechanism. Of specific
importance, are the GABAergic neurons that are closely associated with
dopaminergic neurons in the substantia nigra such as the previously mentioned
D-GABAergic neurons. These neurons are distinct from other midbrain
GABAergic neurons as they are derived from adjacent brain regions and under
control of a distinct set of transcription factors (Lahti et al., 2013). Because of
these unique properties, GABAergic neurons of the substantia nigra may be
especially sensitive to changes in the environmental milieu, and as such, have
the capacity to act as a source of dopamine in a dopamine-depleted
environment.
What remain to be described are the cellular mechanisms by which TH
expression is being triggered in a neuronal population not known to express this
marker under normal physiological conditions. In order to further understand the
expression and function of TH in GABAergic neurons, we would need to
elucidate the regulating mechanism(s). As discussed above TH can be regulated
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by multiple mechanisms, phosphorylation playing the most prominent role. For
example, direct phosphorylation of serine 31 by ERK1 and ERK2 will increase
TH activity. Whereas phosphorylation of serine 19 by either mitogen-activated
protein kinase-activated protein kinase 2 (MAPKAPK2) or calcium-calmodulindependent protein kinase II (CaMKII) will increase the phosphorylation of serine
40 ultimately resulting in an increase in TH activity. The chemical compound
nicotine has been proposed to have an interesting role in the regulation of TH by
phosphorylation for as long as 48 hour in vitro (Haavik and Toska, 1998;
Bobrovskaya et al., 2007). Furthermore, there is an inverse correlation between
smoking and developing PD, suggesting a neuroprotective action of nicotine
(Quik, 2004).
Another avenue by which TH expression may be suddenly triggered in
GABAergic neurons is due to removal of inhibitory signals. Since TH is regulated
via feedback inhibition, following dopaminergic neuronal death the feedback
inhibition may be lifted due to the diminished dopamine levels. More research is
needed to evaluate the phosphorylation pattern of TH in GABAergic neurons as
well as the level of protein kinases, second messengers, TH mRNA and protein
levels.
Compensatory mechanisms in Parkinson’s disease
Pathological hallmarks of PD include a significant loss of the dopaminergic
neurons in the substantia nigra and striatal termini. However, by the time
symptoms appear greater than 50% of dopaminergic neuronal bodies and up to
80% of striatal termini have been lost. This suggests a physiological
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compensation for the slow loss of dopaminergic neurons (Lloyd et al., 1975). It is
unlikely that only one compensatory mechanism ensues during PD progression,
but rather several mechanisms come into play during different stages of PD
development. These compensatory mechanisms include, but are not limited to,
increased sensitivity to dopamine, increased expression of dopamine receptors,
and increased enzymatic activity of TH. While these compensatory mechanisms
may delay symptom onset, they do not stop disease progression, and as
dopaminergic neurons continue to die the compensatory mechanisms ultimately
fail and physical symptoms appear. There is strong evidence for a striatal
dopamine:acetylcholine imbalance in PD (Greenblatt and Shader, 1973) and it
has been proposed that in early PD, a homeostatic dampening of striatal
cholinergic activity maintains a normal striatal dopamine:acetylcholine balance
(Lloyd et al., 1975). This mechanism is proposed to be active during early PD,
but upon continued dopaminergic neuron loss, can no longer maintain the
homoeostatic balance.
Dopaminergic:GABAergic interactions within the nigrostriatal pathway play
a large role in maintaining proper signaling pathways. Normally, GABAergic
neurons inhibit dopaminergic cell bodies in the substantia nigra, controlling the
firing rate of the cells (Lloyd et al., 1975). During the early stages of PD, one of
the proposed compensatory mechanisms exploits the dopaminergic:GABAergic
interaction. Decreasing the activity of GABAergic neurons allows the surviving
dopaminergic neurons to fire at an increased rate and maintains normal motor
control. However, as previously stated, this compensatory mechanism cannot
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keep up with the continuous dopaminergic cell death and will eventually be
insufficient to overcome the severe dopamine deficit with presentation of PD
symptoms and signs.
Additional compensatory mechanisms have been proposed, all with the
endpoint of enhancing the effects of remaining dopamine in the striatum. These
mechanisms include increased synthesis and release of dopamine by surviving
dopaminergic neurons (Zigmond et al., 1990), increasing the number or
sensitivity of dopamine receptors in the striatum, decreasing the turnover of
striatal dopamine, using striatal interneurons as an alternative source for
dopamine production, upregulation of the enzymes responsible for dopamine
synthesis,

and

increased

sprouting

of

neuron

terminals

by

surviving

dopaminergic neurons (Turjanski et al., 1997; Brotchie and Fitzer-Attas, 2009).
While evidence exists that support a role for these mechanisms in the delaying of
PD symptom onset (Brotchie and Fitzer-Attas, 2009), symptoms do ultimately
appear indicating the mechanisms do not afford a definitive solution, but are
merely delaying the inevitable. Gaining insight as to which compensatory
mechanisms come into play at which stages of disease, may help to develop
treatments that target prolonging the effectiveness of these mechanisms and
help to delay intervention by L-DOPA and dopamine replacement therapy.
Summary and conclusions
Neurodevelopment of the midbrain that can adequately support proper brain
function requires very complex and multifaceted processes that interact both at
the temporal and spatial levels. Loss of dopaminergic neurons within the

24

substantia nigra and their striatal termini, as in PD and MPTP models of PD,
results in deficits in motor function and control. While these physical symptoms
can be lessened through the use of dopamine replacement therapy, it affords no
cure for PD, and patients will most likely become refractory after long-term use.
Interestingly, classical physical symptoms associated with PD do not become
apparent until greater than 50% of neurons are lost within the substantia
suggesting either that a threshold concentration of dopamine must be maintained
or intrinsic compensatory mechanisms are in place to maintain proper function
and control within the CNS. However, these mechanisms untimely fail as the
levels of dopamine continue to drop with the progression of PD. With an
extensive understanding of the homeostatic balance in the CNS, new therapies
aimed at stopping, slowing, or even reversing disease progression will lead to
restoration of neuron numbers and dopamine concentrations, ultimately
improving neurologic and motor deficits seen in disorders of the CNS. We further
posit that under pathological conditions such as neuroinflammation and
dopaminergic neuronal loss, that mature neurons in the midbrain shift phenotype
and as such, could serve as a source of neurons capable of producing dopamine
and restoring proper motor control. In toto, increased dopaminergic neuron
numbers, termini densities, and/or endogenous dopamine levels achieved either
by neuron or dopamine replacement therapies or by targeting upregulation of
compensatory mechanisms may provide improved therapeutic outcomes for PD
patients.
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CHAPTER TWO
PHENOTYPIC SHIFT OF GABAERGIC NERUONS IN MPTP INTOXICATED
MICE
ABSTRACT
We previously showed that chronic administration for 35 days of L-3,4dihydroxyphenylalanine (L-DOPA) or BL-1023 [an L-DOPA-gamma-aminobutyric
acid (GABA) conjoined compound] improved locomotor function and increased
numbers of tyrosine hydroxylase (TH) immunoreactive (TH+) neurons in the
substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated
mice compared to those given no drug. We therefore sought to identify whether
the increase in TH+ neurons was a consequence of neurogenesis or rather from
a phenotypic shift of surviving neurons in the substantia nigra. Using the
thymidine analogue bromodeoxyuridine (BrdU), we sought to identify newly
formed neurons after 21 days of L-DOPA or BL-1023 treatment, but were unable
to do so. Dual immunofluorescent analysis of tissues for TH and glutamic acid
decarboxylase-67 (GAD67), a marker for GABAergic neurons revealed that mice
treated with either L-DOPA or BL-1023 showed significant increases in the
numbers of TH+GAD67+ neurons in the substantia nigra compared to controls.
These findings support the notion that numbers of GAD67+ neurons upregulate
TH expression and effectively increase the numbers of TH+ neurons in response
to

MPTP-intoxication,

loss

of

dopaminergic

administration of dopamine-replacement drugs.

neurons,

and/or

chronic
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INTRODUCTION
Parkinson’s disease (PD) is the most common neurodegenerative movement
disorder and the second most common neurodegenerative disorder overall next
to Alzheimer’s disease (AD). PD is characterized by the progressive loss of TH+
dopaminergic neurons in the substantia nigra and their termini in the striatum.
The symptoms and clinical signs of PD originate from the loss of dopamine
characteristically produced by the neurons that are progressively lost. Current
therapeutics are primary palliative and include dopamine replacement and
dopamine receptor agonists, which decrease in efficacy over time and can cause
significant side effects that may become intolerable (Bjorklund and Cenci, 2010).
Thus, therapies that slow or reverse neuronal death and disease progression,
rather than treating symptoms, are greatly needed.
TH is the rate-limiting enzyme in catecholamine synthesis and loss of TH+
neurons in PD results in a significant reduction in striatal dopamine levels. LDOPA is the gold standard for the treatment of PD (Agid, 1998; Agid et al., 1998)
and works to effectively bypass TH in the dopamine synthesis pathway to
restore striatal dopamine levels. While therapies aimed at restoration of
dopamine levels are beneficial to patients, targeting gamma-aminobutyric acid
(GABA) may also prove to be a valuable treatment option. In rats, GABA therapy
was shown to reduce motor asymmetry (Mehta and Chesselet, 2005) and GABA
receptor agonists suppress limb tremor in PD patients (Pahapill et al., 1999).
However, the therapeutic potential of GABA is hindered by its chemical structure.
The hydrophilic functional groups on GABA greatly limit its ability to cross the
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blood brain barrier (BBB), thus covalently linking L-DOPA and GABA in the form
of the drug BL-1023 effectively increases the transport of GABA across the BBB
(Stein, 2012).
Recent studies demonstrated that TH+ neurons in the substantia nigra
and striatum of MPTP-intoxicated animals are increased several weeks postintoxication (Mao et al., 2001; Tande et al., 2006; Bjorklund and Dunnett, 2007;
Hutter-Saunders et al., 2011). Initially the increase in TH was explained by
neurogenesis of dopaminergic neurons. However, this theory lacks critical
support in studies where dopaminergic neurogenesis has been examined after
MPTP treatment (Mao et al., 2001; Tande et al., 2006; Bjorklund and Dunnett,
2007), but has never been tested in the MPTP murine model. In light of the lack
of substantial neurogenic activity, subsequent theories herein suggested the
increase in TH is due to phenotypic shift or up-regulation of TH from surviving
cells within the substantia nigra. However, the cell type responsible for increased
TH production had not been identified. Furthermore, whether purported
neuroprotective pharmaceuticals function via induction of TH has not been
assessed.
Dopaminergic neurons represent a heterogeneous group of cells localized
to specific regions in the brain including the diencephalon, mesencephalon
[including the substantia nigra and ventral tegmental area (VTA)], olfactory bulb,
and retina with approximately 75-90% of the total number of brain dopaminergic
neurons residing in the mesencephalon (Dahlstroem and Fuxe, 1964; Wallen and
Perlmann, 2003; Chinta and Andersen, 2005; Bjorklund and Dunnett, 2007). TH
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expression occurs only transiently in neurons derived from the neural crest
(Jaeger and Joh, 1983) and cells that retain TH expression may signify the
establishment of these cells developing into a mature dopaminergic neuron
(Black, 1982). Appearance of dopaminergic neurons within the ventral neural
tube begins between embryonic day 11 and 13 in mice. These neurons then
migrate to locations within the substantia nigra compacta and VTA (Kawano et
al., 1995; Matsushita et al., 2002), become post-mitotic and begin to innervate
other brain regions (Wallen and Perlmann, 2003; Chinta and Andersen, 2005).
Axonal processes from the dopaminergic neurons that remain within the
substantia nigra and VTA target the striatum, with the former comprising the
nigrostriatal

dopaminergic

pathway

and

the

latter

comprising

the

mesocorticolimbic dopaminergic pathways. The importance of nigrostriatal
development is underscored as the loss of neuronal bodies and axons along the
nigrostriatal pathway due to PD or MPTP-intoxication is thought to play a critical
role in development of motor deficits associated with PD (Chesselet, 2002).
Dopaminergic systems (nigrostriatal, mesolimbic, and mesocortical)
interact with GABAergic neurons, both at their cell body and termini. Dopamine
within the nigrostriatal pathway plays a crucial role in the regulation of GABAergic
neurons, and a reduction in dopamine levels in PD can lead to dysregulation of
GABAergic neurons which in turn, can contribute to PD symptomology
(Chesselet, 2002). In the context of dopaminergic-GABAergic interactions,
several reports provided significant evidence that the neuronal markers TH
(dopaminergic) and GAD67 (GABAergic) co-localize naturally in the brain of
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mammals, birds, and reptiles (Kosaka et al., 1987b; Kosaka et al., 1988; Wulle
and Wagner, 1990; Kosaka et al., 1991), but whether a direct relationship
between dopaminergic and GABAergic neurons exists in the substantia nigra is
unknown (Chesselet, 2002). Previous reports showed that within the glomerular
layer and external plexiform layer/mitral cell layer approximately 91% of TH
immunoreactive cells were also GAD67 immunoreactive for a period of time
(Kosaka et al., 1991). Using a TH-GFP transgenic mouse, wherein green
fluorescent protein (GFP) transcription and expression is under control of the TH
promoter, studies revealed that not all GFP+ neurons within the substantia nigra
and VTA were dopaminergic, and were postulated to be of a GABA lineage
(Matsushita et al., 2002). While evidence suggest that during development, coexpression of both TH and GAD67 is normal, these neurons are typically
eliminated by the action of extracellular dopamine between postnatal day 4 and
postnatal day 8 (Busceti et al., 2012) with some studies reporting their existence
as late as postnatal day 18 (Masuda et al., 2011). However, to date, no reports
have been provided with definitive evidence for the co-expression of TH and
GAD67 in mature neurons within the substantia nigra of adult animals, or that this
phenotype is inducible.
Expression and activity of TH within the CNS is controlled by multiple
short- and long-term regulatory mechanisms including, but not limited to,
dopamine concentrations (Ames et al., 1978; Busceti et al., 2012) and posttranslational modifications (Haycock and Haycock, 1991). Phosphorylation of TH
at various serine residues within the N-terminal regulatory domain has been
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shown to have an effect on both the activity and stability of the enzyme (Lazar et
al., 1981; Vrana et al., 1981; Vrana and Roskoski, 1983; Kumer and Vrana,
1996; Nakashima et al., 2013b). Findings suggest that phosphorylation of TH
converts the enzyme to a more active state that is simultaneously less stable, as
demonstrated by a shorter half-life compared to its non-phosphorylated
counterpart (Gahn and Roskoski, 1995; Kumer and Vrana, 1996). In models of
neurodegeneration, reports indicate that phosphorylation state of serine 31
(Ser31) and serine 40 (Ser40) within the regulatory domain of TH are altered,
presumably in an attempt to increase the activity of remaining TH and restore
levels of endogenous dopamine (Ames et al., 1978; Vrana et al., 1981; Kumer
and Vrana, 1996; Kumar et al., 2003; Bobrovskaya et al., 2007; Ong et al., 2012;
Nakashima

et

al.,

2013a;

Salvatore,

2014).

Whether

neuroprotective

pharmaceuticals function via induction of TH transcription or through posttranslational phosphorylation of TH to increase activity has not been thoroughly
assessed. The latter is supported by long-term studies that showed an inverse
correlation between cigarette smoking and the development of PD (Fratiglioni
and Wang, 2000; Galanaud et al., 2005) whereby nicotine, a major component of
cigarette smoke, has been shown to induce phosphorylation of TH in vitro for up
to 48 hours (Haavik and Toska, 1998; Bobrovskaya et al., 2007). Therefore the
potential neuroprotective role of nicotine, and possibly other drugs, could be
through the induction of TH phosphorylation (Quik, 2004).
Herein we hypothesize that a novel compensatory mechanism exists in
which surviving GABAergic neurons within the substantia nigra undergo a
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phenotypic shift and begin expressing TH as a putative mechanism to increase
dopamine production in a dopamine-depleted environment.
MATERIALS and METHODS
Animals
C57BL/6J (wild-type) mice were purchased from Jackson Laboratory. For direct
visualization of dopaminergic neurons, mice on the C57BL/6 background
expressing GFP driven by the TH promoter (C57BL/6.TH-GFP, or TH-GFP mice)
were obtained from Osaka, Japan (Sawamoto et al., 2001) and bred in our
facility. All mice were housed and maintained on a 12:12 hr light/dark cycle with
ad libitum access to food and water and were randomly assigned to treatment
groups. Studies were conducted in accordance with the animal care guidelines
issued by the National Institutes of Health and approved by the Institutional
Animal Care and Use Committee of the University of Nebraska Medical Center.
TH-GFP mice were crossed with C57BL/6J mice and pups genotyped to identify
mice positive for the GFP gene. Primers for each marker were custom designed
(Table 1) using Invitrogen Primer Design, reconstituted in water to a
concentration of 20 nM, aliquotted, and stored at -20o C. PCR cycle was as
follows: 94o C for 3 min, 31 cycles (94o C for 30 sec, 56o C for 1 min, and 72o C
for 1 min), 72o C for 2 min, and held at 4o C. DNA samples were loaded onto
1.5% agarose gels and ran at 110 V for 35 minutes to obtain sufficient band
separation. The fluorescent DNA stain GelRed was added to the agarose mixture
to identify DNA bands at the correct molecular weight.
Acute MPTP intoxication
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To address the sensitivity of dopaminergic neurons in TH-GFP mice to MPTP
induced death we directly compared the level of neuronal death as a function of
neuronal survival observed in wild-type and TH-GFP mice when intoxicated with
increasing levels of MPTP. Male mice, 8 - 10 weeks of age, were randomized
into 4 treatment groups, on day 0 four subcutaneous injections (s.c.) were
administered at 2 hour intervals per injection of either PBS (10 ml/kg) or MPTP
(calculated for free base dose of 10, 14 or 18 mg/kg). For drug treatment studies,
male TH-GFP mice, 8-10 weeks old, were randomized into 8 treatment groups
and immunized with 4 s.c. injections of MPTP (18 mg/kg in a 10 ml/kg volume) or
PBS (10 ml/kg) on day 0; each injection given at 2 hour intervals. MPTP handling
and safety measures were in accordance with the National Institutes of Health,
the University of Nebraska Medical Center, and prior published guidelines
(Przedborski et al., 2001).
Drug treatment
MPTP-treated mice were administered daily injections for 21 days of either LDOPA or BL-1023. L-DOPA was reconstituted in water, pH 2.7, to a
concentration of 28.4 mg/mL which is equimolar to the amount of L-DOPA in the
BL-1023 compound. BL-1023 (BioLineRx, Ltd., Jerusalem, Israel) was
reconstituted in water, pH 7, to a concentration of 40 mg/mL. Drugs were made
fresh every 2 days. Daily intraperitoneal (i.p.) drug treatments began on day 7
post-MPTP and continued until day 28. To detect possible neurogenic activity
occurring as a consequence of neuronal assault and/or drug treatment, the
thymidine analogue bromodeoxyuridine (BrdU) was added to the drinking water
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of mice at a concentration of 1 mg/mL starting on day 7 post-MPTP. To ensure
animals did not decrease water intake due to taste aversion, glucose was added
to BrdU-containing water for the first 7 days. BrdU-containing water was
protected from light and changed every 7 days until day 21 post-MPTP when
animals returned to normal water for the remainder of the study.
Immunohistochemistry
Upon completion of study, 7 or 28 days post-MPTP, animals were terminally
anesthetized with pentobarbital and perfused first with PBS at a flow rate of 10.5
– 11.5 mL/minute for 3 minutes. Animals were then perfused with 4%
paraformaldehyde (PFA) dissolve in PBS (pH 7.4) for 8 minutes. After perfusion,
brains were carefully harvested and post-fixed in 4% PFA overnight, and
cryopreserved in 30% sucrose/PBS for 48 hours. Brains were then snap-frozen
in 2-methylbutane that had been cooled on dry ice and were embedded in
optimum cutting temperature (OCT) compound (TissueTek, Sakura Finetek,
Torrance, CA). Thirty µm sections collected through the midbrain. Tissue
sections were processed free-floating in 48-well plates and neuron numbers
quantified using stereological software (StereoInvestigator, MBF Bioscience,
Williston, VT).
Stereological analysis of neurons in the substantia nigra was performed
using optical fractionator module stereology software (StereoInvestigator, MBF
Bioscience, Williston, VT) interfaced with a Nikon Eclipse 90i fluorescence
microscope equipped with a monochrome camera and three filter blocks.. Using
simple random sampling (SRS) image series workflow, the region of interest
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(ROI) containing the substantia nigra was outlined for one hemisphere of each
tissue section at a 4x magnification. Fluorescent images of each ROI taken using
a 40x objective with FITC, Texas red (TR), and DAPI fluorescent cubes, and
merged Workflow parameters were defined to count approximately 20% of the
total neuron population in the substantia nigra (counting frame size 120 x 100
um, 245 x 240 um grid size) and Gunderson coefficient of error (C.E. m=1) was ≤
0.10. Estimated population size was generate by the software and multiplied by 2
to obtain the overall population estimation for both hemispheres of the brain.
Verification of TH-GFP animals.
Following MPTP-intoxication, mice were terminally-anesthetized and brains were
harvested and sectioned as previously described (Hutter-Saunders et al., 2011).
Following sectioning, 30 μm tissue sections were processed free-floating in 48well plates. Tissues were incubated with one of the following primary antibodies:
rabbit anti- TH (1:2000, Calbiochem/EMD Chemicals, Billerica, MA); rabbit antiglutamic acid decarboxylase 67 (GAD67) (1:500, Spring Bioscience, Pleasanton,
CA); rabbit anti-microtubule-associated protein 2 (MAP2) (1:1000, EMD Millipore,
Billerica, MA). Detection of TH+ neurons was carried out using both HRP and
immunofluorescent conjugated secondary antibodies. Anti-TH stained tissues
were incubated with either biotinylated goat anti-rabbit IgG (1:400, Vector
Laboratories, Inc., Burlingame, CA) or Texas red (TR) conjugated donkey antirabbit IgG (DyLite 594 1:1000, Jackson ImmunoReserach, West Grove, PA).
Color development was carried out in a streptavidin-horseradish peroxidase
(HRP) solution (ABC Elite vector kit, Vector Laboratories, Burlingame, CA) and
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Nissl substance counter stained with thionin. Tissues stained in anti-GAD67 or
anti-MAP2 antibodies were incubated with TR DyLight-594 donkey anti-rabbit
IgG (1:2000, Jackson ImmunoResearch, West Grove, PA). Nuclei were
visualized

with

4',6-diamidino-2-phenylindole

(DAPI)

containing

mounting

medium (Vector Laboratories, Inc., Burlingame, CA). Expected outcome of wildtype and TH-GFP mice stained with anti-TH, anti-GAD67, and anti-MAP2
antibodies outlined in Table 2.
Dual immunofluorescent staining.
For simultaneous visualization of dopaminergic and GABAergic neurons in a
single tissue, a free-floating method of immunofluorescence was used. Thirty μm
tissue sections from drug-treated mice were incubated with sheep anti-TH
(1:2000 EMD Millipore, Billerica, MA) followed by fluorescein isothiocyanate
(FITC) conjugated donkey anti-sheep IgG [1:2000, DyLight 488 (FITC), Jackson
ImmunoResearch, West Grove, PA)]. Sections were then incubated with rabbit
anti-GAD67 (1:500, Spring Bioscience) followed by TR-conjugated donkey antirabbit IgG [1:2000, DyLight 594 (Jackson ImmunoResearch, West Grove, PA).
All antibodies were absorbed by the vendor to remove inter-species crossreactive antibodies.

Nuclei were visualized with DAPI-containing mounting

medium (Vector Laboratories, Inc., Burlingame, CA).
Staining of drug-treated TH-GFP mice.
Upon completion of drug injections, L-DOPA or BL-1023 treated mice were
terminally anesthetized, perfused, and brains removed. Thirty µm sections were
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stained with rabbit anti-GAD67 (1:500, Spring Bioscience, Pleasanton, CA)
followed

by

TR-conjugated

donkey

anti-rabbit

IgG

(1:2000,

Jackson

ImmunoResearch, West Grove, PA). Tissues were mounted onto slides and
cover-slipped with DAPI containing mounting medium (Vector Laboratories, Inc.,
Burlingame, CA). Use of TH-GFP mice allowed for the detection of TH+
dopaminergic neurons without the need for immunofluorescent staining.
BrdU detection.
To detect incorporation of BrdU, tissue sections were incubated in 2 M HCl for 15
minutes at 37o C to denature DNA (Matsuura and Suzuki, 1997) prior to
incubation in rat anti-BrdU primary antibody (1:1000, Santa Cruz Biotechnology,
Dallas, TX) followed by incubation in TR-conjugated donkey anti-rat IgG
secondary antibody (1:2000, Molecular Probes, Carlsbad, CA). To serve as a
positive control, tissue sections from the olfactory bulb, an area of known
neurogenesis, were collected and stained in the same manner. Tissues were
mounted onto slides and cover-slipped with Vectashield Hardset mounting
medium (Vector Laboratories, Inc., Burlingame, CA).
Western blot analysis
Western blot analyses were performed to evaluate the expression level of TH
and phosphorylated TH within the substantia nigra and striatum of treated mice.
Using the same MPTP and drug treatment regimen described above, mice were
sacrificed on day 28 and brains removed. The midbrain containing the substantia
nigra and striatum was isolated separately, placed in tubes containing RNAlater
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(Applied Biosystems, Carlsbad, CA) and held on ice. Tissue was homogenized
and protein purified using protein and RNA isolation system (PARIS) (Life
Technologies, Carlsbad, CA) per the manufactures instructions. Protein
concentration in the samples was quantified using Pierce BCA Protein Assay Kit
(Life Technologies, Carlsbad, CA) and RNA samples quantified using NanoDrop
1000 (Fisher Scientific, Waltham, MA).
Forty µg of total protein was resuspended in a reducing sample buffer and
boiled for 5 minutes at 95° C, electrophoresed onto 4 – 20% PAGE gel
(GenScript, Piscataway, NJ) and transferred to a PVDF membrane. Membranes
were blocked with 5% BSA/TBST or 5% dry milk/TBST and subsequently probed
with primary antibodies specific for TH (1:500, Santa Cruz Biotechnology),
phospho-tyrosine hydroxylase serine 31 (Ser31) (1:500, Cell Signaling
Technology, Danvers, MA), or phospho-tyrosine hydroxylase serine 40 (Ser40)
(1:500, Cell Signaling Technology, Danvers, MA). Membranes were incubated
with HRP-conjugated goat anti-donkey IgG (1:20,000, Santa Cruz Biotechnology,
Dallas, TX) prior to being developed with SuperSignal West Femto substrate
(Life Technologies, Carlsbad, CA) for 1 minute and imaged using enhanced
chemiluminescence (FluorChem HD2, Protein Simple, San Jose, CA). HRPconjugated β-actin (1:5000, Sigma Aldrich, St. Louis, MO) was used as a protein
loading control. Protein band density was determined using Image J software
(National Institutes of Health).
Initial experimental design included the analysis of RNA isolated from the
substantia nigra and striatum for expression of TH and GAD67 using quantitative
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PCR (qPCR) to further verify increases in TH with MPTP and/or drug treatment.
However, the highly lipid concentration of the brain and small tissue volume
collected made RNA quality and yield sub-optimal. Therefore we were not able to
proceed with qPCR protocols.
In vitro neuron culture
Currently, few useful GABAergic cell lines are suitable for in vitro studies. Cell
lines exist that express or over-express GAD65 or GAD67 or that produce GABA
in vitro (Giordano et al., 1993; Giordano et al., 1996; Eaton et al., 1999;
Behrstock et al., 2000; Conejero-Goldberg et al., 2000); however to date none
have been studied in the context of increasing TH expression. The P19
embryonic carcinoma cell line (Pinal et al., 1997), human fibroblasts, and
neuroectodermal and insulinoma cell lines (Kono et al., 2001; Salazar et al.,
2001; Varju et al., 2002) have all been evaluated for use in GABAergic neuronal
studies, but none have been proven to be of long-term use that will further the
field of GABAergic studies. The majority of published studies on GABAergic
neurons have used cell lines that require a high degree of manipulation and subculturing techniques to yield consistent results (Trojanowski et al., 1997; Sanchez
et al., 2006). Therefore a GABAergic cell line relevant to studies of
neurodegeneration would be a very useful tool.
AF5 cells, an immortalized rat CNS progenitor cell line, were obtained as a
generous gift from Dr. William J. Freed (National Institute of Health, New Jersey).
AF5 cells are a CNS-derived line immortalized with the N-terminal fragment of
the large SV40 T antigen (Truckenmiller et al., 1998; Sanchez et al., 2006).
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Differentiated AF5 cells significantly upregulate their expression of Pitx2 mRNA,
the GABAergic neuron specification transcription factor. Additionally, expression
of GAD65 and GAD67 are upregulated in differentiated AF5 cells, suggesting
that AF5 cells have adopted a GABAergic lineage (Sanchez et al., 2006). AF5
cells were cultured in T75 tissue culture flasks at a density of 5 x 10 6 in
maintenance media [high glucose media (DMEM/F12 Glutamax) supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin] and incubated
at 37° C/5% CO2. To differentiate AF5 cells into a GABAergic lineage, after 5
days maintenance media was replaced with serum-free differentiating media
[neural basal media (Invitrogen, Waltham, MA) supplemented with B27 serum
free supplement (Invitrogen, Waltham, MA) and 50 µM of the anti-proliferative
agent N6,2’O-dibutyryladenosine 3’:5’-cyclic monophosphate sodium (dbcAMP,
Sigma, St. Louis, MA) to prevent growth of any non-neuronal cells and shown to
aid in the differentiation of AF5 cells to a GABAergic lineage. As an additional
study, I addressed whether AF5 cells could retain their GABAergic markers for a
longer period of time. AF5 cells were maintained in differentiating media for 21
days with half-media exchanges twice a week.
Limited availability of reliable GABAergic cell lines necessitated an
alternative approach to study the induction of TH, and underlying mechanisms, in
vitro. Therefore, primary neurons were isolated from the midbrain of postnatal
mice. When isolated from mice between postnatal days 1 and 7, the neuronal
populations isolated retain the ability to survive in culture and respond to
conditions chosen, in this case the presence or absence of dopamine
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replacement therapy. Brains were isolated from wild-type mice pups and
midbrain containing the substantia nigra carefully isolated. Care was taken to
remove any meninges surrounding brain tissue. Neural tissue was dissociated
using a kit specifically designed for the isolation of neurons from postnatal mice
(neural tissue dissociation kit – postnatal neurons, Miltenyi Biotec, San Diego,
CA ). Neurons were made into single cell suspensions and plated on poly-Dlysine coated flasks at a concentration of 1 x 10 6 cells/tissue flask in plating
media: MEM, 10% filtered, head inactivated FBS, 0.45% glucose (20% w.v.), 100
mM (1x) sodium pyruvate, 200 mM (1x) glutamine, 1x penicillin/streptomycin
(Beaudoin et al., 2012). Cells were incubated at 37o C for 2 - 6 hours until cells
were attached to flask at which time media was replaced with maintenance
media: Neuralbasal media supplemented with B-27 serum-free supplement, 200
mM (1x) glutamine, 1x penicillin/streptomycin. Cells were maintained at 37 o C
with half-media exchanges twice a week. Due to the heterogeneous population of
neurons in the midbrain, steps were taken to deplete the number of nonGABAergic cells in primary culture. MPP+, the active metabolite of the neurotoxin
MPTP, is routinely added to culture resulting in the selective killing of
dopaminergic cells (Notter et al., 1988; Radad et al., 2015). Five µM MPP+
(Sigma, St. Louis, MO) was added to primary neuron cultures 24 hours after cells
were switched to maintenance media. MPP+ was maintained in media for 48
hours.
Various concentrations of nicotine (positive control to induce TH
expression), L-DOPA, and BL-1023, and pro-inflammatory cocktails were added
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to AF5 or primary neuronal cultures for predefined periods of time prior to RNA
isolation and quantitative PCR analysis of DNA expression for genes of interest
(Table 4). The pro-inflammatory cytokines IFN-γ (2 ng/mL), IL-23 (10 ng/mL), and
IL-1β (5 ng/mL) were added to cultures to address the hypothesis that the
inflammatory response following MPTP intoxication plays a role in upregulation of
TH expression in vivo. Preliminary tests showed an unusual effect of L-DOPA
and BL-1023 on the culture media in that both compounds caused a significant
color change to the culture media after 24 hours, even at very low
concentrations. Therefore, experiments using L-DOPA or BL-1023 in culture
were kept to time points less than 24 hours. At end-points stated in Table 3, cells
were removed from flasks and RNA isolated to be used in quantitative PCR
reactions as described in the following section.
Quantitative PCR
Cells were kept in differentiating media for 4 or 21 hours following which the cells
were detached and lysed with 0.05% trypsin and RNA extracted using RNeasy
mini kit (Qiagen) per manufacture’s protocol. RNA concentration was
approximated using NanoDrop 1000 (Thermo Scientific) and reverse transcribed
into cDNA using RT First Strand kit (Qiagen). cDNA was used in quantitative
PCR reactions to look for the expression of astrocytic markers [glial fibrillary
acidic protein (GFAP)], GABAergic markers (GAD67, Pitx2), dopaminergic
markers (TH, Pitx3), and β-actin as a housekeeping gene. Primers for each
marker were custom designed (Table 4) using Invitrogen Primer Design and
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reconstituted in water to a concentration of 20 nM, aliquoted, and stored at -20o
C.
SYBR GreenSybr green (Qiagen, Valencia, CA) was used as a detection
method to quantify the amount of cDNA present in AF5 cells and primary
neurons cultured under various conditions. SYBR Green is used as a nucleic
acid stain that binds in the minor groove of double-stranded DNA and emits a
signal at 520 nm. The resulting signal intensity is measured with a real-time
thermocycler (Eppendorf Mastercycler ep realplex) and an increase in signal
correlates with an increase in mRNA concentration in the sample. cDNA samples
were mixed with RT2 SYBR Green qPCR master mix and the appropriate primer
pair (Table 4). Eppendorf Mastercycler ep realplex with ROX filter set was used
to run samples in triplicate with the following cycle conditions: 95 o C, 10 minutes;
40 cycles of (95o C, 15 seconds; 60o C, 60 seconds); melting curve cycle. The
number of cycles required to produce a Sybr green signal above threshold (deltaCT values) of sample triplicates were averaged and samples that did not produce
a signal during melting curve analysis excluded.
Statistical analysis
Tests were performed using Statistica (StatSoft, Inc. Tulsa, OK) or Prism
GraphPad and data expressed as mean ± standard error of the mean (SEM).
Statistical significance was evaluated by one-way ANOVA followed by post-hoc
comparisons using Fisher’s LSD or Tukey’s correction.
RESULTS
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TH-GFP mice are not more susceptible to MPTP-intoxication
Preliminary studies were performed to determine the practicality of using THGFP mice in further MPTP studies. Because homozygosity of the GFP gene is
lethal when under control of the chicken β-actin promoter, I verified overlapping
expression of TH and GAD67 by comparing unstained TH-GFP mice (Figure 1A)
to wild-type (Figure 1B) and TH-GFP (Figure 1C) mice with anti-TH antibodies
conjugated with Texas red. A summary of the expected immunohistochemical
and immunofluorescent stained results of wild-type and TH-GFP mice is in Table
2. Next, I explored the possibility that TH+GFP+ neurons may be more
susceptible to MPTP-induced death. To address that possibility, we compared
the number of surviving dopaminergic neurons in wild-type and TH-GFP mice
treated with MPTP or PBS. To ensure that larger doses of neurotoxin would not
over-reach a GFP-toxic threshold, we administered small, medium, and large
doses of MPTP (10, 14, or 18 mg/kg) or PBS (10 mL/kg). Mice were treated with
4 s.c. injections of either PBS or MPTP at 10, 14, or 18 mg/kg in 10 mL/kg PBS.
Seven days following MPTP intoxication, mice were sacrificed, brains removed,
embedded in OCT, and cut into 30 μm serial sections through the substantia
nigra. Serial sections were immunostained with primary antibodies (anti-TH, antiGAD67, or anti-MAP2) and probed with the appropriate biotinylated or
fluorochrome-conjugated anti-IgG.
No significant differences were detected in numbers of dopaminergic
neurons between wild-type and TH-GFP mice in the PBS control group using
immunohistochemical (Figure 2A) or immunofluorescent (Figure 2B) analysis,
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suggesting that GFP expression is an accurate method to quantify surviving
dopaminergic neurons. Moreover, linear regression showed that both strains
responded similarly to MPTP dose in both the immunohistochemical and
immunofluorescent stained tissue groups (immunohistochemical: wild-type r2 =
0.90, p = 0.014 and TH-GFP r2 = 0.939, p = 0.007; immunofluorescent: wild-type
r2 = 0.959, p = 0.021 and TH-GFP, r2 = 0.996, p = 0.002). Loss of dopaminergic
neurons due to MPTP dose between wild-type or TH-GFP strains were not
different (immunohistochemical p = 0.89; immunofluorescent p = 0.83), indicating
that TH+GFP+ neurons are no more sensitive to MPTP than those of wild-type
animals. No significant differences were seen in the number of MAP2+ (Figure
2C) or GAD67+ (Figure 2D) neurons between strains of mice within treatment
groups.
To verify all GFP positive neurons were also positive for TH expression,
and that all TH expressing neurons expressed GFP, we utilized stereological
analysis to first assess the numbers of TH+, GFP+, and TH+GFP+ neurons in
TH-GFP mice. No significant differences in the total number of TH+ or GFP+
neurons were detected at any MPTP dose, suggesting all GFP+ neurons are also
TH expressing and all TH+ neurons express GFP (Figure 3A). To further verify
that GFP expression is restricted to dopaminergic neurons, the total number of
GAD67+ neurons were quantified and compared to the number of neurons that
were positive for GAD67 expression and negative for GFP expression
(GAD67+GFP-). Numbers of neurons expressing both GAD67 and GFP
(GAD67+GFP+) averaged less than 1% of the total number of GAD67+ and
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GFP+ neuron population (data not shown). No significant differences were seen

between the number of GAD67+GFP- neurons and total GFP+ neurons (Figure
3B). If GFP expression was not specific to dopaminergic neurons, we would
expect to see differences between the numbers of total GAD67+ neurons and
those that are GAD67+GFP-. These results show that GFP expression is
restricted to dopaminergic neurons at day 7 post-MPTP.
Number of MAP2+ neurons compared to TH+ plus GAD67+.
MAP2 is a non-specific neuronal marker expressed by all neurons within the
region being evaluated, in this case the substantia nigra. MAP2 is commonly
used to ensure the reduction in dopaminergic neurons following MPTP
intoxication is due to neuronal death and not merely a temporary loss of TH
expression. Since MAP2 is expressed by all neurons, the number of MAP2+
neurons determined by stereological analysis should very closely match those
numbers of TH+ neurons added to the number of GAD67+ neurons. Consistent
differences in the number of MAP2+ neurons compared to population estimates
of TH+ and GAD67+ neurons were summed. (Figure 4A, B). This was
hypothesized to be due to some neurons expressing both TH and GAD67, and
thus being included in both populations of neuron counts. This is in contrast to
MAP2 expression when TH+ and GAD67+ neurons would be included only once
in population estimates. The differences in neuron counts were especially
different with higher doses of MPTP intoxication indicating neuronal assault
causes changes to neuronal profiles not seen in PBS animals.
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Dual immunofluorescent staining reveals co-localization of TH and GAD67 in
neurons of the substantia nigra
To look for induction of TH expression by GABAergic neurons following MPTP
assault, we first assessed the extent of changes in TH+GAD67+ neuron numbers
in the substantia nigra through two-color immunofluorescent staining. Tissues
were isolated from MPTP-intoxicated mice sacrificed after 21 – 28 days postMPTP (14 or 21 days of dopamine replacement therapy injections). Stereological

analysis showed a 7.8-fold increase in the number of TH+GAD67+ neurons
following MPTP intoxication and L-DOPA administration compared to animals
given only PBS. A 5.6-fold increase was seen in animals following MPTP assault
and BL-1023 administration (Figure 5). No statistically significant change in the
number of TH+GAD67+ neurons was seen in animals treated with MPTP only.
Moreover, the increase in TH+GAD67+ neurons were directly correlated with the
loss of neurons that express only GAD67 (TH-GAD67+) (r = 0.896, p = 0.0018)
(data not shown). This suggests that after MPTP intoxication, TH expression is
induced in surviving GABAergic neurons as a compensatory mechanism for
dopaminergic neuronal loss resulting in a phenotypic shift of GABAergic neurons.
This led to question whether the increase in TH by GABAergic neurons was a
consequence of drug treatment alone or a combination of MPTP-induced lesion
and drug treatment. Additionally, this led us to further characterize the phenotypic
profile of substantia nigra neurons from drug-treated animals to identify the
source of increased TH+ neurons.
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Increase of TH+ neurons is due to a phenotypic shift of GABAergic neurons and
not neurogenesis
Having demonstrated TH+ neurons in the substantia nigra of TH-GFP mice are
no more susceptible to MPTP-induced death, we next sought to evaluate the
number of TH+GAD67+ neurons 28 days post-MPTP using TH-GFP animals as
well as address the alternative hypothesis that the increase in TH+ neurons are a
result of neurogenesis using BrdU. The experimental timeline is provided in
Figure 6. Tissues from TH-GFP animals were stained with anti-GAD67 followed
by TR-conjugated secondary antibody. Expression of GFP was used to identify
TH+ neurons. Representative images showing TH+GAD67- (Figure 7A), THGAD67+ (Figure 7B), and TH+GAD67+ (figure 7C) neurons demonstrate the colocalization of TH and GAD67 results in yellow staining. Co-expression of THdriven GFP and GAD67 was detectable in neuronal populations within the
substantia nigra following MPTP intoxication alone, drug treatment alone, or
MPTP intoxication and drug treatment (Figure 8A, B). In contrast to the low level
of neurons expressing TH and GAD67 in PBS-treated, treatment with L-DOPA,
or BL-1023 alone, or MPTP + PBS increased TH+GAD67+ neurons by 3.2-, 3.8-,
and 2.6-fold compared to PBS controls. Interestingly, MPTP + L-DOPA or MPTP
+ BL-1023 treatment increased TH+GAD67+ neuron numbers 5.0- and 5.4-fold
above PBS control levels and 1.9- and 2.1-fold above MPTP controls indicating
an additive effect of neuronal insult and dopamine replacement therapy.
Incorporation of the thymidine analog, BrdU, is considered the gold
standard for detection of neurogenesis in the adult mammalian brain (Arias-
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Carrion et al., 2009) which is normally limited to specific areas of the adult
mammalian brain, specifically the hippocampus, olfactory bulb, and epithelium
(Altman and Das, 1965; Altman, 1969). Newly synthesized DNA will incorporate
BrdU which can be detected with an anti-BrdU antibody. Past studies of
neuroegenesis within the substantia nigra were limited to short term
administration of BrdU, thus due to the short in vivo half-life of BrdU in circulation,
approximately 2 hours (Deng et al., 2010), the possibility existed that using those
regimens, nigral-associated neurogenesis could have been underevaluated;
particularly should neurogenic differentiation be slower than BrdU is cleared. To
preclude that possibility, BrdU was administered in the drinking water of animals
to detect any neurogenic activity occurring over the course of the study.
To serve as a positive control that both BrdU administration and the
staining protocol were appropriate for the experiment, sections containing the
olfactory bulb (Figure 9A) and substantia nigra (Figure 9B) were stained and
analyzed. Nuclear BrdU+ cells were found the olfactory bulb indicating the
methodology was capable of detecting neurons derived from neurogenesis and
thus validating the results obtained from the substantia nigra. MPTP alone or
MPTP followed by treatment with L-DOPA or BL-1023 for 21 days did not
significantly increase the total number of nuclear BrdU+ neurons or TH+ nuclear
BrdU+ neurons within the substantia nigra (Figure 10). Interestingly, mice that
exhibited the greater number of and increase in TH+GAD67+ neurons (Figure 7)
had fewer nuclear BrdU+ neurons (Figure 10), although not at significant levels.
Initial analysis of tissue sections stained with BrdU revealed cells that appeared
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to be positive for BrdU staining. However, upon closer evaluation of these cells,
BrdU incorporation was only in the cytoplasmic area (Figure 11) and is therefore
indicative of a reparative mechanism instead of a neurogenic one (Cooper-Kuhn
and Kuhn, 2002). Therefore, data presented here represents stereological results
only from cells that had BrdU expression in the nuclear region. This suggests that
the phenotypic shift of GABAergic neurons to express TH in response to L-DOPA
or BL-1023, suppresses the normally low levels of BrdU incorporation within the
substantia nigra.
In vitro changes of TH mRNA and protein in response to drug
In an attempt to explain the mechanism responsible for TH upregulation by
GABAergic neurons two in vitro approaches were used; a transformed cell line
(AF5) and primary neuronal cultures. Quantitative PCR analysis of mRNA from
cells was measured for expression of GFAP, GAD67, Pitx2, Pitx3, TH, and βactin. Primers were designed using InVitrogen Primer Design and listed in Table
4. Despite using multiple culture conditions (Table 3), neither in vitro method
utilized resulted increased measurable TH expression. The lack of positive data
points to the likelihood that upregulation of TH by GABAergic neurons is a highly
regulated process that only occurs under a set of very specific and extraordinary
conditions. If GABAergic neurons easily express TH, the effects could be
detrimental to the homeostatic environment of the CNS and therefore
upregulation of TH may be seen as a “last resort” to restore the environmental
milieu to normal.
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Post-translations phosphorylation is increased following MPTP and drug
treatment
To evaluate the changes in TH phosphorylation following dopaminergic insult,
PBS and MPTP-intoxicated mice were administered PBS, L-DOPA or BL-1023,
for 21 days post-MPTP and mice were sacrificed on day 28 post MPTP. Ventral
midbrain

containing

the

substantia

nigra

and

striatum

was

isolated,

homogenized, and protein extracted. Western blot analysis was performed for
quantification of TH, phospho-TH (Ser31), phospho-TH (Ser40), and β-actin.
Protein levels were normalized to β-actin and fold changes relative to PBS/PBS
controls calculated (fold change ± SEM for n=4 mice/group).
While no significant increases were seen in Ser40 phosphorylation with
MPTP and drug treatment (data not shown), phosphorylation of Ser31 was
increased compared to PBS controls in MPTP intoxicated animals who received
L-DOPA or BL-1023 daily for 21 day by 2.47- and 7.89-fold respectively (Figure
12A) within the substantia nigra. Drug treatment in the absence of dopaminergic
insult did not yield any significant increases in phosphorylation of TH, suggesting
initial insult to neurons, or decreased levels of endogenous dopamine, is
necessary to induce the phosphorylation of TH Ser31 within the substantia nigra.
Analysis of protein levels within the striatum showed no significant increase in the
level of phosphorylated Ser31 (Figure 12B). Unlike the stereological results,
Western blot analysis for TH did not show any significant increases between the
drug or vehicle treated groups within the substantia nigra (Figure 13A) or striatum
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(Figure 13B), presumably is due to analysis of whole brain lysate versus
evaluation of TH on a per-cell basis.
DISCUSSION
Herein using dual immunofluorescent staining and TH-GFP transgenic mice, we
showed that surviving GABAergic neurons within the substantia nigra undergo a
phenotypic shift and begin expressing TH following neuronal assault and/or
dopamine replacement therapy. To address the possibility that the increase in
TH+ cells was due to an increase in neurogenic activity, the thymidine analogue
BrdU was given over the course of 14 days. Results demonstrated a lack of
BrdU+ neurons in the substantia nigra of animals and thus ruled out the
possibility of newly formed TH+ neurons. Furthermore, the majority of BrdU
incorporation was detected within the cytoplasm of cells rather than in nuclear
DNA suggesting either a DNA reparative mechanism rather than neurogenesis or
merely uptake and retention of BrdU in the cytoplasm (Arias-Carrion et al., 2009).
Interestingly, the combination of MPTP followed by dopamine replacement
therapy in the form of either L-DOPA or BL-1023 after lesion development yields
an additive increase in numbers of GABAergic neurons that upregulate TH when
compared to both PBS and MPTP controls. These findings are the first of their
nature to successfully demonstrate that dopamine replacement therapy can have
an effect on surviving GABAergic neurons within the substantia nigra of adult
mice and provide evidence as to a putative compensatory or reparative
mechanism
environment.

to

increase

dopamine

production

in

a

dopamine-depleted
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Within the striatum, dopamine concentrations appear to regulate the
numerical density of TH+ neurons in a dose-dependent manner. α-Methyl-ptyrosine, a TH inhibitor, given to animals at post-natal day 4 significantly reduces
the concentration of dopamine within the striatum, but results in an overall
increase in the number of TH+ neurons (Busceti et al., 2012). It was shown that
the TH+ neurons within the striatum did not incorporate BrdU and were therefore
not a result of neurogenesis. While not specifically addressed by Busceti and
colleagues,

the

increase

in TH+ neurons following

α-methyl-p-tyrosine

administration, and subsequent dopamine decrease, was proposed to be a result
of unopposed trophic factors that have yet to be elucidated. However, the finding
that TH+ neurons in these studies were also GAD+ implicate GABAergic neurons
as a potential source for the increased number of TH+ neurons in these studies.
Data provided herein supports the hypothesis that dopamine negatively regulates
the number of TH+ neurons and a reduction in endogenous dopamine results in
an increased survival of TH+GAD67+ neurons normally eliminated by
extracellular dopamine (Busceti et al., 2012). Separate studies examining the
number of TH+ neurons within the striatum showed clear discrepancies between
the effects of dopamine replacement therapy in the form of L-DOPA; one set
demonstrating decreases in the number of TH+ striatal neurons (Lloyd et al.,
1975; Huot et al., 2008) and another set showing an overall increase in striatal
TH+ neurons (Lopez-Real et al., 2003; Jollivet et al., 2004; Tande et al., 2006).
Ultimately these contradictory findings may be explained by the fact that the
studies utilized very different doses of L-DOPA and the effects of L-DOPA effects
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may be highly dose-dependent. Above a certain level, as with the studies
performed by Lopez-Real and Jollivet, dopamine is proposed to act in
conjunction with growth factors to up-regulate TH expressing neurons within the
striatum (Huot and Parent, 2007). At lower levels, dopamine is suggested to
control TH expression by means of conventional feedback mechanisms. These
findings allude to the hypothesis that local dopamine concentrations regulate the
numerical density of dopaminergic neurons in the substantia nigra and/or the
relative density of TH termini within the striatum.
In the absence of dopamine, due to PD progression or neurotoxin induced
neuronal death, the increase in TH+ neurons is feasibly due to a de-repression of
TH expression and a phenotypic shift of surviving GABAergic neurons so that
they may act as a local source of dopamine-secreting cells. As such they would
be part of a compensatory mechanism in response to dopaminergic neuronal
death (Kosaka et al., 1991; Jollivet et al., 2004; Abe et al., 2010; Busceti et al.,
2012). Our studies suggest that dopamine replacement therapy, given daily for
21 days, elevates dopamine levels beyond the inhibitory threshold for TH
expression. It is interesting however, that dopamine replacement therapy can
increase the number of TH+GAD67+ neurons with and without initial
dopaminergic neuronal assault, but an increase in Ser31 phosphorylation only
occurs in the presence of dopaminergic insult. This finding suggests that either a
threshold level of dopamine depletion must be reached before changes in
phosphorylation are detectable or, alternatively, increased levels of proinflammatory cytokines in the MPTP-intoxicated animals (Koprich et al., 2008)
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further increase phosphorylation of TH (Nakashima et al., 2013b). This also
suggests that additional mechanisms, as yet unknown, are playing a role in the
induction of TH expression by GABAergic neurons. These data also support the
hypothesis that TH expression is regulated by multiple mechanisms which are
highly dependent on the surrounding environmental milieu. Our results indicate
that at the dosage given in our study, dopamine was present at concentrations
that affected multiple TH regulatory mechanisms; one mechanism that ultimately
led to increase expression of TH by GABAergic neurons and one resulting in
increased phosphorylation of Ser31 within the substantia nigra. Whether these
mechanisms represent separate pathways or are intricately associated has yet to
be determined.
Another regulatory mechanism is concerned with the continuous presence
of transcription factors that are needed to maintain cellular phenotype. The loss
or expression of one or more specific transcription factor may influence the loss
or activation of a critical cell type necessary for the production of dopamine or
dopaminergic function. It may be worth exploring the many different TF’s needed
to maintain/trigger a dopaminergic phenotype and evaluate whether they are
upregulated in GABAergic neurons. Another method of regulation may center
around the different neuronal firing patterns associated with dopaminergic and
GABAergic neurons and how the induction of TH expression and production of
dopamine by GABAergic neurons may influence not only the firing patterns of
those neurons, but also on the surrounding surviving dopaminergic neurons,
Further characterization of the TH+GAD67+ neurons would be informative as to
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the possibility of this phenotype aligning with any of the subtype(s) of GABAergic
interneurons and whether those shift phenotypes in response to MPTP and/or
dopamine replacement therapy. Because the interneuron subtypes are so distinct
in their transcription factors and topographical organization, and are rather
numerous, it is likely that not all subtypes may be capable of expressing TH;
however the elucidation of specific TH-producing phenotypic subsets have yet to
be initiated.
Several reports have alluded to the fact that GABAergic research is
leagues behind research into other neuronal populations within the midbrain.
This underscores the minimum level of effort afforded to the development of a
stable GABAergic cell line. One of the few GABAergic cell lines available, AF5
cells, is an immortalized rat CNS progenitor cell line that is able to assume
differentiated states with neuronal properties (Sanchez et al., 2006). While AF5
cells can be induced into a GABAergic lineage, they did not prove to be
beneficial in regards to evaluating the upregulation of TH mRNA by GABAergic
neuron in vitro. Because of the heterogenetic nature of GABAergic neurons in the
CNS, it is plausible that AF5 cells may lack essential factors that GABAergic
neurons in the substantia nigra possess. However, still unknown are the factor(s)
that induce GABAergic neurons to undergo this phenotypic shift in vivo in
response to dopamine depletion and/or dopamine replacement therapy. Data
suggesting that even subtle differences between GABAergic neurons in distinct
brain regions have profound effects on neuron function (Tepper, 2010; Lahti et
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al., 2013; Achim et al., 2014; Morales and Root, 2014), warrants further research
into GABAergic neuronal phenotype, function, and plasticity.
Extensive data suggests that post-translation phosphorylation of serine
residues has a large effect on TH expression and activity (Vrana et al., 1981;
Vrana and Roskoski, 1983; Gahn and Roskoski, 1995; Kumer and Vrana, 1996;
Wallen and Perlmann, 2003; Bobrovskaya et al., 2007); however the kinase(s)
responsible in our model remain unknown. In vitro, more than 7 protein kinase
systems have been identified that can modulate TH phosphorylation (Kumer and
Vrana, 1996). Not only does phosphorylation of serine residues within TH occur
by multiple mechanisms, but reports show these mechanisms are activated
under a number of different conditions (Lazar et al., 1981; Kumar et al., 2003;
Bobrovskaya et al., 2007; Ong et al., 2012). This helps to explain our findings
that suggest phosphorylation of TH is differently regulated within the substantia
nigra and striatum in the MPTP model of PD. Specifically, our data indicates a
compensatory mechanism to increase phosphorylation of Ser31 is present in the
substantia nigra, but not the striatum; results that are consistent with other
reports (Salvatore, 2014). Alternatively, prior to detectable changes to the
phosphorylation status of serine residues in TH, a threshold level of TH loss
might be necessary and our MPTP regimen may not have been sufficient to
attain that level of loss. A clearer picture as to the level of kinase expression and
activity within the midbrain and striatum following MPTP or dopamine
replacement therapy, and whether it corresponds to an increase in dopamine
concentrations, would provide a better understanding as to the role of
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phosphorylated TH behind the mechanism of TH expression by GABAergic
neurons.
Due to multiple reports indicating that midbrain GABAergic neurons are an
exceptionally

heterogeneous

subset

of

neurons

(Floran

et

al.,

1990;

Soghomonian et al., 1992; Nakatani et al., 2007; Tepper, 2010; Achim et al.,
2012; Vasudevan et al., 2012; Lahti et al., 2013; Achim et al., 2014; Li et al.,
2014), I focused my efforts on isolating neurons from only this specific region to
have the greatest chance of replicating in vivo results in vitro. Neurons were
isolated from the midbrain from postnatal tissues and depleted of dopaminergic
neurons with MPP+. However, this approach yielded similar results to those
obtained with AF5 cells in that upregulation of TH mRNA was not seen ex vivo.
Multiple concentrations of nicotine were used as positive controls due to the
known ability of nicotine to modulate TH in vitro (Radcliffe et al., 2009; Ferrari et
al., 2011; Suen et al., 2013). This likely may be due to a very unique phenotype
or idiosyncratic characteristic that midbrain GABAergic neurons possess as well
specific cues derived from the surrounding environmental milieu. The possibility
exists that to induce TH expression by GABAergic neurons requires either one or
more factors that include 1) a pro-inflammatory environment either due to MPTPinduced cell death or T cell infiltration; 2) the presence of actively dying or dead
dopaminergic neurons; or 3) a reduction in the concentration of endogenous
dopamine in the area. Without reproducing one or more of these factors,
induction of TH by GABAergic neurons in vitro may be difficult.
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Taken together, we believe these findings serve to demonstrate the ability
of dopamine replacement therapy to induce a phenotypic shift of surviving
neurons in the MPTP model of PD. Additionally, we provide evidence that
dopamine replacement therapy acts through a protein kinase pathway to
increase the phosphorylation of Ser31 that corresponds to a significant increase
in TH+ neurons within the substantia nigra. Ultimately, these findings will help
improve PD drug development and advance drug design for the treatment of PD
by providing novel targets to which new lines therapeutic strategies can focus.
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Table 1. TH-GFP genotyping primers.
Primer name

Primer sequence 5’ – 3’

Wild-type (forward)

CAAATGTTGCTTGTCTGGTG

Wild-type (reverse)

GTCAGTCGAGTGCACAGTTT

GFP (forward)

AAGTTCATCTGCACCACCG

GFP (reverse)

TGCTCAGGTAGTGGTTGTCG

Product size (b.p.)
200 b.p.

475 b.p.
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Table 2. Expected immunohistochemical and immunofluorescent staining results
of wild-type and TH-GFP mice.
WT
Dopaminergic

TH-GFP
GABAergic

Dopaminergic

GABAergic

TH IHC

Brown

Blue

Brown

Blue

TH TR

Red

None

Yellow

None

GAD67 TR

None

Red

Green

Red

MAP2 TR

Red

Red

Yellow

Red
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Table 3. Culture conditions to study induction of TH expression by AF5 cells in
vitro.

Media additive

Concentration

Duration of
treatment (hours)

1, 10, 100 uM

24 hrs

10, 100 uM

48 hrs

10, 100 uM

4 hrs

10, 100 uM

12 hrs

10, 50, 100 uM

24 hrs

10 uM

4 hrs

10 uM

12 hrs

10 uM

24 hrs

2 ng/mL, 10 ng/mL, 5 ng/mL
Pro-inflammatory
cytokines
2 ng/mL, 10 ng/mL, 5 ng/mL
(IFNγ, IL-23, IL-1β)
2 ng/mL, 10 ng/mL, 5 ng/mL

4 hrs

Nicotine

L-DOPA

BL-1023

12 hrs
24 hrs
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Table 4. Quantitative PCR primer sequences.

Primer Name

Primer Sequence (5’ – 3’)

GFAP (forward)

TCAACGTTAAGCTAGCCCTGGACA

GFAP (reverse)

TCTGTACAGGAATGGTGATGCGGT

GAD67 (forward)

GCCGGGGCTGCGCTTGGCTTTG

GAD67 (reverse)

TGGGCGGTGCTTCCGGGACATGAGC

Pitx2 (forward)

CAAATGGAGAAAGCGGGAGC

Pitx2 (reverse)

ATGGATGAGATGGAGTTGGGCG

TH (forward)

TTGAAAAACTCTCCACGGTGTACT

TH (reverse)

TACGGGTCAAACTTCACAGAGAAT

Pitx3 (forward)

CTCTCTGAAGAAGAAGCAGCG

Pitx3 (reverse)

CCGAGGGCACCATGGAGGCAGC

β-actin (forward)

TGAGAGGGAAATCGTGCGTGACAT

β-actin (reverse)

ACCGCTCGTTGCCAATAGTGATGA
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A

B

C

Figure 1. Representative image of wild-type and TH-GFP tissues stained with
anti-TH and Texas red-conjugated IgG.
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Figure 1. Staining outcome of the substantia nigra in wild-type versus TH-GFP
mice. (A) In the absence of staining, identification of dopaminergic neurons is still
plausible when using the TH-GFP mouse. Because GFP is under control of the
TH promoter in these mice, expression of GFP is an indicator of a dopaminergic
neuron. (B) In order to identify dopaminergic neurons in wild-type mice the
tissues must first be incubated in a primary antibody specific for TH followed by
the appropriate secondary antibody conjugated with a fluorescent fluorochrome
(TR). To ensure GFP expressing neurons were also immunoreactive for TH,
tissues from TH-GFP mice were incubated with anti-TH antibodies followed by
TR- conjugated secondary IgG. The resulting dopaminergic neurons in the
substantia nigra of TH-GFP mice were yellow due to the co-expression of TR and
GFP. All tissue were mounted on slides and coverslipped with DAPI containing
mounting medium to identify nuclei. All images acquired using a 4x objective and
Nikon 90i microscope equipped with a monochrome camera and 3 filter blocks.
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Figure 2. Dopaminergic neurons expressing GFP are not more susceptible to
MPTP
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Figure 2. Dopaminergic neurons expressing GFP are not more susceptible to
MPTP. (A) Quantification of TH+ neurons using immunohistochemical analysis
and DAB color generation in wild-type and TH-GFP mice 7 days post PBS or
MPTP (10, 14, or 18 mg/kg). (B) Quantification of TH+ neurons using
immunofluorescent analysis in wild-type and TH-GFP mice 7 days post PBS or
MPTP (10, 14, or 18 mg/kg). (C) Quantification of MAP2+ neurons in wild-type
and TH-GFP mice 7 days post PBS or MPTP (10, 14, or 18 mg/kg). (D)
Quantification of GAD67+ neurons in wild-type and TH-GFP mice 7 days post
PBS or MPTP (10, 14, or 18 mg/kg). Linear regression showed that both strains
responded similarly to MPTP dose in both the immunohistochemical and
immunofluorescent stained tissue groups: (A) wild-type r2 = 0.90, p = 0.014 and
TH-GFP r2 = 0.939, p = 0.007; (B) wild-type r2 = 0.959, p = 0.021 and TH-GFP, r2
= 0.996, p = 0.002. No significant differences were seen in the number of (C)
MAP2+ or (D) GAD67+ neurons between strains of mice within treatment groups
Data represented as mean ± SEM for n = 5 – 7 animals.
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Figure 3. GFP expression is restricted to TH expressing dopaminergic neurons.
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Figure 3. GFP expression is restricted to TH expressing dopaminergic neurons.
30 μm sections from the midbrain of TH-GFP mice intoxicated with MPTP (10, 14,
or 18 mg/kg) or PBS controls were stained with anti-GAD67 and TR-conjugated
IgG. Sections were imaged using a Nikon 90i microscope equipped with a
monochrome camera and 3 fluorescent filter cubes. Images were taken at 40x
and neurons classified as (A) TH+ or GFP+ (green); (B) GAD67+/GFP- (red) and
GAD67+ (red). (A) No significant differences in the total number of TH+ or GFP+
neurons were detected at any MPTP dose. (B) No significant differences were
seen between the number of GAD67+GFP- neurons and total GFP+ neurons.
Data presented as mean ± SEM for n = 5 – 9 animals.
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Figure 4. MAP2+ neuron populations are consistently less than the populations of
TH+ + GAD67+ neurons.
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Figure 4. MAP2+ neuron populations are consistently less than the populations of
TH+ + GAD67+ neurons. Tissue sections from mice intoxicated with increasing
does of MPTP (10, 14, 18 mg/kg) or PBS were stained with anti-TH, anti-GAD67,
and anti-MAP2 antibodies followed by TR-conjugated IgG. Sections were imaged
using a Nikon 90i microscope equipped with a monochrome camera and 3
fluorescent filter cubes. Images were taken with separate fluorescent filter cubes
and merged into one image with a 40x objective. (A) Neurons were quantified as
TH+, GAD67+, MAP2+ based upon the expression criteria summarized in Table
2. Mean number of neurons were determined for 10-16 mice per group.
Significant differences (p ≤ 0.05) in neuron numbers from mice treated with
graded doses of MPTP compared to non-intoxicated controls (0 mg/kg) were
denoted for each neuronal phenotype expressing compared to; aMAP2; bTH; or cTH
+ GAD67. Notably, no significant differences were noted in neurons expressing

only GAD67. (B) In addition to the number of TH+, GAD67+, and MAP2+
neurons, the numbers of TH+ and GAD67+ neurons were summed and the
means ± SEM determined for 10 – 16 animals per group. The numbers of
MAP2+ neurons and the sum of the TH+ and GAD67+ neurons (TH + GAD67)
were compared at each dose level without discernible significant differences.
Significant differences were detected in the mean neuron number in mice treated
with each dose of MPTP: p ≤ 0.05 compared to non-intoxicated controls (0 mg/kg
MPTP) within aMAP2/PBS or bTH + GAD67 neuronal phenotypes./PBS.
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Figure 5. Dopamine replacement therapy following MPTP causes significant fold
change in the number of TH by GABAergic neurons.
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Figure 5. Dopamine replacement therapy following MPTP causes significant fold
change in the number of TH by GABAergic neurons. Sections were imaged using
a Nikon 90i microscope equipped with a monochrome camera and 3 fluorescent
filter cubes. Images were taken with separate fluorescent filter cubes and merged
into one image with a 40x objective. Fold changes of TH+GAD67- or
TH+GAD67+ neurons within the substantia nigra of drug treated animals. Mean ±
SEM determined for 5-7 mice per group and P ≤ 0.05 compared to neuron
numbers from controls treated with aPBS at day 0 and days 7-34 (PBS) or
b

MPTP on day 0 and PBS on days 7-34 (MPTP/PBS).
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Figure 6. Experimental timeline to assess upregulation of TH expression by GABAergic neurons. The ability of
MPTP-intoxication and/or dopamine replacement therapy was assessed using the MPTP mouse model of PD. On
day 0 mice were intoxicated with 4 doses of MPTP and 7 days later daily i.p. injections of dopamine replacement
therapy began (L-DOPA or BL-1023) or PBS. Concurrently, BrdU was administered via the drinking water for the
first 14 days of treatment. Dopamine replacement therapy continued until day 28 post-MPTP (21 days of injections)
at which time mice were sacrificed and numbers of TH+ and GAD67+ neurons quantified using stereological
analysis.
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Figure 7. TH and GAD67 co-localize in neurons.
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Figure 7. TH and GAD67 co-localize in neurons of the midbrain of mice.
Representative image of (A) TH+ dopaminergic neurons (green) (B) GAD67+
(red) and (C) TH+GAD67+ neurons. 30 µm sections were collected through the
midbrain of TH-GFP mice and stained with anti-GAD67 primary antibodies
followed by a Texas red-conjugated secondary IgG. Nuclei were stained using
DAPI containing mounting medium. Sections were imaged using a Nikon 90i
microscope equipped with a monochrome camera and 3 fluorescent filter cubes.
Images were taken with separate fluorescent filter cubes and merged into one
image with a 40x objective.
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Figure 8. Dopamine replacement therapy increases number of TH+ GABAergic
neurons with and without neuronal lesion.
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Figure 8. Dopamine replacement therapy increases number of TH+ GABAergic
neurons with and without neuronal lesion. Sections were imaged using a Nikon
90i microscope equipped with a monochrome camera and 3 fluorescent filter
cubes. Images were taken with separate fluorescent filter cubes and merged into
one image with a 40x objective. (A) Quantification of TH+GAD67- and
TH+GAD67+ neurons from TH-GFP animals following 21 days of PBS, L-DOPA,
or BL-1023 injection. Numbers of neurons were determined by stereological
analysis by sampling approximately 20% of the neuronal population and
achieving a coefficient of error (C.E.) of less than 0.10 (10%). Means ± SEM
were determined for 7-8 mice per group, and P ≤ 0.05 compared to mice treated
with aPBS on day 0 and days 7-27 (PBS/PBS) or bMPTP on day 0 and PBS on
days 7-27 (MPTP/PBS) (B) Fold changes in TH+GAD67- and TH+GAD67+
neuron populations were calculated relative to PBS/PBS control animals. Means
of fold changes ± SEM were calculated for 7-8 mice per group, and significant
a

differences determined wherein P ≤ 0.05 from mice treated with

PBS on days 0

and 7-27 (PBS/PBS); bPBS on day 0 and L-DOPA on days 7-27 (PBS/L-DOPA);
c

PBS on day 0 and BL-1023 on days 7-27 (PBS/BL-1023); or

and PBS on days 7-27(MPTP/PBS).
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Figure 9. BrdU incorporation (red) was detected in the olfactory bulbs (A), but not
the SN (B) of mice following 14 days of continuous BrdU administration.
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Figure 9. BrdU incorporation was detected in the olfactory bulbs, but not the SN
of mice following 14 days of continuous BrdU administration. To assess
neurogenic activity of TH-GFP mice, BrdU was administered for 14 days in the
drinking water at 1 mg/mL starting at day 7 post-MPTP (time of drug initiation).
To avoid taste aversion, glucose was added to the water and mice were
observed to ensure normal drinking. Tissues known to contain neurogenic cells,
such as (A) olfactory bulbs served as positive controls for incorporation of BrdU
and were compared to tissues sections containing the (B) substantia nigra.
Sections, 30 μm thick, were stained with rat anti-BrdU primary antibodies
following denaturation of DNA with 2M HCl for 15 minutes and TR-conjugated
secondary IgG. Sections were imaged using a Nikon 90i microscope equipped
with a monochrome camera and 3 fluorescent filter cubes. Images were taken
with separate fluorescent filter cubes and merged into one image with a 4x
objective.
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Figure 10. Increase in TH+GAD67+ neurons does not appear to be a
consequence of neurogenesis. Quantification of BrdU+ neurons as determined
by stereological analysis. Sections, 30 μm thick, were stained with rat anti-BrdU
primary antibodies following denaturation of DNA with 2M HCl for 15 minutes and
TR-conjugated secondary IgG. Sections were imaged using a Nikon 90i
microscope equipped with a monochrome camera and 3 fluorescent filter cubes.
Images were taken with separate fluorescent filter cubes and merged into one
image with a 40x objective. Number of TH+, Nuclear BrdU+, and TH+Nuclear
BrdU+ neurons were determined by stereological analysis by sampling
approximately 20% of the neuronal population and achieving a coefficient of error
(C.E.) of less than 0.10 (10%). Mean neuron numbers ± SEM were determined
for 7 - 8 mice per group, and P ≤ 0.05 compared to control mice treated with
a

PBS on days 0 and 7-27 (PBS/PBS).
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Figure 11. BrdU incorporation in the cytoplasmic region of neuron in the
substantia nigra.
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Figure 11. BrdU incorporation in the cytoplasmic region of neuron in the
substantia nigra. Representative image showing cytoplasmic incorporation of
BrdU (white box). Tissue sections, 30 μm thick, were stained with rat anti-BrdU
primary antibodies following denaturation of DNA with 2M HCl for 15 minutes and
TR-conjugated secondary IgG. Sections were imaged using a Nikon 90i
microscope equipped with a monochrome camera and 3 fluorescent filter cubes.
Images were taken with separate fluorescent filter cubes and merged into one
Image with a image with a 40x objective.
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Figure 12. Phosphorylation of TH at serine 31 is increased by dopamine
replacement therapy following MPTP intoxication.
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Figure 12. Phosphorylation of TH at serine 31 is increased by dopamine
replacement therapy following MPTP intoxication. Western blot analysis of
protein levels within the ventral midbrain containing the substantia nigra or
striatum was isolated, homogenized, and protein extracted following 21 days of
PBS, BL-1023, or L-DOPA administration and 28 days post-MPTP to assess
changes to TH phosphorylation. (A) Fold changes of phosphorylation of ser31
within the substantia nigra and (B) striatum. Protein levels were normalized to βactin and fold changes relative to PBS/PBS controls calculated. Mean fold
change ± SEM were calculated for 4 mice per group.
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Figure 13. Phosphorylation of TH at serine 31 is increased by dopamine
replacement therapy following MPTP intoxication. Western blot analysis of
protein levels within the ventral midbrain containing the substantia nigra or
striatum was isolated, homogenized, and protein extracted following 21 days of
PBS, BL-1023, or L-DOPA administration and 28 days post-MPTP to assess
changes to TH phosphorylation. (A) Fold changes of TH within the substantia
nigra and (B) striatum. Protein levels were normalized to β-actin and fold
changes relative to PBS/PBS controls calculated. Mean fold change ± SEM were
determined for 4 mice per group).

88

CHAPTER THREE
Neuronal and behavioral analysis of p19 deficient mice
ABSTRACT
Behavioral and motor characteristics were evaluated in mice deficient in one or
both copies of the IL-23p19 chain, the unique subunit of the proinflammatory
cytokine IL-23. This genotype leads to an absence of CD4+ TH17 cells in
circulation. Such mice were shown to have a significantly reduced number of
dopaminergic neurons in the substantia nigra compared to wild-type controls.
The dopaminergic termini in the striatum were also aberrant, however only in the
homozygote p19 knockout mice. Furthermore, p19 knockout mice showed no
difference in the sensitivity to MPTP-induced lesion. Behavioral and motor
characterization of p19 knockout mice using multiple forced and unforced tests
ultimately showed that knockout mice, despite their significantly reduced neuron
numbers exhibited few behaviors or abilities in motor functions compared to wild
type control mice.
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INTRODUCTION
Multiple lines of evidence have pointed to the detrimental role of TH17 cell
in PD and the MPTP mouse model of PD (Benner et al., 2008; Reynolds et al.,
2010; Gaffen et al., 2014; Sie et al., 2014). The findings that TH17 rely on IL-23
for survival suggested IL-23 as a promising therapeutic target in immunological
diseases driven by aberrant TH17 cell responses. IL-23 itself is a heterodimer
composed of a p40 and p19 subunit. While p40 is a common subunit with IL-12,
p19 is unique to IL-23. This led to the development of a mouse model wherein
the 4 exon coding region of p19 has been replaced with GFP, effectively
preventing transcription of p19. These animals display no overt phenotype and
the unaffected p40 subunit is available for normal generation of IL-12 and
humoral responses (Ghilardi et al., 2004). Based on findings that adoptive
transfer of TH17 cells exacerbate MPTP lesion, the loss of TH17 cells was
hypothesized to result in the lack of neurodegenerative exacerbation and
possible neuroprotection in MPTP-intoxicated mice (Reynolds et al., 2010).
Pro-inflammatory cytokines such as those secreted by TH1, TH17, and
activated mononuclear phagocytes typically serve as major players in
inflammatory responses and clearance of pathogens, but they also play an
important role in neurogenesis and proper neuronal patterning. Neurogenesis
refers to the process of generating new neurons from neural stem cells (Emsley
et al., 2005) and consists of multiple steps including proliferation, differentiation
into the correct neuronal lineage, and integration into the proper brain region to
form functional neuronal circuitry (Ming and Song, 2005; Kim et al., 2015).
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Recently, a collective of evidence suggests that neurogenesis is affected by the
dysregulation of cytokines, chemokines, and neurotransmitters (Whitney et al.,
2009). For example, during the early period of development pro-inflammatory
cytokines may exert detrimental effects on the brain (Kim et al., 2015), but during
mild acute inflammation, inflammatory cytokines can stimulate neurogenesis
(Whitney et al., 2009). Tumor necrosis factor-α (TNF-α) is one of the major proinflammatory cytokines that plays a role in neurogenesis; either supporting or
suppressing it depending on the type of TNF receptor it binds (Arnett et al., 2001;
Dybedal et al., 2001; Ben-Hur et al., 2003; Monje et al., 2003; Chen et al., 2004;
Iosif et al., 2006; Keohane et al., 2010). A broader picture of the interplay
between PD, neuroinflammation, cytokines, and neurogenesis would vastly
improve our understanding of the chronic nature of PD and aid the development
of therapeutic modalities aimed at restoring neuronal numbers. In PD, clinical
symptoms do not present until a significant number of dopaminergic neurons
have been lost, therefore knowing the cytokines and levels needed to support
neurogenesis would benefit the design of neuroprotective or neuroregenerative
efforts before disease progresses to later stages.
To restore normal motor function and control in PD patients, appropriate
animal models will be essential to test behavior and demonstrate improvements
in behavior following treatment. Several forced and unforced motor tests have
been extensively used and described in mice models of PD. Many of these tests
have been found to be of little utility due in part to the lack of sensitivity, but also
due to the relative small lesions induced in most animal models. Our laboratory
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has

previously

implemented

several

of

these

tests

and

successfully

demonstrated differences between drug-treated and controls following MPTPintoxication (Hutter-Saunders et al., 2011). Due to the results that successfully
demonstrated motor impairments following MPTP-intoxication, any improvements
seen in this test can be confidently reported to be a consequence of disease
intervention and possible restoration of striatal dopamine levels. These animalbased behavioral tests will help create the foundation on which human therapies
will be built that target restoring proper motor control in PD. Herein, we evaluate
the involvement of IL-23, a cytokine known to be critical in TH17 development, in
dopaminergic neurodevelopment and the extent that Mendelian genotypes affect
behavioral phenotypes.
MATERIALS and METHODS
Animals
IL-23p19 deficient (p19-/-) mice were obtained from Genetech (San Francisco,
CA) and wild-type (WT) C57BL/6J mice were obtained from Jackson
Laboratories (Bar Harber, ME). Animals were housed and bred in our animal
facilities, and maintained on a 12:12 hr light/dark cycle with ad libitum access to
food and water. The study was conducted in accordance with the animal care
guidelines issued by the National Institutes of Health and approved by the
Institutional Animal Care and Use Committee of the University of Nebraska
Medical Center. Generation of p19+/- mice were generated by crossing female
p19-/- homozygous knockout mice and C57BL/6J males. F1 offspring were then
genotyped to ensure all were heterozygous p19 knockout. Male and female F1
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p19+/- heterozygous animals were then crossed, the resulting litters genotyped,
and assigned to p19+/+ WT, p19+/- heterozygotes, and p19-/- homozygotes.
Genotyping
Genotyping was carried out to correctly identify wild-type, heterozygous, and
homozygous knockout animals. DNA was isolated from ear tissue using DNesy
Blood and Tissue kit (Qiagen, Valencia, CA). For routine genotyping, a PCRbased method with a common antisense primer, wild-type specific and knockout
specific sense primers. Primers for each marker were custom designed (Table 1)
using Invitrogen Primer Design and re-constituted in water to a concentration of
20 nM, aliquotted, and stored at -20° C. The primer triplet amplifies a 210-bp
fragment for the wild-type allele and a 289-bp fragment for the knockout allele.
PCR was conducted in a thermocycler using the following conditions: 1 cycle of
94°C, 60 s; 35 cycles of 94°C, 30 s; 58°C, 30 s; 72°C, 60 s; 1 cycle of 72°C, 7
min; and held at 4° C. DNA samples were loaded onto 3% agarose gels and ran
at 110 V for 35 minutes to obtain sufficient band separation. The fluorescent DNA
stain GelRed (Biotium, Inc., Hayward, CA) was added to the agarose mixture to
identify DNA bands at the correct molecular weight.
Acute MPTP intoxication
To address sensitivity of dopaminergic neurons among the 3 different genotypes
under neurodegenerative conditions, we compared the level of neuronal survival
to MPTP-intoxication in p19 WT, heterozygous, and homozygous mice. Mice
received 4 subcutaneous (s.c.) injections of MPTP-HCL (18 mg/kg free base in a
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volume of 10 ml/kg) in PBS or PBS (10 mL/kg); each injection administered every
2 hours. MPTP handling and safety measures were in accordance with the
National Institutes of Health, the University of Nebraska Medical Center, and
prior published guidelines (Przedborski et al., 2001).
Immunohistochemistry
Seven days after MPTP or PBS administration, mice were terminally
anesthetized, transcardially perfused with PBS followed by 4% paraformaldehyde
(PFA) in PBS. Brains were harvested and post-fixed in 4% PFA overnight,
cryoprotected in 30% sucrose/PBS for 48 hours, snap frozen in 2-methylbutane,
embedded in OCT compound, and 30 µm sections collected through the
midbrain. Tissue sections were processed free-floating in 48-well plates.
Sections containing the substantia nigra were immunostained with sheep anti-TH
primary antibody (1:2000, EMD Millipore, Billerica, MA) and FITC conjugated
donkey anti-sheep IgG (1:1000, Vector laboratories, Burlingame, CA). Tissue
sections were mounted onto slides, cover-slipped with DAPI containing mounting
medium (Vector laboratories, Burlingame, CA), and neuronal numbers quantified
using stereological software (StereoInvestigator, MBF Bioscience, Williston, VT).
Tissue sections containing the striatum were immunostained with rabbit anti-TH
(1:1000, Cal-Biochem/EMD Millipore, Billerica MA) primary antibody and HRPconjugated goat anti-rabbit IgG (1:400 Vector laboratories, Burlingame, CA), and
visualized with diaminobenzidine (DAB). Relative striatal density was quantified
using ImageJ software (National Institute of Health).
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Stereological analysis of neurons in the substantia nigra was performed
using optical fractionator module stereology software (StereoInvestigator, MBF
Bioscience, Williston, VT) interfaced with a Nikon Eclipse 90i fluorescence
microscope equipped with a monochrome camera and three fluorescence filter
blocks. Using simple random sampling (SRS) image series workflow for every 4th
serial section, the region of interest (ROI) containing the substantia nigra was
outlined for one hemisphere of each tissue section at a 4x magnification.
Fluorescent images of each ROI were taken using a 40x objective with FITC and
DAPI fluorescent cubes, and merged. Workflow parameters were defined to
count approximately 20% of the total neuron population in the substantia nigra
(counting frame size 120 x 100 um, 245 x 240 um grid size) and Gunderson
coefficient of error (C.E. m=1) was ≤ 0.10. Estimated population size was
generated by the software and multiplied by 2 to achieve an overall population
estimation for both hemispheres of the brain.
Behavioral testing
Natural behavior and movement were measured using the home cage monitoring
system, open field test, and analysis of syntactic grooming. Forced motor
function was measured using both constant speed rotarod and accelerating
rotarod methods and adhesive removal test.
Home cage monitoring (HCM)
Existing behavioral assays typically examine behavior over a limited time and
focus on a single behavioral domain (Tecott and Nestler, 2004; de Visser et al.,
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2006). Furthermore, these behaviors tested under forced conditions may differ
from the behavior of animals acting freely in their home cage leading to results
that may not accurately reflect behavior. Using a unique home cage monitoring
(HCM) system allow for simultaneous measure of patterns of feeding, drinking,
activity, and movement in individually housed animals so as to elucidate complex
organization of diverse behaviors exhibited by mice (Goulding et al., 2008).
Mouse position was determined by the force and torques acting on the system
strain gauges; feeding events were detected by a photobeam across the food
hopper, and drinking events were detected by a capacitive lick sensor. Validation
studies show agreement between mouse position and drinking events measured
by the system compared with video-based observation (Parkison et al., 2012) .
Baseline mouse day-to-day behavior was measured using a customdesigned HCM that measures behaviors with 1 ms temporal and 0.5 cm spatial
resolution. Thirty-two mice (10 p19+/+ wild-type, 12 p19+/- heterozygous, and10
p19-/- homozygous) 8-10 weeks of age, were acclimated for 5 days and
observed for 16 days. All data was sampled at 1 kHz, and written to disk using a
real-time computer (to prevent potential skipped data points). All mouse data
underwent rigorous quality control to eliminate known spurious points (arising
from blocked photobeams or sipper tubes, sudden changes in cage center of
mass, etc.), followed by a data classification workflow to determine mouse active
and inactive states, mouse bouts of feeding, drinking, and movement, and
differences in circadian variation (Goulding et al., 2008).
Constant speed and accelerating rotarod
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A pilot study was conducted to first determine the appropriate speed at which to
test the motor function of wild-type and knockout mice. The apparatus was fitted
with a 7-cm diameter rod and was interfaced with automatic timing
instrumentation (Rotamex, Columbus Instruments, Inc., Columbus, OH). A
preliminary study was performed to determine the appropriate rotational speed(s)
at which to test mice so that differences in motor control between wild-type and
knockout mice could be detected, if present. To do this, mice were acclimated
and trained to perform on the rotarod using an accelerating method (0 – 16 rpm)
for 5 minutes x4 daily sessions on 3 consecutive days. On the 4th and 5th days
animals were tested at constant speeds of 6, 8, 10, 12, 14, and 16 rpm for runs
with a maximum run time of 90 sections. Latency to fall was recorded for each
animal and averaged for the 3 runs calculated.
Preliminary experiments indicated two speeds at which rotarod testing had
the potential to show differences between strains of mice, 14 and 16 rpm.
Following 3 days of acclimation to the apparatus using an accelerating method (0
– 16 rpm) for 5 minutes x4 daily sessions, experimental animals (p19+/+ wildtype, p19+/- heterozygous, and p19-/- homozygous knockout animals) were
tested at constant speeds of 14 and 16 rpm for 3 runs with a maximum run time
of 90 seconds. Latency to fall was recorded for each animal. Due to previous
reports suggesting the accelerating rotarod may be more sensitive to motor
function differences than traditional constant speed rotarod (Keshet et al., 2007),
on the 5th day, the animals were evaluated for their ability to perform on an
accelerating rotarod model. The accelerating rotarod differs from the constant
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speed in that the apparatus increases in speed at a constant rate over a defined
period of time. Mice were placed on the stationary rod and tested for their ability
to stay on the apparatus as it increased in speed from 0 rpm to 18 rpm over the
course of 5 minutes. Animals were tested for 3 runs with a maximum time of 5
minutes. Latency to fall was recorded for each animal and averages calculated.
Open field activity testing
Evaluation of normal activity and behaviors were evaluated using an automated
open field activity system (Tru Scan 2.0, Coulbourn Instruments, Whitehall, PA,
USA) to measure different types of unforced movements over the course of 20
minutes. Activities evaluated included total movements within the floor and
vertical (i.e. rearing) planes, move and rest time, total distance covered,
stereotypic behaviors (i.e. grooming), zone time (center vs. margin). Movements
of each mouse were automatically recorded and measured by recording breaks
in photo beams spaced 2.4 cm apart and span floor and vertical planes. The area
measured 40.64 cm x 40.64 cm x 40.64 cm and was kept in a quiet and
undisturbed area whilst recording mouse behaviors. Per the manufacturer,
stereotypic movements are repetitive movements that start and return to the
original position in less than 2 seconds with at least 3 such movements occurring
prior to the event being considered a stereotypic episode. OFAT distinguishes
between two types of stereotypic behaviors, movements that changes less than ±
0.999 bean spaces are denoted type 1, and movements that change less than ±
1.499 bean spaces are denoted type 2.
Syntactic grooming evaluation
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Syntactic grooming consists of serially-ordered movements of four phases
(elliptical strokes, unilateral strokes, bilateral strokes, and flank licking) and
together is considered a form of stereotypic behavior. The chain of grooming
events occurs in a frequency that is over 13,000x greater than could be expected
by chance (Berridge et al., 1987). Due to the nature of the grooming chains, the
OFAT arena and software cannot distinguish syntactic versus non-syntactic
grooming. The chain of movements that distinguish syntactic grooming are
controlled by neurons in the striatum and a depletion of dopamine should
interrupt syntactic grooming. Each of the movements in the syntactic grooming
chain can occur alone, or out of order, but the individual movements are similarly
dependent on dopamine (Aldridge and Berridge, 1998; Aldridge et al., 2004).
Male wild-type, heterozygous, and homozygous knockout mice (n = 7 – 8) were
videotaped in their home cage and visually scored for complete syntactic
grooming sequences over the course of 10 minutes in a blinded fashion (HutterSaunders et al., 2011). Numbers of incomplete grooming events, either an
incomplete grooming cycle or grooming movement that occurred alone, were
recorded.
Adhesive removal test
Sensitive and reliable behavioral test are critical in testing the therapeutic efficacy
and potential disease-modifying therapies in preclinical trials for PD (Peghini et
al., 1990). The ability of an animal to remove an adhesive dot from the snout
requires fine control of the forepaws. Published data supports the use of the
adhesive removal test as a method to detect sensorimotor function differences in
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newer strains of mice. In Pitx3-aphakia mice, wherein nigrostriatal dopamine
neurons are significantly reduced, the adhesive removal test successfully
showed a significantly increased time to remove the adhesive dot compared to
wild-type controls (Peghini et al., 1990). To evaluate differences in the ability of
knockout and wild-type animals to perform this task, we used a small adhesive
dot (8-mm) and placed it on the snout of the animal using forceps. The animal
was then placed in a clean cage and the time to remove the sticker recorded.
Each trial run was conducted 3 times per animal.
Statistical analysis
All tests were performed using Statistica (StatSoft, Inc. Tulsa, OK) and data
expressed as mean ± standard error of the mean (SEM). Statistical significance
was evaluated by one-way ANOVA followed by post-hoc comparisons using
Tukey’s comparison or Fisher’s LSD.
RESULTS
Stereological analysis of naïve mice
To assess the effects that p19 deficiencies on nigrostriatal dopaminergic neuron
populations, we assessed the number of TH+ neurons in the substantia nigra and
terminal densities in the striatum for p19+/+ wild-type, p19+/- heterozygous, and
p19-/- homozygous knockout mice at 7 – 8 weeks of age. Stereological
evaluation of dopaminergic neurons of naïve mice revealed significant
differences in the number of TH+ neurons between wild-type, heterozygous
knockout, and homozygous knockout mice, (8905 ± 692, 3724 ± 291 and 4003 ±
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437 respectively) (Figure 1A). Unlike neuronal bodies in the substantia nigra,
wild-type mice did not show a significant difference in the striatal dopaminergic
density compared to heterozygous knockout mice (29.5 ± 3.1 and 36.5 ± 2.3
respectively, Figure 1B). However, striatal density in p19-/- homozygous
knockout mice (16.9 ± 3.5) was significantly reduced compared to both wild-type
and heterozygous mice.
MPTP intoxication
To

assess

whether

dopaminergic

neurons

were

more

sensitive

to

neurodegenerative processes, we treated the 3 strains of mice with the
neurotoxin MPTP which induces death of dopaminergic neurons along the
nigrostriatal pathway. Previous studies showed that T cell-mediated immunity
plays a piviotol role in exacerbating and attenuating neuronal death (KurkowskaJastrzebska et al., 1999; Benner et al., 2004; Reynolds et al., 2007; Benner et
al., 2008; Reynolds et al., 2008; Schneider, 2008; Reynolds et al., 2009;
Reynolds et al., 2010; Mosley et al., 2012). Particularly noteworthy was that
TH17 and to a lesser degree TH1 cells exacerbate neuroinflammation and
subsequent neurodegeneration. Therefore, we sought to determine if animals
lacking the p19 subunit of IL-23 would be protected from MPTP-induced cell
death. At 7 days post-MPTP or PBS treatment, the numbers of surviving TH+
neurons in the substantia nigra were quantified using stereological software. The
number of surviving TH+ neurons in wild-type mice injected with PBS (7765 ±
538) was significantly higher compared to PBS injected p19+/- heterozygous
knockout (4204 ± 197) and p19-/- homozygous knockout (2544 ± 223) mice
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(Figure 2A). Among all three genotypes, MPTP-intoxication yielded significant
reduction in the numbers of surviving TH+ neurons compared to the respective
genotype treated PBS control animals. At 7 days post-MPTP intoxication all
animals exhibited similar reduction in the percentage of TH+ neurons lost within
the substantia nigra (56% for wild-type, 53% for heterozygous, mice, and 58% for
homozygous knockout mice; p = 0.7804) (Figure 2B). Similar to numbers of nigral
neurons, the relative striatal densities of control mice were correlated with the
three genotypes of p19 (p19+/+ wild-type, 77 ± 1.4; p19+/- heterozygous, 69 ±
2.5; and p19-/- homozygous, 46 ± 2.4) (Figure 2C). However, the percentages of
lost striatal densities in MPTP-intoxicated mice among all genotypes were not
significantly different compared to PBS controls (wild-type 41%; heterozygous
51%, and homozygous knockout 45%; p = 0.214) (Figure 2D).
Home cage monitoring
Home cage monitoring of mice for 14 days allows for constant monitoring of
animals and provides information about their habitual behaviors. Using sensitive
and cost-effective home cage monitoring systems that utilize force and torque
measurements to determine behavior bouts such as feeding and drinking as well
as temporal inactive versus active behaviors. Behaviors of mice were
categorized as inactive (black), active but not in forward locomotion (red),
forward locomotion (green), drinking (blue), and food (orange) (Figure 3 A-C).
Percentage of a 24-hour cycle spent in each category was calculated for p19+/+
wild-type (Figure 3A), p19+/- heterozygous (Figure 3B) and p19-/- homozygous
mice (Figure 3C). Time percentages were calculated for each 24-hour period and

102

averaged over the course of the observational period (16 days). While no
significant differences were detected in any of these behavioral categories
between strains of mice, wild-type mice consistently spent lesser time eating and
more time in forward locomotion compared to heterozygous and homozygous
knockout strains of mice.
Activities of mice greatly differ between light and dark cycles with the most
active periods being during dark cycles. Therefore, I sought to evaluate whether
or not differences in behaviors would become apparent when directly comparing
light and dark cycle time budgets (Figure 4). In a similar manner to the 24-hour
time budget analysis, mice were observed and behaviors categorized for p19+/+
wild-type (Figure 4A and B), p19+/- heterozygous (Figure 4C and D), and p19-/homozygous knockout (Figure 3E and F) mice with time being broken down into
the dark cycle (Figure 4A, C, and E) and light cycle (Figure 4B, D, and F). Similar
to the 24-hour time budget results (Figure 3), no significant differences were
detected in any of these behavioral categories between strains of mice. However
a proclivity of wild-type mice to feed less and exhibit forward locomotion more
compared to knockout mice was demonstrated.
Because of the consistent finding that wild-type mice show differences in
percentage of the time spent in locomotion, despite reaching a significance of p ≤
0.05, this behavior was further analyzed (Figure 5). Upon completion of the 16day study, averages were calculated for the percentage of each hour spent in
locomotion over the course of a 24-hour period for each animal. The hourly
averages for each strain of mice were calculated and plotted against averages of
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other strains. Figure 5A wild-type (green) versus heterozygous knockout (red);
Figure 5B wild-type (green) versus homozygous knockout (red); Figure 5C
heterozygous knockout (green) versus homozygous knockout (red). The plots
were each divided (dashed bars) into light and dark cycles with X-axis values of 6
– 12 and 24 – 30 representing light cycle and 12 – 24 representing dark cycles.
Expectedly, all mice were more active during the dark cycle compared to light.
While significant differences were detected in the amount of time heterozygous
mice spend in locomotion during the dark cycle compared to wild-type (Figure
5A), other behaviors involving locomotion were not significantly different, and
therefore, locomotor behaviors could not be confidently reported as being
different in heterozygous mice. No significant differences were detected between
wild-type and homozygous knockout (Figure 5B) or homozygous and
heterozygous knockout (Figure 5C).
OFAT
Automated open field activity testing (OFAT) allows for measurement of multiple
unforced movements such as total distance travelled over the course of the
observation period, average speed of movements, time spent in areas of the
arena, and rearing and stereotypic behaviors. Animals with neurological
impairments may not move normally or explore the arena in a similar manner to
wild-type animals. Therefore, we chose to evaluate wild-type and p19 deficient
animals over the course of 20 minutes and identify differences in these
measurements.
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Comparisons of movement are shown in Figure 6. The following type of
movements were measured for wild-type, heterozygous, and homozygous
knockout mice and evaluated for statistical significance: total floor plane move
time (seconds) (Figure 6A); total floor plane rest time (seconds) (Figure 6B); total
floor plane movements (Figure 6C); total floor plane distance travelled (cm)
(Figure 6D); mean floor plane velocity (Figure 6E); average distance travelled
(cm) per movement (Figure 6F); total number of jumps (Figure 6G); mean
number counter-clockwise turns (Figure 6H); mean number clockwise turns
(Figure 6I). We did not find any significant differences in these types of
movement in wild-type mice or mice deficient in one or two p19 genes.
Comparisons of stereotypic movements are shown in Figure 7.
Stereotypic-1 (Figure 7A, B, and C) and stereotypic-2 (Figure 7D, E, and F)
movements were observed over the course of 20 minutes for wild-type,
heterozygous, and homozygous knockout mice. Stereotypic events included total
number stereotypic-1 moves (Figure 7A); total number stereotypic-1 episodes
(Figure 7B); total stereotypic-1 time (seconds) (Figure 7C); total number
stereotypic-2 moves (Figure 7D); total number stereotypic-2 episodes (Figure
7E); total stereotypic-2 time (seconds) (Figure 7F). No significant differences
were observed between p19+/+, p19+/-, or p19-/- mice.
Comparisons of zone time are shown in Figure 8. The OFAT arena is
sectioned into a center and margin portion. Time budgeted in these two areas
were calculated as total margin distance covered (cm) (Figure 8A); total time
spend in arena margin (seconds) (Figure 8B); total arena center distance
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covered (cm) (Figure 8C); total time spend in arena center (seconds) (Figure
8D); total number of arena center entries (Figure 8E); percentage of time spent in
area center (Figure 8F); and percentage of time spent in arena margin (Figure
8G). No significant differences were observed between wild-type mice or either
strain deficient in one or two p19 genes.
Comparisons of vertical plane movements (rearings) are shown in Figure
9. Beam breaks were used to detect movements in the vertical plane and
categorized as: total number vertical plane entries (Figure 9A); total number
vertical plane moves (Figure 9B); total time spent in vertical plane (seconds)
(Figure 9C); and total vertical plane distance travelled (cm) (Figure 9D). No
significant differences were observed between wild-type and p19 knockout mice.
Comparisons between p19+/+ wild-type, p19+/- heterozygous, and p19-/homozygous knockout mice in a plethora different activities (total movements
within the floor and vertical, planes, move and rest time, total distance covered,
stereotypic behaviors, zone time) showed no significant differences between
strains of mice.
Rotarod
The rotarod is a widely used motor function test in mice and can be used in the
traditional constant speed mode or an accelerating mode. Initial studies aimed at
determining a constant speed at which differences between strains of mice
become apparent, demonstrated 14 and 16 rpms were best suited to testing wildtype and p19 knockout mice (Figure 10). No significant differences in the latency
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to fall between strains of mice were found when tested at 14 rpm (p = 0.274)
(Figure 11A), at 16 rpm (p = 0.525) (Figure 11B), or at 0-18 rpm accelerating
rotarod (p = 0.573) (Figure 11C). Average latency to fall for 3 trials were 64 ±
10.6 sec, 44 ± 8.4 sec, and 230 ± 12.7 sec for wild-type mice; 48 ± 10.5 sec, 36 ±
6.9 sec, and 211 ± 16.9 sec for heterozygous mice; and 69 ± 6.9 sec, 48 ± 7.1
sec, and 229 ± 12.8 sec for homozygous knockout mice at 14 rpm, 16 rpm, and
accelerating respectively.
Adhesive removal test
The ability of an animal to remove an adhesive dot from the tip of their nose
requires fine motor control of the forepaws. Altered neuronal numbers or
pathways involved in motor control could therefore lead to differences in the
ability of animals to complete the task. To evaluate this, a small adhesive dot was
carefully placed on the nose of the mouse and the mouse placed in an empty
cage. The latency to successfully remove the sticker was recorded and repeated
for a total of 3 trials (Figure 12A). Interestingly, homozygous knockout animals
exhibited the smallest mean latency to remove the adhesive dot (4.1 ± 1.1 sec)
which was significantly faster than mean time for wild-type mice (7.5 ± 0.61 sec)
(p < 0.01), but not the mean for heterozygous mice (5.4 ± 0.85 sec). No
significant difference was detected in the mean latency to remove the adhesive
dot between wild-type and heterozygous animals, though the trends were
relatively strong (p = 0.068). Evaluation of each of the 3 individual runs
demonstrated that all animals became faster at removing the adhesive dot with

107

each subsequent trial, but latency to remove the sticker was not different
between strains at the same trial run (Figure 12B).
Syntactic grooming
Grooming patterns of mice have been well-studied and shown to occur in a
predictable pattern. Dopamine levels in the basal ganglia play a role in controlling
this grooming pattern, and therefore, altered dopaminergic neurons and reduced
dopamine production in knockout animals could lead to differences in the number
of completed grooming cycles (Berridge et al., 1987; Taylor et al., 2010; HutterSaunders et al., 2011). Animals were recorded for 10 minutes in their home cage
and the number of complete and incomplete grooming cycles recorded in a
blinded fashion. No significant differences were seen between genotypes in the
mean

number of

complete

grooming cycles

(wild-type:

2.25

±

0.90;

heterozygous: 0.29 ± 0.29; homozygous knockout: 0.89 ± 0.35) or incomplete
grooming cycles (wild-type: 1.5 ± 0.33; heterozygous: 2.9 ± 0.67; homozygous
knockout: 2.9 ± 0.68) (Figure 13). While no significant differences were detected
between any of the genotypes, clear trends were evident that the loss of p19
gene and dopaminergic neurons were associated with fewer complete and
greater interrupted grooming cycles.
DISCUSSION
Extensive data exists that support the hypothesis implicating the immune system
in PD progression as well as in the MPTP-mouse model of PD. Studies from our
own laboratory have shown that antigen specific TH17 cells are especially potent
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in their ability to exacerbate MPTP-induced dopaminergic neuronal lesions within
the nigrostriatal axis (Benner et al., 2004; Benner et al., 2008; Reynolds et al.,
2010). This effect is not seen to such an extent with TH1 cells even though both
are classically considered pro-inflammatory immune cells. However, other cells in
the T cell lineage, regulatory T cells (Tregs), have the ability to mitigate MPTPinduced lesions and significantly reduce dopaminergic cell loss (Reynolds et al.,
2010).
Evidence suggests that inflammatory processes and the CD4+ T cells
responsible for these responses show a degree of plasticity. Therefore in mice
lacking fully functional TH17 cells, other CD4+ T cells may take over the usual
TH17 cell role and carry exacerbation of the inflammatory process. This would
provide an explanation as to why p19 knockout mice afford no obvious
neuroprotection against MPTP-intoxication, even though they lack the ability to
induce TH17 cells. the other explanation is that TH17 cells may not be induced
until the lesion or diseae develops into a chronic state. These findings will help in
the development of therapeutic approaches to treating neuroinflammatory
diseases by shedding light on the complex and multifaceted aspect of the
disease. The balance between pro- and anti-inflammatory cells must be altered
in a way that keeps neuroinflammation to a minimum, but does not deplete the
immune system completely and leave the CNS vulnerable to other pathogenic
entities. Data from p19 knockout mice indicates that monotherapy targeting only
TH17 cells may not reduce neuroinflammation to a level whereby disease
progression

and

neurodegeneration

are

slowed

or

stopped.

However,
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immunomodulatory agents that target multiple immune cells may prove to be
beneficial and should be further investigated.
The physical symptoms associated with PD generally do not appear until
greater than 50% of dopaminergic neurons in the substantia nigra have been
lost. The number of existing dopaminergic neurons in the substantia nigra
compared to the number of neurons needed helps to explain why PD symptoms
do not appear until late in the disease process, and provides an example of
“safeguards” set up in the CNS to maintain normal processes. However below a
certain level, the surviving dopaminergic neurons are thought no longer able to
produce enough dopamine to fully support normal functions. Therefore, we
hypothesized that p19 knockout mice, newly found to have significantly reduced
numbers of dopaminergic neurons in the substantia nigra, would have similar
motor and behavioral deficiencies.
Using multiple motor and behavior tests proven to demonstrate motor
dysfunction in other models of nigrostriatal damage, including the MPTP model,
motor behavior deficits were found to be few in p19 knockout mice. These tests
included forced motor tests (rotarod), normal behavior observations (home cage
monitoring, open field activity testing, syntactic grooming), and fine motor skills
(adhesive dot removal). Previous studies in the MPTP model have been able to
successfully demonstrate motor or behavior deficits with far less severe
substantia nigra neuron and striatal termini loss (Hutter-Saunders et al., 2011;
Bove and Perier, 2012); therefore we are confident that the appropriate tests and
conditions were utilized in this study. Home cage monitoring (HCM), which
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observed animals over the course of 16 days in an undisturbed environment, was
the most wide-ranging and sensitive test carried out, and would have therefore
detected any abnormal behaviors in knockout mice compared to controls. Thus,
unexpected results of finding no significant differences using the HCM system in
any behaviors (movement, locomotion, feeding, drinking) proves that knockout
mice are fully functional and are indistinguishable from wild-type mice in terms of
unforced behavior and movement.
While not specifically validated by this study, we posit that the number of
dopaminergic neurons in p19 knockout mice is significantly reduced from the
time of birth, rather than a gradual decline in neuron numbers as the animal
ages. This points to a role of p19 or IL-23 in the early stages of neuronal
patterning. Taking cues from findings in Pitx3 knockout mice (ak/ak), which also
display significant reductions in substantia nigra dopaminergic neurons number
(Vasudevan et al., 2012), it is possible that dopaminergic neurons in p19
knockout mice are unable to reach their final destination and fully differentiate
into a dopaminergic phenotype. The hypothesis that neuron numbers are
reduced from before birth, would help to explain why p19 knockout mice showed
no significant differences in the behavioral tests performed. As in the ak/ak
mouse model, which show no behavior abnormalities despite significantly
reduced dopaminergic neuron numbers (Vasudevan et al., 2012), p19 knockout
mice are hypothesized to utilize the same compensatory mechanisms to function
in a manner that is indistinguishable from wild-type mice. The data presented
herein is consistent with other reports, showing that preserved motor function is
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associated with residual dopamine and that the behavioral and motor
consequences of decreased dopaminergic neuron number are dependent on
whether neurons are lost pre- or post-natally (Golden et al., 2013). Whereas
substantial lesions to the substantia nigra in adult mice result in significant and
measurable deficits in motor function, mice born with fewer dopaminergic
neurons show no measurable deficits.
The time of lesion development may also play a crucial role on the
behavioral outcome can possibly be explained through multiple mechanisms.
First, additional mechanisms of plasticity may be induced when damage occurs
in developing animals (Golden et al., 2013). Reduced excitation of the indirect
dopamine pathway, through a reduction in glutamatergic excitation or reduction
of GABA release, can help to alleviate PD symptoms (Stephens et al., 2005; Day
et al., 2006; Brotchie and Fitzer-Attas, 2009). Secondly, the decreased level of
dopamine in knockout mice from birth could result in a hypersensitivity of the
neurons in the striatum to dopamine (Hussong, 2014). Alternatively, the number
of dopamine receptors in the striatum could be increased compared to wild-type
mice. As such, even small amounts of dopamine in the area would be able to
sufficiently control motor functions. Third, the intrinsic regulatory property of TH,
i.e., that it can be regulated by dopamine itself, suggests that in the absence of
normal levels of dopamine, the activity of TH can be upregulated resulting in the
increased production of dopamine by remaining neurons (Zigmond et al., 1984).
The use of animal models has led to multiple advances in our
understanding of diseases and how to best treat them. However, it is important to
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understand that all animal models have limitations and may not be a perfect
model to study human diseases. Two common rodent models to study PD use
the neurotoxins MPTP or 6-hydroxy dopamine (6-OHDA); each having their own
advantages and disadvantages. Therefore, new animal models for studying PD
are necessary. Data from these studies could lead to the use of p19 knockout
mice in future studies of neurodegeneration. Due to the inherent characteristics
of p19 knockout mice to present a significant reduction in the number of
dopaminergic neurons and termini in the nigrostriatal pathway, these mice could
be useful for potential methods to increase the levels of striatal dopamine. This
may prove to be advantageous over traditional MPTP or 6-OHDA models
wherein the initial reduction along the nigrostriatal pathway is achieved with
chemical compounds or neurotoxins. The novel finding regarding the neuron
numbers in p19 knockout mice suggests multiple uses for p19 knockout mice
reaching beyond our laboratory.
The results from this study will help to further our understanding of
interactions between the brain and immune system and how these two work in
synergy to establish proper neuronal pattering and connections. Results showing
that mice lacking the distinct p19 subunit of IL-23 have significantly reduced
numbers of dopaminergic neurons in the substantia nigra and striatal density
provides insight into a previously undescribed relationship between IL-23 and
dopaminergic neurodevelopment. Even more importantly however, is the finding
that mice are able to function normally despite their significantly reduced
nigrostriatal pathway. This points to possible compensatory mechanism(s) that
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allow proper neuronal signaling with minimal amounts of dopamine. Using these
findings we can better develop therapeutic strategies for neurodegenerative
diseases during the early stages of disease and help maintain or regain normal
motor function (Hussong, 2014).
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Table 1. p19 knockout and wild-type genotyping primers.
Primer name

Primer sequence 5’ – 3’

Product
size

Common reverse

GCCTGGGCTCACTTTTTCTG

N/A

Wild-type specific (forward)

GCGTGAAGGGAAGGACACC

210 b.p.

Knock-out specific (forward)

AGGGGGAGGATTGGGAAGAC

289 b.p.
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Figure 1. Quantification of TH+ cells in substantia nigra and density of striatal
termini.
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Figure 1. Quantification of TH+ cells and striatal termini. Number of TH+ neurons
in the substantia nigra of naïve wild-type and p19 deficient mice. Naive mice
were terminally anesthetized, transcardially perfused with PBS, fixed with 4%
paraformaldehyde,

and

brains

removed

and

processed

for

immunohistochemistry. Brains were sectioned through the midbrain containing
the substantia nigra and striatum. Substantia nigra sections were immunostained
with sheep anti-tyrosine hydroxylase and FITC-conjugated donkey anti-sheep
IgG. Neuron numbers were quantified by stereological analysis (Stereo
Investigator, MBF Bioscience). Striatal sections were immunostained with sheep
anti-tyrosine hydroxylase and biotinylated goat anti-sheep IgG. Relative striatal
densitometry was quantified using ImageJ. Means ± SEM of total numbers of
surviving neurons or striatal density was determined for 6-8 mice per group and
analyzed by one way ANOVA and Fisher’s LSD post-hoc test with. Each group is
compared to aB6.IL-23 p19 (+/+) and bB6.IL-23 p19 (+/-).
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Figure 2. Neuronal quantification and striatal density in PBS and MPTPintoxicated mice.
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Figure 2. Neuronal quantification and striatal density in PBS and MPTPintoxicated mice. Animals were intoxicated with four injections of PBS or MPTPHCL (18 mg/kg free base). Seven days post-MPTP, mice were terminally
anesthetized, transcardially perfused with PBS, fixed with 4% paraformaldehyde,
and brains removed and processed for immunohistochemistry. (A) Quantification
of surviving TH+ dopaminergic numbers within the midbrain of PBS and MPTPintoxicated B6.Il-23 p19 (+/+) and B6.IL-23 p19 (-/-); (B) Calculation in the
percentage of neuronal loss following MPTP-intoxication in B6.Il-23 p19 (+/+) and
B6.IL-23 p19 (-/-) mice. Neuron numbers were quantified by stereological
analysis (Stereo Investigator, MBF Bioscience) and data presented as means ±
SEM of total numbers of surviving neurons or striatal density was determined for
7-8 mice per group and analyzed by one way ANOVA and Tukey’s post-hoc test.
Each group is compared to aPBS-B6.IL-23 p19 (+/+); bMPTP-B6.IL-23 p19 (+/+);
c

PBS-B6.IL-23 p19 (+/-);

d

PBS-B6.IL-23 p19 (-/-) with p < 0.05 indicating

statistical significance.
(C) Relative TH striatal density of PBS and MPTP-intoxicated mice (B6.IL-23 p19
(+/+); B6.IL-23 p19 (+/-); and B6.IL-23 p19 (-/-). (D) Calculation of percent
reduction in striatal density following MPTP compared to PBS control. Striatal
densitometry was quantified using ImageJ. Means ± SEM of total numbers of
surviving neurons or striatal density was determined for 7-8 mice per group and
analyzed by one way ANOVA and Fisher’s LSD post-hoc test. Each group is
compared to aPBS-B6.IL-23 p19 (+/+) and bMPTP-B6.IL-23 p19 (+/+).cPBS-
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B6.IL-23 p19 (+/-); dMPTP-B6.IL-23 p19 (+/-); ePBS-B6.IL-23 p19 (-/-) with p <
0.05 indicating statistical significance.
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Figure 3 Categorization of behaviors in a 24-hour period. Following 5 days of
acclimation, mice were placed singly in cages to monitor precise temporal and
spatial measurement of mouse home cage behavior (including movement,
feeding, and drinking). Behaviors were monitored continuously for 16 days
followed by robust statistical evaluation. (A) Wild-type p19 +/+; (B) heterozygous
p19 knockout; and (C) homozygous knockout p19 mice underwent 24-hour
monitoring. Behaviors were analyzed and categorized as inactive (black); active
(not forward locomotion, red); forward locomotion (green); time spent at water
(blue); time spent at food (orange). N = 10 – 12 animals per group.
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Figure 4. Categorization of behaviors in a 12-hour light and dark cycles.
Behaviors during (A, C, D) 12-hour dark cycle and (B, D, F) light cycles were
monitored and analyzed for (A, B) wild-type p19 (+/+); (C, D) heterozygous p19
knockout mice; and (E, F) homozygous knockout mice. Behaviors were
categorized as the following: inactive (black); active (not forward locomotion,
red); forward locomotion (green); time spent at water (blue); time spent at food
(orange) and percentage of each 12 hours cycle spend in that behavior
calculated. N = 10 – 12 animals per group
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Figure 5. Differences in locomotion time between strains of mice between 12hour light and dark cycles. Comparisons between (A) B6.IL-23 p19 (+/+) (green)
and B6.IL-23 p19 (+/-) (red); (B) B6.IL-23 p19 (+/+) (green) and B6.IL-23 p19 (-/-)
(red); and (C) B6.IL-23 p19 (-/-) (green) and B6.IL-23 p19 (+/-) (red). Data
expressed as means ± SEM for n = 10 – 12 animals per group with percent
locomotion (Y-axis) plotted against hour (X-axis) with hours 6 – 12 and 24 – 30
representing the light cycle and 12 – 24 representing dark cycle. *p ≤ 0.05
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Figure 6 (continued on pages 45 and 46)…
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Figure 6. Analysis of movements observed during open field activity testing.
Analysis of general activity and natural behaviors were assessed using an
automated open field activity system (Tru Scan 2.0, Coulbourn Instruments,
Whitehall, PA, USA) to measure different types of movement recorded over a 20min observation period for each animal. Types of movement, classified as X-Y
coordinate changes in the floor plane, were measured and broken down into the
following categories: (A) total floor plane move time; (B) total floor plane rest
time; (C) total floor plane movements; (D) total floor plane distance travelled; (E)
mean floor plane velocity; (F) average distance traveled per movement; (G) total
number of jumps; (H) mean number counter-clockwise turns; and (I) mean
number clockwise turns. Means ± SEM were determined for 10 – 12 animals per
group and analyzed by one way ANOVA and Tukey’s post-hoc test.
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Figure 7. Analysis of stereotypic movements observed during open field activity
testing.
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Figure 7. Analysis of stereotypic movements observed during open field activity
testing. Stereotypic movement is described as repetitive behaviors that do not
contribute to large location changes progressively further from the starting point.
Stereotypic movements are further defined as type-1 (plus or minus 0.999 bean
spaces) and type-2 (plus or minus 1.499 beam spaces). Movement is considered
stereotypic when movement is made in the X-Y dimensions and back to the
original starting point that do not exceed 2 seconds apart. Three such
movements must be made before a stereotypy episode starts. When the subject
moves outside of the region of qualified coordinates, or fails to move within them
for 2 seconds, the stereotypy episode breaks. OFAT data was categorized as (A)
total number stereotypic-1 movements; (B) total number stereotypic-1 episodes;
(C) total stereotypic-1 time; (D) total number stereotypic-2 moves; (E) total
number stereotypic-2 episodes; (F) total stereotypic-2 time. Means ± SEM were
determined for 10 – 12 animals per group and analyzed by one way ANOVA and
Tukey’s post-hoc test.
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Figure 8. Analysis of zone time during open field activity testing.
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Figure 8. Analysis of zone time observed during open field activity testing. Time
spent in distinct areas of the open field arena was observed and recorded,
specifically the time that was spent in the margin of the arena (within a 2.5-beam
margin of the walls) and center of the arena (region that is more than 2.5-beam
spaces away from the arena walls) and the distance that was covered in these
two areas of the arena. (A) Total distance travelled in the area margin; (B) total
time spent in arena margins; (C) total center distance travelled; (D) total time
spend in area center); (E) total number of area center entries; (F) percentage of
time spent in arena center; (G) percentage of time spent in arena margins. Data
expressed as means ± SEM were determined for 10 – 12 animals per group and
analyzed by one way ANOVA and Tukey’s post-hoc test.
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Figure 9. Analysis of vertical plane movements observed during open field
activity testing.
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Figure 9. Analysis of vertical plane movements observed during open field
activity testing. In addition to movements along the floor plane, movements in the
vertical plane are also observed and measured. These include (A) the total
number of vertical plane entries; (B) total number vertical plan movements; (C)
total time spent in the vertical plane; and (D) the total distance traveled in the
vertical plane. Means ± SEM were determined for 10 – 12 animals per group and
analyzed by one way ANOVA and Tukey’s post-hoc test.
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Figure 10. Pilot study of latency to fall in wild-type and p19 knockout mice. .
Preliminary rotarod speed testing. Animals were habituated to the rotarod using
the accelerating setting (6 - 16 rpm) over the course of 5 minutes. Mice were
habituated 4 times a day for 3 consecutive days. On day 4, mice were tested for
their ability to remain on the rotarod at a constant speed. Animals were 6, 8, 10,
12, 14, and 16 rpm. Three trials were performed at each of the speed and latency
to fall recorded for each animal with a maximum run time of 90 seconds.
Averages for the 3 runs at each speed were calculated. Results expressed as
average latency to fall ± SEM for n = 7 – 8 animals.
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Figure 11. Evaluation of forced behavior using two rotarod methods.
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Figure 11. Evaluation of forced behavior using two rotarod methods. Animals
were habituated on an accelerating rotarod (6 – 16 rpm) for 5 minutes x 3 trials
on 4 consecutive days. Following habituation, animals were placed on the
rotarod at a constant speed of (A) 14 or (B) 16 rpm for a maximum of 90 seconds
x 3 trials. Latency to fall was recorded and trials were averaged. (C) For the
accelerating rotarod test, animals were tested for a maximum of 5 minutes on a
rotarod accelerating from 0 – 18 rpm for 3 trials. Latency to fall was recorded and
trials averaged. Means ± SEM were determined for 10 – 12 animals per group
and analyzed by one way ANOVA and Tukey’s post-hoc test.
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Figure 12. Evaluation of fine motor skill using adhesive removal test
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Figure 12. Evaluation of fine motor skills using adhesive removal test. Analysis of
fine motor skills was performed by evaluating latency for animals to remove a
small adhesive dot from the tip of their nose. Adhesive dots were carefully placed
on the nose of the animals and the animal was placed in a clean cage. Latency
to successfully remove the dot was timed for three separate trials. Means ± SEM
for 7 animals per group were calculated and analyzed by one way ANOVA and
Tukeys post-hoc test. (A) 3-trial average latency to remove sticker. (B) Latency to
remove sticker for each of the 3 trials. Means ± SEM were determined for 10 –
12 animals per group and analyzed by one way ANOVA and Tukey’s post-hoc
test.
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Figure 13. Syntactic grooming in wild-type and p19 knockout mice. Each mouse
was videotaped by an observer for 10 minutes in their home cage. Numbers of
complete and incomplete grooming cycles were counted in a blinded fashion.
Data presented as means ± SEM were determined for n = 7 - 8 animals per
group and analyzed by one way ANOVA and Tukey’s post-hoc test.
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CHAPTER FOUR
TARGETING CELLULAR MIGRATION AS A NOVEL TREATMENT FOR
PARKINSON’S DISEASE
ABSTRCT
Infiltration of CD4+ T cells in the substantia nigra has been described in post
mortem tissues from Parkinson’s disease (PD) patients and these findings were
later replicated in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
mouse model of PD. While halting infiltration of CD4+ T cells has proven
beneficial in other neurodegenerative disease, it has yet to be adequately tested
or utilized in PD and PD models. Using therapies targeting CD4+ T cell adhesion
molecules we aimed to block the infiltration of antigen-specific T cells into the
brain of MPTP-intoxicated mice and elicit dopaminergic neuroprotection. We
conclude that monotherapy did not elicit significant neuroprotection given at the
dose and times chosen.
INTRODUCTION
The brain was once thought to be an immune privileged site and not subject to
the same immune surveillance as in other areas of the body. This theory was first
disproven using the experimental autoimmune encephalomyelitis (EAE) model of
multiple

sclerosis

(MS)

wherein

injections

of

radioactively

labeled

encephaliotgenic T cell blasts were found within the brain parenchyma after 6
hours (Engelhardt, 2010). Since then studies have worked to understand to
understand

how

the

immune

system

can

play

a

role

in

several
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neurodegenerative diseases including MS, amyotrophic lateral sclerosis (ALS),
Alzheimer’s disease (AD) and PD. Data from post-mortem studies provided the
first evidence for neuroinflammatory processes in PD. In these studies both
CD4+ and CD8+ T cells were found in close proximity to dopaminergic neurons
in PD brains as well as MPTP-intoxicated mice at levels exceeding 10-fold those
found in brains of healthy controls (Speciale et al., 2007; Brochard et al., 2009;
Saunders et al., 2012).
In order for peripheral immune cells to remain in the brain they must be
antigen specific and encounter their antigen of interest. Within the substantia
nigra of PD patients, nitration of α-syn (N-α-syn) leads to accumulation within
Lewy bodies (McCormack et al., 2012) . Upon examination of the microglial
phenotype induced by nitrated and aggregated α-syn, it was shown that the
modified protein induces a neurotoxic inflammatory phenotype that accelerates
the death of dopaminergic neurons (Bassotti et al., 2000; Zhang et al., 2005;
Zhou et al., 2005; Thomas et al., 2007; Reynolds et al., 2008). This suggests
aggregated α-syn or N-α-syn, when released from dying neurons, may stimulate
resident brain microglia resulting in their sustained activation (Benner et al.,
2008). This theory was confirmed in vitro showing N-α-syn can activate microglia
causing them to secrete inflammatory proteins (Reynolds et al., 2009).
Compounding evidence specifically examining effects of N-α-syn in mouse
models of PD have shown the presence of N-α-syn in draining cervical lymph
nodes that in turn “educate” peripheral leukocytes. Furthering the interest in N-αsyn and its effects on neurodegeneration came from findings that showed
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adoptive transfer of N-α-syn specific T cells exacerbated MPTP-induced
dopaminergic cell death (Benner et al., 2008). These studies show that N-α-syn
specific T cells accelerate neuronal death by activating microglia and promoting
the release of neurotoxic cytokines. Taken together, these studies make a strong
case implicating N-α-syn as a contributing factor to neuroinflammation in PD.
While the brain is not completely devoid of immune cells, entry of
peripheral immune cells into the brain is tightly controlled and regulated.
Expression of correct cell adhesion molecules (CAMs) on peripheral immune
cells and brain endothelial cells is absolutely essential for extravasation from
circulation into the brain (Figure 1). An additional level of regulation is provided
by the unique profile of CAMs upregulated in response to different antigens and
disease states. For example, the ability to transfer EAE using myelin basic
protein (MBP) T cells was dependent on glycosylation of PSGL-1, the binding
ligand for the CAM P-selectin (Deshpande et al., 2006). In human MS patients,
the number of circulating CD4+ T cells expressing high levels of PSGL-1 was
shown to be increased, indicating these cells have an enhanced ability to interact
with brain endothelial cells (Bahbouhi et al., 2009; Engelhardt, 2010). Therefore,
therapies that are aimed at modifying cellular migration and targeting specific
CAMs may prove to be very beneficial in neurodegenerative diseases including
PD.
Research looking at infiltration of circulating lymphocytes across ECs has
proven that the expression of CAMs and cell adhesion ligands changes following
antigen activation and/or cytokine release. These changes typically precede
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disease initiation and work to either increase or decrease the binding affinity of
circulating lymphocytes to target endothelium. Therefore, release of N-α-syn
could be the initiating factor that leads to changes in CAM expression on
peripheral immune cells and leads to their enhanced ability to cross the BBB and
exacerbate dopaminergic neurodegeneration.
Unlike MS, the CAM(s) and CAM ligands involved in T cell infiltration in
PD and PD models have not yet been identified. Studies have shown that the T
cell subset of major interest in the MPTP-model are CD4+ TH17 cells (Benner et
al., 2004; Reynolds et al., 2007; Reynolds et al., 2009; Reynolds et al., 2010;
Mosley et al., 2012). The more prominent ability of TH17 cells to exacerbate
neurodegeneration in MPTP-models may, in part, be explained by the CAM
expression on these cells. A recent study identified melanoma cell adhesion
molecule [MCAM (CD146)] expressed on TH17 cells and its ligand, laminin 411,
expressed within the vascular endothelial basement membrane (Flanagan et al.,
2012), which does not appear to be expressed by TH1 cells. Anti-MCAM
antibodies inhibited the in vitro interaction of MCAM and laminin 411, and
administration of anti-MCAM antibodies to recipient mice prior to adoptive
transfer of encephalitogenic TH17 cells reduced TH17 cell infiltration and
ameliorated disease in EAE. These data suggested that MCAM expression, if
highly restricted to TH17 cells and this may provide insight into the role of the
adaptive immune system in PD progression as well as other TH17-driven
immune reactions. Thus, the goal of the current study was to evaluate whether
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blocking MCAM could provide a level of protection against MPTP and adoptive
transfer of N-α-syn specific T cells.
MATERIALS AND METHODS
Animals
Adult male C57BL/6J and B6.Cg-Tg (CAG-DsRed.MST) (DsRed) mice were
purchased from Jackson Laboratories (Bar Harbor, ME). Mice 6 – 10 weeks of
age were housed and maintained on a 12:12 hr light/dark cycle with ad libitum
access to food and water and were randomly assigned to treatment groups. The
study was conducted in accordance with the animal care guidelines issued by the
National Institutes of Health and approved by the Institutional Animal Care and
Use Committee of the University of Nebraska Medical Center.
N-4ySyn immunization
DsRed mice that possess red fluorescent protein (RFP) expression under control
of the chicken β-actin promoter were used as donor mice. DsRed mice were
immunized with N-4ySyn (10 µg) emulsified Freund’s complete adjuvant (CFA)
containing 1mg/mL Mycobacterium tuberculosis. Immunized animals were
boosted 2 weeks later with N-4ySyn emulsified in Freund’s incomplete adjuvant
(IFA). 5 days after boost, splenocytes were isolated and resuspended as a single
cell suspension in Hank’s balanced salt solution (HBSS) to be used in adoptive
transfer.
Acute MPTP intoxication and adoptive transfer
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Mice received 4 subcutaneous (s.c.) injections of MPTP-HCL (18 mg/kg free
base in a volume of 10 ml/kg) or PBS (10 mL/kg) every 2 hours for 4 doses.
Twelve hours after the last MPTP dose, 30 x 106 donor cells from N-4ySyn
immunized animals were adoptively transferred via tail vein injection. MPTP
handling and safety measures were in accordance with the National Institutes of
Health, the University of Nebraska Medical Center, and prior published
guidelines (Przedborski et al., 2001).
Blocking T cell infiltration
Studies done by our lab have previously shown that adoptive transfer of TH1 or
TH17-polarized T cells can exacerbate MPTP-induced neuronal lesion.
Therefore, blockage of T cell infiltration into the CNS could lead to a level of
neuroprotection or reduction in MPTP-induced neuroinflammation. Using the
sphingosine-1-phosphage inhibitor, fingolimod, prevents peripheral immune cells
from exiting secondary lymph organs, effectively reducing the number of
circulating immune cells. Therefore, we chose to evaluate the efficacy of
fingolimod to prevent or reduce T cell infiltration into the midbrain of MPTPintoxicated mice and quantify surviving dopaminergic neurons. Twenty-four hours
prior to the first MPTP injection and adoptive transfer, groups of animals were
treated with either 1 mg/kg fingolimod (MPTP/fing/AT) or 10 mg/kg anti-MCAM
antibody (MPTP/anti-MCAM/AT). Daily injections with anti-MCAM or fingolimod
continued until the end of the study. To serve as controls, one group of MPTPintoxicated

mice

received

10

mg/kg

rat

isotype

control

antibody

(MPTP/Isotype/AT) and one group received no additional treatment (MPTP/AT).
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Immunohistochemistry and stereological analysis
7 days post-MPTP or PBS administration, mice were terminally anesthetized,
transcardially perfused with PBS followed by 4% paraformaldehyde (PFA) in
PBS. Brains were harvested and post fixed in PFA overnight, cryoprotected in
30% sucrose in PBS for 48 hours, snap frozen in 2-methylbutane, embedded in
OCT compound, and 30 µm sections collected through the midbrain. Tissue
sections were processed free-floating in 48-well plates. Tissues were
immunostained with rabbit anti-TH (1:2000 CalBiochem/EMD Millipore, Billerica,
MA) and HRP-conjugated goat anti-rabbit IgG (1:400, Vector laboratories,
Burlingame, CA), and visualized with diaminobenzidine (DAB). Tissues were
mounted on slides and counterstained for Nissl substance using thionin. Neurons
expressing TH and nissl (TH+Nissl+) were considered dopaminergic and
quantified by stereological analysis (StereoInvestigator, MBF Bioscience,
Williston, VT). Additional sets of tissues were mounted on slides and
coverslipped with Vectashield mounting medium for fluorescent tissues (Vector
laboratories, Burlingame, CA) to be evaluated for the expression of infiltrating
cells from DsRed donor mice.
Stereological analysis of neurons in the substantia nigra was performed
using optical fractionator module stereology software (StereoInvestigator, MBF
Bioscience, Williston, VT) interfaced with a Nikon Eclipse 90i fluorescence
microscope equipped with a bright camera. Using simple random sampling
(SRS) image series workflow, the region of interest (ROI) containing the
substantia nigra was outlined for one hemisphere of each tissue section at a 4x
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magnification. Images of each ROI taken using a 40x were taken at random,
equally spaced intervals. Workflow parameters were defined to count
approximately 20% of the total neuron population in the substantia nigra
(counting frame size 120 x 100 um, 245 x 240 um grid size) and Gunderson
coefficient of error (C.E. m=1) was ≤ 0.01. Estimated population size was
generate by the software and multiplied by 2 to get an overall population
estimation for both hemispheres of the brain.
Flow cytometric analysis
Prior to perfusion, a small volume of whole blood was collected from mice (PBS,
MPTP/AT, and MPTP/Fing/AT) and held in EDTA coated tubes. Red blood cells
(RBCs) were lysed and cells incubated with FITC-conjugated anti-CD4+
antibodies. Cells were then fixed and submitted to the University of Nebraska
Center flow cytometric core facility. Using forward scatter (FSC) and side scatter
(SSC) lymphocyte populations were first gated from the total cell population.
Using the quadrant gate CD4+ and DsRed+ cells were isolated to identify single
and double positive cells. Percentages of CD4+, DsRed+, and CD4+/DsRed+
cells was calculated based on the parental population.
Statistical analysis
All tests were performed using Statistica (StatSoft, Inc. Tulsa, OK) and data
expressed as mean ± standard error of the mean (SEM). Statistical significance
was evaluated by one-way ANOVA followed by post-hoc comparisons using
Fisher’s LSD.

156

RESULTS
Blocking MCAM provides partial neuroprotection against N-4ySyn-specific
splenocytes following MPTP
TH17 cells have been shown to play a role in exacerbating dopaminergic
neurodegeneration. Therefore specific targeting of TH17 using an antibody
specific to MCAM was utilized in the MPTP/adoptive transfer model of PD.
Splenocytes isolated from donor mice immunized with the antigen N-4ySyn were
adoptively transferred into recipient mice 12 hours after the last MPTP dose. To
determine the effects blocking TH17 cell infiltration would have we administered
an antibody specific for MCAM to beginning 24-hours pre-MPTP and continuing
until day 7 post-MPTP, wherein the number of surviving neurons were
quantified.. Additionally, a group of animals were administered fingolimod, a
sphingosine-1 phosphate inhibitor known to sequester T cells within secondary
lymphoid organs (Mehling et al., 2008; Mehling et al., 2010; Slavin and Zamvil,
2010; Sheridan and Dev, 2014). Mice that received anti-MCAM therapy showed
a slight increase in the number of surviving dopaminergic neurons compared to
those mice treated with MPTP/AT or MPTP/Isotype/AT (Figure 2).
Fingolimod did not decrease number of CD4+ cells in circulation
Fingolimod is a sphingosine-1 phosphate inhibitor that is an approved drug for
the treatment of MS. By sequestering lymphocytes in lymph nodes, the cells are
unable to circulate and infiltrate the brain where they would elicit a response. By
administering fingolimod to MPTP-intoxicated animals that received donor cells
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from N-4ySyn immunized animals, we hypothesized that the MPTP-intoxicated
animals would be protected from MPTP-induced neurodegeneration in a similar
manner to mice receiving anti-MCAM therapy. However, we did not show any
neuroprotection in the fingolimod group, but rather we saw increased
neurodegeneration compared to mice who received anti-MCAM (Figure 2).
Whole blood was collected from PBS and MPTP-intoxicated animals who
received adoptively transferred cells and lymphocytes stained with anti-CD4
antibodies. Adoptively transferred cells were isolated from N-4ySyn-immunized
DsRed donor mice so that donor antigen-specific cells could be easily detected in
the circulation and CNS of MPTP-intoxicated mice. Using forward and side
scatter flow cytometric data, CD4+ lymphocytes populations were gated based
upon parent lymphocyte populations (Figure 3A) and DsRed expression (Figure
3B). CD4+DsRed+ cells were calculated based upon the parental lymphocyte
population (Figure 3C). Unexpectedly, an increased percent of CD4+ cells were
found in circulation in fingolimod treated animals compared to PBS controls,
however it did not reach statistical significance. The percentage of DsRed+
(donor cells) in circulation was marginally decreased in fingolimod treated mice
compared to controls, but not to the level of statistical significance (Figure 3B).
Similarly, slight differences were seen in the percentage CD4+DsRed+ in
animals that received fingolimod compared to those who did not (Figure 3C).
Donor cells were not detectable in the substantia nigra of MPTP-intoxicated
recipient mice
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In this study we chose to us DsRed mice as the source of adoptively transferred
N-4ySyn splenocytes. DsRed mice expressed RFP under control of the β-actin
promoter so all their cells express RFP. By using these mice we would be able to
identify and quantitate infiltrating splenocytes in the substantia nigra of MPTPintoxicated mice. Following processing of tissues and mounting on slides, tissues
were analyzed under fluorescent microscopy. In this study we were unable to
identify any cells within the substantia nigra that expressed RFP.
DISCUSSION
The lack of significant neuroprotection afforded with anti-MCAM therapy in this
study could be due to a number of factors. First, administration of the MCAM
antibody may have been needed at times other than 1 hour prior to adoptive
transfer or the antibody may have needed to be given at a greater concentration
to effectively inhibit MCAM binding. Secondly, a relatively low percentage of
adoptively transferred cells expressed MCAM prior to adoptive transfer and this
would have reduced, even further, the chance of anti-MCAM antibodies finding
its target within the entire circulation. Third, because we did not activate
splenocytes from donor mice prior to AT, the cells may not have upregulated
MCAM expression as they would have if stimulated with N-4ySyn or anti-CD3.
Lastly, T cells extravasation from the circulation is not dependent on only one
CAM but rather a multiple CAMs that act in redundant and synergistic
mechanisms. This leads to the possibility that MCAM may be playing a minor role
in the infiltration of TH17 cells following MPTP lesion or, alternatively, other
subsets of CAMs may be compensating for the blockage of MCAM and allowing
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for CD4+ T cells to enter the. Interestingly, animals that received fingolimod
treatment following MPTP and AT had significantly fewer surviving dopaminergic
neurons suggesting the sequestration of all T cells in lymphoid organs is
particularly detrimental. This explanation is in agreement with other findings that
show CD4+ regulatory T cells provide a level of protection against MPTP-lesion
and blocking all CD4+ T cells is a therapeutic approach that should be avoided
but rather a variety of CAMs should be administered to block only the CAMs that
play a large role in cell extravasation.
Fingolimod is an approved drug for the treatment of relapsing/remitting MS
and works by preventing lymphocytes from leaving the lymph nodes and
returning to circulation. We hypothesized that administering fingolimod in the
MPTP-mouse model of PD would work in much the same way and sequester
lymphocytes in the lymph nodes, thus reducing the number of lymphocytes in
circulation. Administration of fingolimod at 1 mg/mL staring 1 day prior to MPTPintoxication and continuing until day 7 did not result in reduced number of
circulating lymph nodes as measured by flow cytometric analysis. Fingolimod has
been proven to sequester T cells in secondary lymph organs, effectively reducing
the number of T cells in circulation. In the study discussed here, we were unable
to validate these results in the MPTP mouse model of PD. We expected that in
MPTP-intoxicated mice that received cells from donor mice, there were be a
reduced number of T cells in the blood of mice that also received fingolimod to
those that did not. These unexpected results could be a result of inappropriate
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fingolimod dosage or time of administration or a result of the collection process
used when obtaining a sample of blood from the animals.
The lack of red donor cells within the substantia nigra of MPTP/AT control
mice does not in itself prove cells never crossed the BBB and infiltrated into the
substantia nigra but rather can be explained by several mechanisms. First,
MPTP induces peak neuroinflammation and rate of neuronal death by 48 hours,
both of which are typically resolved by 4 days post-treatment (Jackson-Lewis et
al., 1995; Kurkowska-Jastrzebska et al., 1999; Jackson-Lewis and Przedborski,
2007). Therefore at 7 days post-MPTP, when the tissues were harvested, donor
CD4+ T cells that infiltrated into the substantia nigra could have migrated back
out of the substantia nigra or undergone cell death. Secondly, the number of cells
adoptively transferred, 30 x 10^6, could have been too low for a large enough
number of cells to successfully cross the BBB and be visible with the microscopy
method utilized in our study. Lastly, the stability and intensity of RFP on CD4+ T
cells was not specifically addressed in this study and it is plausible that RFP
expression was lost or significantly reduced so as these cells were no longer
distinguishable by the presence of RFP.
In conclusion, we demonstrated that a dose of 10 mg/kg of anti-MCAM
therapy alone is not sufficient to elicit neuroprotection in the MPTP-mouse model.
While our results were not as expected, it does not rule out that a combination
therapy that includes anti-MCAM as well as other CAM blocking agents would
not be protective. The tests described herein should provide a foundation for
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which additional studies could be performed aimed at blocking T cell entry to the
substantia nigra and provide a level of neuroprotection to dopaminergic neurons.
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Figure1. Migration of activated T cells into brain. Peripherally, naïve T cells (N)
encounter APC that present peptides from aberrant, misfolded, or aggregated
proteins associated with neuroinflammatory processes. Upon presentation of
antigen and delivery of appropriate co-stimulatory signals by APC, naïve T cells
recognizing the antigen/MHC complex via the TCR become activated (A) leading
to upregulation of CAMs on the T cell surface. These receptors and ligands
include, but are not limited to, integrins, MCAM, and PSGL-1. Similarly, at sites of
neuronal injury and neuroinflammation, danger signals, pro-inflammatory
cytokines, and chemokines induce upregulation of endothelial associated CAMs
on the basolateral side of the blood brain barrier. Following upregulation of
CAMs, activated T cells (such as pro-inflammatory, anti-inflammatory or
regulatory T cells) enter the vasculature and begin the process of extravasation
via either a trans- or para-cellular route. This migratory process occurs in a step-
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wise manner beginning with T cells loosely tethering to endothelial cells via the
binding of T cell ligands to selectins, such as E-selectin and other CAMs, such as
VCAM, ICAM, and laminin 411 on the luminal side of the endothelial cells. Loose
tethering allows the cell to roll along the luminal side of the endothelium and
interact with CAMs, pulling it closer to the endothelial cell layer to eventual
capture. Upon clustering of receptors and ligands on T cell and endothelial cell
surfaces, the T cell begins “crawling” across the endothelial surface until
reaching an endothelial cell junction, which signals the initiation of extravasation.
Transmigration proceeds, via a chemotactic gradient allowing antigen-specific T
cells entrance to the brain. Once in the parenchyma, activated T cells recognize
antigen presented by MHC, initiating the efferent response program of the T cells
to deliver either effector or regulatory function that supports the respective
neurodegenerative or neuroprotective outcome.
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Figure 2. Blocking MCAM following N-4YSyn-specific splenocyte transfers elicits
partial neuroprotection
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Figure 2. Blocking MCAM following N-4YSyn-specific splenocyte transfers elicits
partial neuroprotection. N-4YSyn-specific Teffs were adoptively transferred into
MPTP-intoxicated mice. Appropriate controls included MPTP-only mice, MPTP +
adoptive transfer, MPTP + adoptive transfer + isotype control. Antibody and
fingolimod treatments began the day before adoptive transfer and continued until
the end of study. One group was treated with only PBS (PBS), and served as
total neuron control. Brains were sectioned through the midbrain, immunostained
with rabbit anti-TH and HRP-conjugated goat anti rabbit IgG, and visualized with
DAB. Total numbers of surviving dopaminergic neurons (TH+) in the SN were
quantified by stereological analysis (Stereo Investigator, MBF Bioscience).
Means ± SEMs of total numbers of surviving dopaminergic neurons were
determined from 5–8 mice per treatment group and were compared by one way
ANOVA and Fisher’s LSD post-hoc test.
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Figure 3. Flow cytometric analysis of blood from animals with and without
fingolimod treatment.
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Figure 3 Flow cytometric analysis of blood from animals with and without
fingolimod treatment. Seven days post-MPTP, blood samples were collect from
mice who received adoptive transfer of DsRed N-4ySyn specific splenocytes with
and without fingolimod or anti-MCAM antibodies as well as no-treatment controls.
Red blood cells were lysed with ACK lysis buffer and remaining cells were
stained with FITC-conjugated anti-CD4+ antibodies. Single cell suspensions
were submitted to the University of Nebraska Medical Center flow cytometric
core facility for expression of DsRed and FITC. Flow cytometric data was first
gated on the parental lymphocyte population based on forward and side scatter.
The parental population was then gated on (A) FITC (CD4+) and (B) DsRed (N4ySyn adoptively transferred) and percentages of CD4+DsRed+ calculated (C).
Values represented as mean ± SEM for n = 4 mice/group.

168

CONCLUSIONS

From the data presented above, it is obvious that many safeguards are in place
to protect and maintain normal neuronal signaling. This includes the possession
of an excess number of dopaminergic neurons which allow maintenance of
normal motor and behavior functions in the event that a significant number of
dopaminergic neurons are lost. Secondly, a short time after ablation of
dopaminergic

neurons,

surviving

non-dopaminergic

neurons

undergo

a

phenotypic shift which is hypothesized to compensate for the loss of neurons and
allow normal levels of dopamine signaling. Third, from a decreased number of
dopaminergic neurons, surviving neurons can possibly express double the
number of termini as a normal neuron, presumably to preserve adequate
signaling in the striatum.
Unlike GABAergic neurons in other areas of the CNS (Achim et al., 2012;
Achim et al., 2014) molecular cues that midbrain GABAergic neurons rely on are
poorly understood and described. This extends to their migration patterns and
temporal appearance, as well as transcriptional regulation of these processes
(Achim et al., 2012). Throughout the CNS, dopaminergic neurons are known to
have a direct effect on GABAergic neurons; negatively regulating TH expression
by GABAergic neurons and positively regulating GABAergic neuron migration
and establishment. As shown in chapter 2, these neurons, previously believed to
represent distinct and non-overlapping populations, exhibit some plasticity upon
injury with MPTP. This opens new possibilities for PD therapy. For example, as
an alternative to restoring dopamine levels using dopamine replacement therapy
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with drugs such as L-DOPA, other strategies could instead target GABAergic
neurons in the vicinity to induce TH expression and synthesize dopamine. These
neurons would then comprise a novel population in the adult midbrain; namely
functional TH+GAD67+ neurons. Determining the conditions and factors
necessary to trigger phenotypic and/or functional changes in GABAergic neurons
would greatly aid in the development of novel therapies for PD.
An increase in phosphorylated serine residues within the regulatory
domain of TH was demonstrated in this study and has been well described by
others. The lingering question is whether the increased phosphorylated Ser31 is
on TH expressed on the surviving dopaminergic neurons or if it is a consequence
of TH expression in the newly described TH+GAD67+ neurons. If the latter, then
that suggests an additional mechanism by which dopamine synthesis could be
increased

in

an

otherwise

dopamine-depleted

environment.

Because

phosphorylation controls both the expression and activity of TH, it is plausible
that TH produced by both the dopaminergic and GABAergic neurons is being
phosphorylated to provide the best opportunity to increase dopamine synthesis.
In addition to the TH expression in neurons, cytokines involved in
neuroinflammation have been proven to play a role in the migration,
differentiation, and survival of neurons (Whitney et al., 2009; Kim et al., 2015).
The severity and duration of neuroinflammation, as well as the profile of
inflammatory molecules involved in neuroinflammation has a profound effect on
the neurogenic or neurodestructive outcome (Whitney et al., 2009). Extensive
studies have shown that inflammation and cytokines affect neurogenesis in
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neurodegenerative diseases in a positive and negative manner (Arnett et al.,
2001; Dybedal et al., 2001; Ben-Hur et al., 2003; Ming and Song, 2005; Iosif et
al., 2006; Whitney et al., 2009; Keohane et al., 2010; Kim et al., 2015). However,
current literature does not adequately address the role that IL-23 or TH17associated cytokines play in dopaminergic neurogenesis, survival, or migration.
Data presented herein in p19 knockout mice, suggests that IL-23 plays a role in
the establishment of normal numbers of dopaminergic neurons in the substantia
nigra, but whether that role lies in neurogenic, migration, integration, or survival
processes remains enigmatic. One possible mechanism explaining the
significantly reduced number of dopaminergic neurons in p19 knockout mice
draws on findings that show cytokines play a role in the expression of CAMs on
cellular surfaces. CAMs play an important role in neuronal development, aiding in
migration from sites of neurogenesis to their final target location as well as
ensuring permanent residence in the area. In mice lacking p19 and IL-23, the
expression of adhesion molecules on dopaminergic neurons is plausibly
insufficient to allow integration into the midbrain due to inadequate cytokine
levels. Neurons without the proper expression pattern of CAMs on their surface
fail to take permanent residence in the substantia nigra and innervate into the
striatum and signaling along the IL-23/IL-17 axis has been shown to regulate
migration of cells (Kawano et al., 1995; Blum, 1998; Mehler and Kessler, 1998).
In contrast to homozygous p19-/- knockout mice, heterozygous p19+/mice have normal densities of dopaminergic termini within the striatum. The
normal striatal density, despite the significant reduction in neuronal bodies within
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the substantia nigra, suggests that each dopaminergic neuron in the substantia
nigra possesses roughly double the number of termini that innervate into the
striatum. I posit that alterations in cytokine profiles between heterozygous and
homozygous knockout mice are, in part, responsible for this finding.
Heterozygous mice presumably have some level of functional TH17 cells and
therefore are capable of secreting TH17 associated cytokines. If cytokine levels
are responsible for the development or migration of neurons versus sprouting of
neurons, higher amounts of cytokines present in heterozygous knockout mice
may result in the establishment of proper striatal innervation regardless of the
number of cell bodies present (Mehler and Kessler, 1998). Homozygous
knockout mice lacking all TH17 cells also lack the cytokine signals needed for
neuronal establishment of the substantia nigra and innervation into the striatum.
Cell replacement therapy is an area of research that is gaining popularity
as a method to restore both the numbers of dopaminergic neurons in the
substantia nigra as well as the amount of dopamine available in the striatum
without the use of pharmaceuticals. The first steps toward clinical utilization of
cell replacement therapy have been taken using transplantation of human fetal
midbrain tissue. These studies have provided proof of concept for cell
replacement therapy being well-tolerated in PD (Lindvall and Bjorklund, 2004;
Drouin-Ouellet and Barker, 2012; Thomsen et al., 2014), and human midbrain
dopaminergic neurons have been successfully generated from multiple cell types
in vitro including by lineage reprogramming (Caiazzo et al., 2011; Kim et al.,
2011; Pfisterer et al., 2011; Arenas et al., 2015). However, major impediments
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with neuronal replacement strategies are the non-autonomous development of
Lewy bodies in transplanted neurons and the susceptibility and eventual loss of
the Lewy body-containing neurons. Another interesting strategy could achieve
successful reprogramming of surviving cells in the substantia nigra which would
lead to monumental advances in the treatment of PD. In order for this to occur, a
full picture of the essential mechanisms that control dopaminergic neuron
development is needed to enable the application to generation of functional
dopaminergic neurons from other neuronal lineages, such as those along the THinducible GABAergic lineage. In order for neuron reprogramming to be
efficacious in PD treatment, newly formed dopaminergic neurons must meet a
number of criteria (Arenas et al., 2015). First, the neurons must acquire a stable
mature dopaminergic phenotype. Second, neurons must re-innervate into only
the striatum and no other off-target locations. Third, they must synthesize and
release dopamine and exhibit appropriate firing patterns associated with
dopaminergic neurons. Fourth, reprogramming of cells into a dopaminergic
lineage must result in improvements in physical symptoms associated with PD.
Lastly, the newly transplanted or reprogrammed neurons must remain resistant
to Lewy body development and induced susceptibility to injury and degenerative
processes. Along those same strategies, if utilized together an interesting
question arises as to whether too much dopamine production by transplanted
neurons and reprogrammed neurons would produce untoward outcomes such as
dyskinesias in the PD patient.
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The data showing significantly decreased numbers of dopaminergic
neurons in p19 knockout leads to the question as to whether this is a
consequence

of

abnormal

neurogenesis,

neuronal

migration,

neuronal

differentiation, or survival of terminally differentiated neurons. To date, over 50
genetic mutations and mutant mice have been described that lead to effects on
dopaminergic neuron development and survival (Hegarty et al., 2013). Using
findings from these modes in combination with my data will help to pinpoint
factors required for normal midbrain development. This would have direct clinical
applications by targeting newly identified factors with the goal of restoring neuron
numbers by mobilizing dopaminergic neurons from neurogenic areas to areas of
neurodegeneration.
If we can delineate the mechanism(s) to increase neuronal migration,
multiple benefits over traditional cell replacement therapy would be gained.
Clinical trials evaluating the efficacy of fetal stem cell transplantation into the
striatum of PD patients failed to show significant improvements to patients
compared to those who underwent sham surgery. In addition to the technical
difficulty of this therapy, fetal stem cell transplantation carries multiple ethical
issues (Chinta and Andersen, 2005). As an alternative to fetal stem cell
transplantation and the associated issues, information collected from my studies
regarding how neuronal phenotypes are controlled could help develop
techniques to enable stem cells or non-dopaminergic neurons from PD patient’s
own bodies to be induced and become dopaminergic neurons. These neurons
can then be triggered to migrate to areas of neurodegeneration and effectively
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restore the number of dopaminergic neurons in the substantia nigra. This will
treat not only the physical symptoms of the disease, but possibly reverse the
disease itself. If dopaminergic neurons can be replaced by one’s own cells at a
rate equal to the rate of neuronal loss, the neuronal population can be
maintained resulting in alleviation or disappearance of physical symptoms.
Based upon original findings from our laboratory showing a detrimental
effect of TH17 cells in the MPTP mouse model of PD (Benner et al., 2004;
Reynolds et al., 2010), we hypothesized knockout of TH17 cells in a transgenic
mouse would result in neuroprotection from MPTP induced cell death. However,
this hypothesis was disproven due to the finding that p19 knockout mice show
the same sensitivity to MPTP within the substantia nigra and striatum compared
to wild-type mice (chapter 4). Expanding on data described above (chapter 3)
wherein pro-inflammatory cytokines were implicated in controlling neuronal
migration (Arnett et al., 2001; Dybedal et al., 2001; Ben-Hur et al., 2003; Monje et
al., 2003; Chen et al., 2004; Iosif et al., 2006; Whitney et al., 2009; Keohane et
al., 2010; Kim et al., 2015), I posit that by blocking TH17 cells with the use of
anti-MCAM or fingolimod, the previously undescribed beneficial effects of proinflammatory cytokines were unknowingly blocked. This conclusion is supported
by data in chapter 3 (figures 5 and 8). These figures demonstrate that in MPTP
intoxicated mice, even in the absence of dopamine replacement therapy, the
numbers of TH+GAD67+ neurons are significantly increased. This suggests that
in the absence of continued neurodegeneration, pro-inflammatory cytokines elicit
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a novel compensatory mechanism to upregulate the expression of TH by
GABAergic neurons.
These results propose three compensatory mechanisms in the MPTP
mouse model of PD in response to a reduction in striatal dopamine levels. First, I
demonstrated a phenotypic shift of GABAergic neurons in the substantia nigra
following MPTP-intoxication. The number of GABAergic neurons that undergo
this phenotypic shift and begin expressing TH increases with the addition of
dopamine replacement therapy in MPTP-lessoned mice. This leads to a potential
increase in the production of dopamine by increasing expression of the ratelimiting enzyme involved in dopamine synthesis. Secondly, using p19 deficient
mice, I showed that a significant reduction of dopaminergic neurons does not
result in measurable behavior or motor deficits compared to wild-type mice. This
could be for a number of reasons: slower removal of dopamine, increased
hypersensitivity of dopamine receptors, or increases in the number of dopamine
producing striatal interneurons (Brotchie and Fitzer-Attas, 2009). The finding that
heterozygous p19+/- mice show no reduction in striatal density compared to wildtype mice, but the number of dopaminergic neurons in the substantia nigra is
roughly half of that found in a wild-type, points to a compensatory mechanism
that results in increased synaptogenesis or sprouting of new terminals by
surviving dopaminergic neurons (Rosenblad et al., 1998; Backman et al., 2006;
Brotchie and Fitzer-Attas, 2009). Lastly, I presented data showing a lack of
dopaminergic neuroprotection with the TH17 blocking agent, MCAM or
sphingosine-1 phosphate inhibitor fingolimod – contradictory to the original
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hypothesis. This finding points to a novel effect of pro-inflammatory in which TH
expression

by

surviving

neurons

is

dependent

on

resolution

of

neurodegeneration and presence of pro-inflammatory cytokines.
Herein, I have presented data showing novel avenues by which to
approach the treatment of PD and other neurodegenerative diseases. First, I
presented the novel finding that GABAergic neurons in the substantia nigra
undergo a phenotypic shift in response to dopaminergic neurodegeneration or
dopamine replacement therapy, in the form of L-DOPA or BL-1023, and begin
expressing TH. This phenotypic shift was seen with and without initial MPTPinduced lesion, but the greatest increase in TH+ GABAergic neurons was in
leisoned animals treated with drug. Showing the initial increase in TH+ neurons
was not due to neurogenesis, proved GABAergic neurons in the substantia nigra
show a degree of plasticity in their neuronal phenotype. This finding can be
applied to future PD treatments aimed at increasing dopamine synthesis and
restoration of dopamine levels in the striatum without the need for dopamine
replacement therapy. Secondly, I presented data that showed significantly fewer
dopaminergic cells are required to control motor function and behavior in p19
knockout animals compared to wild-type. It is hypothesized that the reduced
number of dopaminergic neurons and dopamine levels in knockout animals
results in increased sensitivity of dopamine receptors or an upregulation in the
number of dopamine receptors themselves. This is especially relevant to PD, as
the same reduction in dopaminergic neurons is seen in patients. Understanding
how knockout animals are able to function normally, despite their significantly
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affected neuronal profile, could lead to more efficacious therapies for the
treatment of neurodegenerative disorders. Using the p19 knockout mouse will
help us to better understand how the CNS can function with lower levels of
dopaminergic neurons and dopamine with any consequent neuronal signaling
modifications.
The fact that PD symptom onset does not begin until the disease has
substantially progressed and a majority of dopaminergic neurons in the
substantia nigra have been lost, leads to the hypothesis that multiple
compensatory mechanisms are involved to maintain normal CNS function. It is
likely the numerous compensatory mechanisms are activated at different stages
of disease, and understanding the sequence of action will vastly improve clinical
treatment of disease. The potential for significant improvement in the lives of PD
patients is the rationale for continuing research into these areas. However, as
previously stated, PD symptoms do not begin until well into disease progression,
so a first step would be to identify a biomarker that could identify the very early
stages of PD, and treat accordingly. One such proposed biomarker is the
balanced neurochemical index of the ratio of nigrostriatal pathway traffic versus
dopamine stores (Goldstein, 2013). As disease progresses, it is hypothesized
that different compensatory mechanisms are initiated as a method to maintain
normal dopaminergic function. Each compensatory mechanism results in
different neurochemical profiles in the cerebrospinal fluid that theoretically can be
detected in clinical tests. By tracking compensatory activation in presymptomatic
individuals, the best treatment plan could be established to attenuate or prevent
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further dopaminergic cell death (Goldstein, 2013). Using data from findings
presented in this report will help to reveal some of these compensatory
mechanisms and aid in developing the most efficacious treatment plans for
patients at different stages of PD progression.

179

BIBLIOGRAPHY
Abe M, Kimoto H, Eto R, Sasaki T, Kato H, Kasahara J, Araki T (2010) Postnatal
development of neurons, interneurons and glial cells in the substantia
nigra of mice. Cell Mol Neurobiol 30:917-928.
Achim K, Salminen M, Partanen J (2014) Mechanisms regulating GABAergic
neuron development. Cell Mol Life Sci 71:1395-1415.
Achim K, Peltopuro P, Lahti L, Li J, Salminen M, Partanen J (2012) Distinct
developmental origins and regulatory mechanisms for GABAergic neurons
associated with dopaminergic nuclei in the ventral mesodiencephalic
region. Development 139:2360-2370.
Agid Y (1998) Levodopa: is toxicity a myth? Neurology 50:858-863.
Agid Y, Chase T, Marsden D (1998) Adverse reactions to levodopa: drug toxicity
or progression of disease? Lancet 351:851-852.
Aldridge JW, Berridge KC (1998) Coding of serial order by neostriatal neurons: a
"natural action" approach to movement sequence. J Neurosci 18:27772787.
Aldridge JW, Berridge KC, Rosen AR (2004) Basal ganglia neural mechanisms
of natural movement sequences. Can J Physiol Pharmacol 82:732-739.
Altman J (1969) Autoradiographic and histological studies of postnatal
neurogenesis. 3. Dating the time of production and onset of differentiation
of cerebellar microneurons in rats. J Comp Neurol 136:269-293.
Altman J, Das GD (1965) Post-natal origin of microneurones in the rat brain.
Nature 207:953-956.

180

Ames MM, Lerner P, Lovenberg W (1978) Tyrosine hydroxylase. Activation by
protein phosphorylation and end product inhibition. J Biol Chem 253:2731.
Anderson SA, Eisenstat DD, Shi L, Rubenstein JL (1997) Interneuron migration
from basal forebrain to neocortex: dependence on Dlx genes. Science
278:474-476.
Antony PM, Diederich NJ, Kruger R, Balling R (2013) The hallmarks of
Parkinson's disease. FEBS J 280:5981-5993.
Arenas E, Denham M, Villaescusa JC (2015) How to make a midbrain
dopaminergic neuron. Development 142:1918-1936.
Arias-Carrion O, Yamada E, Freundlieb N, Djufri M, Maurer L, Hermanns G,
Ipach B, Chiu WH, Steiner C, Oertel WH, Hoglinger GU (2009)
Neurogenesis in substantia nigra of parkinsonian brains? J Neural Transm
Suppl:279-285.
Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP (2001) TNF
alpha

promotes

proliferation

of

oligodendrocyte

progenitors

and

remyelination. Nat Neurosci 4:1116-1122.
Axelrod J (1971) Noradrenaline: fate and control of its biosynthesis. Science
173:598-606.
Backman CM, Shan L, Zhang YJ, Hoffer BJ, Leonard S, Troncoso JC, Vonsatel
P, Tomac AC (2006) Gene expression patterns for GDNF and its
receptors in the human putamen affected by Parkinson's disease: a realtime PCR study. Mol Cell Endocrinol 252:160-166.

181

Bahbouhi B, Berthelot L, Pettre S, Michel L, Wiertlewski S, Weksler B, Romero
IA, Miller F, Couraud PO, Brouard S, Laplaud DA, Soulillou JP (2009)
Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are
characterized by higher PSGL-1 expression and transmigration capacity
across a human blood-brain barrier-derived endothelial cell line. J Leukoc
Biol 86:1049-1063.
Bartholini G, Scatton B, Zivkovic B, Lloyd KG (1987) GABA receptor agonists
and extrapyramidal motor function: therapeutic implications for Parkinson's
disease. Adv Neurol 45:79-83.
Bassotti G, Maggio D, Battaglia E, Giulietti O, Spinozzi F, Reboldi G, Serra AM,
Emanuelli G, Chiarioni G (2000) Manometric investigation of anorectal
function in early and late stage Parkinson's disease. J Neurol Neurosurg
Psychiatry 68:768-770.
Beaudoin GM, 3rd, Lee SH, Singh D, Yuan Y, Ng YG, Reichardt LF, Arikkath J
(2012) Culturing pyramidal neurons from the early postnatal mouse
hippocampus and cortex. Nature protocols 7:1741-1754.
Behrstock SP, Anantharam V, Thompson KW, Schweitzer ES, Tobin AJ (2000)
Conditionally-immortalized astrocytic cell line expresses GAD and
secretes GABA under tetracycline regulation. J Neurosci Res 60:302-310.
Ben-Hur T, Ben-Menachem O, Furer V, Einstein O, Mizrachi-Kol R, Grigoriadis N
(2003) Effects of proinflammatory cytokines on the growth, fate, and
motility of multipotential neural precursor cells. Mol Cell Neurosci 24:623631.

182

Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S,
Nemachek C, Green SR, Przedborski S, Gendelman HE (2004)
Therapeutic immunization protects dopaminergic neurons in a mouse
model of Parkinson's disease. Proc Natl Acad Sci U S A 101:9435-9440.
Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V,
Nemachek C, Ciborowski P, Przedborski S, Mosley RL, Gendelman HE
(2008) Nitrated alpha-synuclein immunity accelerates degeneration of
nigral dopaminergic neurons. PloS one 3:e1376.
Benwell RK, Lee DR (2010) Essential and synergistic roles of IL1 and IL6 in
human Th17 differentiation directed by TLR ligand-activated dendritic
cells. Clin Immunol 134:178-187.
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973)
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical,
morphological and neurochemical correlations. J Neurol Sci 20:415-455.
Berridge KC, Fentress JC, Parr H (1987) Natural syntax rules control action
sequence of rats. Behav Brain Res 23:59-68.
Bertler A, Rosengren E (1959a) Occurrence and distribution of catechol amines
in brain. Acta Physiol Scand 47:350-361.
Bertler A, Rosengren E (1959b) Occurrence and distribution of dopamine in brain
and other tissues. Experientia 15:10-11.
Betarbet R, Turner R, Chockkan V, DeLong MR, Allers KA, Walters J, Levey AI,
Greenamyre JT (1997) Dopaminergic neurons intrinsic to the primate
striatum. J Neurosci 17:6761-6768.

183

Birkmayer W, Hornykiewicz O (1961) [The L-3,4-dioxyphenylalanine (DOPA)effect in Parkinson-akinesia]. Wien Klin Wochenschr 73:787-788.
Birkmayer W, Hornykiewicz O (1962) [The L-dihydroxyphenylalanine (L-DOPA)
effect in Parkinson's syndrome in man: On the pathogenesis and
treatment of Parkinson akinesis]. Arch Psychiatr Nervenkr Z Gesamte
Neurol Psychiatr 203:560-574.
Bjorklund A, Dunnett SB (2007) Dopamine neuron systems in the brain: an
update. Trends in neurosciences 30:194-202.
Bjorklund A, Cenci MA (2010) Recent Advances in Parkinson's disease translational and clinical research. Prog Brain Res 184:vii-viii.
Black IB (1982) Stages of neurotransmitter development in autonomic neurons.
Science 215:1198-1204.
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative
stress and Parkinson's disease. Front Neuroanat 9:91.
Blum M (1998) A null mutation in TGF-alpha leads to a reduction in midbrain
dopaminergic neurons in the substantia nigra. Nat Neurosci 1:374-377.
Bobrovskaya L, Gilligan C, Bolster EK, Flaherty JJ, Dickson PW, Dunkley PR
(2007) Sustained phosphorylation of tyrosine hydroxylase at serine 40: a
novel mechanism for maintenance of catecholamine synthesis. J
Neurochem 100:479-489.
Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S (2008)
Systemic immune aberrations in Alzheimer's disease patients. J
Neuroimmunol 193:183-187.

184

Bourdy R, Sanchez-Catalan MJ, Kaufling J, Balcita-Pedicino JJ, Freund-Mercier
MJ, Veinante P, Sesack SR, Georges F, Barrot M (2014) Control of the
nigrostriatal dopamine neuron activity and motor function by the tail of the
ventral tegmental area. Neuropsychopharmacology 39:2788-2798.
Bove J, Perier C (2012) Neurotoxin-based models of Parkinson's disease.
Neuroscience 211:51-76.
Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V,
Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C,
Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes
into the brain contributes to neurodegeneration in a mouse model of
Parkinson disease. J Clin Invest 119:182-192.
Brotchie J, Fitzer-Attas C (2009) Mechanisms compensating for dopamine loss in
early Parkinson disease. Neurology 72:S32-38.
Brown MT, Tan KR, O'Connor EC, Nikonenko I, Muller D, Luscher C (2012)
Ventral tegmental area GABA projections pause accumbal cholinergic
interneurons to enhance associative learning. Nature 492:452-456.
Busceti CL, Bucci D, Molinaro G, Di Pietro P, Zangrandi L, Gradini R, Moratalla
R, Battaglia G, Bruno V, Nicoletti F, Fornai F (2012) Lack or inhibition of
dopaminergic stimulation induces a development increase of striatal
tyrosine hydroxylase-positive interneurons. PloS one 7:e44025.
Caiazzo M, Dell'Anno MT, Dvoretskova E, Lazarevic D, Taverna S, Leo D,
Sotnikova TD, Menegon A, Roncaglia P, Colciago G, Russo G, Carninci
P, Pezzoli G, Gainetdinov RR, Gustincich S, Dityatev A, Broccoli V (2011)

185

Direct generation of functional dopaminergic neurons from mouse and
human fibroblasts. Nature 476:224-227.
Calcagno B, Eyles D, van Alphen B, van Swinderen B (2013) Transient activation
of

dopaminergic

neurons

during

development

modulates

visual

responsiveness, locomotion and brain activity in a dopamine ontogeny
model of schizophrenia. Translational psychiatry 3:e206.
Cameron DL, Williams JT (1993) Dopamine D1 receptors facilitate transmitter
release. Nature 366:344-347.
Carlsson A (1959) The occurrence, distribution and physiological role of
catecholamines in the nervous system. Pharmacol Rev 11:490-493.
Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and
5-hydroxytryptophan as reserpine antagonists. Nature 180:1200.
Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S,
Lucian L, Geissler R, Brodie S, Kimball AB, Gorman DM, Smith K, de
Waal Malefyt R, Kastelein RA, McClanahan TK, Bowman EP (2006) IL-23
stimulates epidermal hyperplasia via TNF and IL-20R2-dependent
mechanisms with implications for psoriasis pathogenesis. J Exp Med
203:2577-2587.
Chen G, Shannon M (2013) Transcription factors and th17 cell development in
experimental autoimmune encephalomyelitis. Crit Rev Immunol 33:165182.
Chen J, Jacobs-Helber SM, Barber DL, Sawyer ST (2004) Erythropoietindependent autocrine secretion of

tumor necrosis factor-alpha in

186

hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and
does not require tyrosine docking sites in the EPO receptor. Exp Cell Res
298:155-166.
Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan
T, Blumenschein W, Churakovsa T, Low J, Presta L, Hunter CA, Kastelein
RA, Cua DJ (2006) Anti-IL-23 therapy inhibits multiple inflammatory
pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest
116:1317-1326.
Chesselet MF (2002) Dopamine - GABA interactions. In: Dopamine in the CNS II
(Di Chiara G, ed), pp 151 -172: Springer.
Chesselet MF, Delfs JM (1996) Basal ganglia and movement disorders: an
update. Trends in neurosciences 19:417-422.
Chinta SJ, Andersen JK (2005) Dopaminergic neurons. Int J Biochem Cell Biol
37:942-946.
Conejero-Goldberg C, Tornatore C, Abi-Saab W, Monaco MC, Dillon-Carter O,
Vawter M, Elsworth J, Freed W (2000) Transduction of human GAD67
cDNA into immortalized striatal cell lines using an Epstein-Barr virusbased plasmid vector increases GABA content. Exp Neurol 161:453-461.
Cooper-Kuhn CM, Kuhn HG (2002) Is it all DNA repair? Methodological
considerations for detecting neurogenesis in the adult brain. Brain Res
Dev Brain Res 134:13-21.

187

Cossette M, Levesque D, Parent A (2005a) Neurochemical characterization of
dopaminergic neurons in human striatum. Parkinsonism Relat Disord
11:277-286.
Cossette M, Lecomte F, Parent A (2005b) Morphology and distribution of
dopaminergic neurons intrinsic to the human striatum. J Chem Neuroanat
29:1-11.
Dahlstroem A, Fuxe K (1964) Evidence for the Existence of MonoamineContaining Neurons in the Central Nervous System. I. Demonstration of
Monoamines in the Cell Bodies of Brain Stem Neurons. Acta Physiol
Scand Suppl:SUPPL 232:231-255.
Damsker JM, Hansen AM, Caspi RR (2010) Th1 and Th17 cells: adversaries and
collaborators. Ann N Y Acad Sci 1183:211-221.
Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models.
Neuron 39:889-909.
Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF, Wokosin D, Ilijic E, Sun
Z, Sampson AR, Mugnaini E, Deutch AY, Sesack SR, Arbuthnott GW,
Surmeier DJ (2006) Selective elimination of glutamatergic synapses on
striatopallidal neurons in Parkinson disease models. Nat Neurosci 9:251259.
de Visser L, van den Bos R, Kuurman WW, Kas MJ, Spruijt BM (2006) Novel
approach to the behavioural characterization of inbred mice: automated
home cage observations. Genes, brain, and behavior 5:458-466.

188

Deng W, Aimone JB, Gage FH (2010) New neurons and new memories: how
does adult hippocampal neurogenesis affect learning and memory?
Nature reviews Neuroscience 11:339-350.
Deshpande P, King IL, Segal BM (2006) IL-12 driven upregulation of P-selectin
ligand on myelin-specific T cells is a critical step in an animal model of
autoimmune demyelination. J Neuroimmunol 173:35-44.
Drouin-Ouellet J, Barker RA (2012) Parkinson's Disease in a Dish: What Patient
Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's
Disease, If Anything? Stem Cells Int 2012:926147.
Dubach M, Schmidt R, Kunkel D, Bowden DM, Martin R, German DC (1987)
Primate

neostriatal

neurons

containing

tyrosine

hydroxylase:

immunohistochemical evidence. Neurosci Lett 75:205-210.
Dybedal I, Bryder D, Fossum A, Rusten LS, Jacobsen SE (2001) Tumor necrosis
factor (TNF)-mediated activation of the p55 TNF receptor negatively
regulates maintenance of cycling reconstituting human hematopoietic
stem cells. Blood 98:1782-1791.
Eaton MJ, Plunkett JA, Martinez MA, Lopez T, Karmally S, Cejas P, Whittemore
SR (1999) Transplants of neuronal cells bioengineered to synthesize
GABA alleviate chronic neuropathic pain. Cell Transplant 8:87-101.
Emsley JG, Mitchell BD, Kempermann G, Macklis JD (2005) Adult neurogenesis
and repair of the adult CNS with neural progenitors, precursors, and stem
cells. Prog Neurobiol 75:321-341.

189

Engelhardt B (2010) T cell migration into the central nervous system during
health and diseas: Different molecular keys allow access to different
central nervous system compartments. Clinical and Experimental
Neuroimmunology:79-93.
Ferrari MF, Coelho EF, Farizatto KL, Chadi G, Fior-Chadi DR (2011) Modulation
of tyrosine hydroxylase, neuropeptide y, glutamate, and substance p in
Ganglia and brain areas involved in cardiovascular control after chronic
exposure to nicotine. International journal of hypertension 2011:216464.
Fields HL, Hjelmstad GO, Margolis EB, Nicola SM (2007) Ventral tegmental area
neurons in learned appetitive behavior and positive reinforcement. Annu
Rev Neurosci 30:289-316.
Flanagan K et al. (2012) Laminin-411 is a vascular ligand for MCAM and
facilitates TH17 cell entry into the CNS. PloS one 7:e40443.
Floran B, Aceves J, Sierra A, Martinez-Fong D (1990) Activation of D1 dopamine
receptors stimulates the release of GABA in the basal ganglia of the rat.
Neurosci Lett 116:136-140.
Fratiglioni L, Wang HX (2000) Smoking and Parkinson's and Alzheimer's
disease: review of the epidemiological studies. Behav Brain Res 113:117120.
Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: from
mechanisms to therapeutic testing. Nature reviews Immunology 14:585600.

190

Gahn LG, Roskoski R, Jr. (1995) Thermal stability and CD analysis of rat tyrosine
hydroxylase. Biochemistry (Mosc) 34:252-256.
Galanaud JP, Elbaz A, Clavel J, Vidal JS, Correze JR, Alperovitch A, Tzourio C
(2005) Cigarette smoking and Parkinson's disease: a case-control study in
a population characterized by a high prevalence of pesticide exposure.
Mov Disord 20:181-189.
Gates MA, Coupe VM, Torres EM, Fricker-Gates RA, Dunnett SB (2004)
Spatially and temporally restricted chemoattractive and chemorepulsive
cues direct the formation of the nigro-striatal circuit. Eur J Neurosci
19:831-844.
German DC, Schlusselberg DS, Woodward DJ (1983) Three-dimensional
computer reconstruction of midbrain dopaminergic neuronal populations:
from mouse to man. J Neural Transm 57:243-254.
Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, De Sauvage FJ (2004)
Compromised humoral and delayed-type hypersensitivity responses in IL23-deficient mice. J Immunol 172:2827-2833.
Giordano M, Takashima H, Poltorak M, Geller HM, Freed WJ (1996) Constitutive
expression of glutamic acid decarboxylase (GAD) by striatal cell lines
immortalized using the tsA58 allele of the SV40 large T antigen. Cell
Transplant 5:563-575.
Giordano M, Takashima H, Herranz A, Poltorak M, Geller HM, Marone M, Freed
WJ (1993) Immortalized GABAergic cell lines derived from rat striatum

191

using a temperature-sensitive allele of the SV40 large T antigen. Exp
Neurol 124:395-400.
Golden JP, Demaro JA, 3rd, Knoten A, Hoshi M, Pehek E, Johnson EM, Jr.,
Gereau

RWt,

Jain

S

(2013)

Dopamine-dependent

compensation

maintains motor behavior in mice with developmental ablation of
dopaminergic neurons. J Neurosci 33:17095-17107.
Goldstein DS (2013) Biomarkers, mechanims, and potential prevention of
catecholamine neuron loss in Parkinson's disease. In: A new era of
catecholamines in the laboratory and clinic (Eiden LE, ed), pp 235-272:
Elseiver.
Goulding EH, Schenk AK, Juneja P, MacKay AW, Wade JM, Tecott LH (2008) A
robust automated system elucidates mouse home cage behavioral
structure. Proc Natl Acad Sci U S A 105:20575-20582.
Greenblatt DJ, Shader RI (1973) Drug therapy. Anticholinergics. N Engl J Med
288:1215-1219.
Guadagno J, Xu X, Karajgikar M, Brown A, Cregan SP (2013) Microglia-derived
TNFalpha induces apoptosis in neural precursor cells via transcriptional
activation of the Bcl-2 family member Puma. Cell death & disease 4:e538.
Haavik J, Toska K (1998) Tyrosine hydroxylase and Parkinson's disease. Mol
Neurobiol 16:285-309.
Haycock JW, Haycock DA (1991) Tyrosine hydroxylase in rat brain dopaminergic
nerve

terminals.

Multiple-site

phosphorylation

synaptosomes. J Biol Chem 266:5650-5657.

in

vivo

and

in

192

Hegarty SV, Sullivan AM, O'Keeffe GW (2013) Midbrain dopaminergic neurons: a
review of the molecular circuitry that regulates their development. Dev Biol
379:123-138.
Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's
disease. Adv Neurol 45:19-34.
Huot P, Parent A (2007) Dopaminergic neurons intrinsic to the striatum. J
Neurochem 101:1441-1447.
Huot P, Levesque M, Morissette M, Calon F, Dridi M, Di Paolo T, Parent A (2008)
L-Dopa

treatment

abolishes

the

numerical

increase

in

striatal

dopaminergic neurons in parkinsonian monkeys. J Chem Neuroanat
35:77-84.
Hussong XBSA (2014) A new mouse model to study compensatory mechanisms
that support normal motor in Parkinson's disease. Journal of Biochemical
and Pharmacological Research 2:1-3.
Hutter-Saunders JA, Kosloski LM, McMillan JM, Yotam N, Rinat T, Mosley RL,
Gendelman HE (2011) BL-1023 improves behavior and neuronal survival
in

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated

mice.

Neuroscience 180:293-304.
Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, Jacobsen SE,
Lindvall O (2006) Tumor necrosis factor receptor 1 is a negative regulator
of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci
26:9703-9712.

193

Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of
Parkinson's disease. Nature protocols 2:141-151.
Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995) Time course and
morphology of dopaminergic neuronal death caused by the neurotoxin 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Neurodegeneration

4:257-

269.
Jaeger CB, Joh TH (1983) Transient expression of tyrosine hydroxylase in some
neurons of the developing inferior colliculus of the rat. Brain Res 313:128132.
Jollivet C, Montero-Menei CN, Venier-Julienne MC, Sapin A, Benoit JP, Menei P
(2004) Striatal tyrosine hydroxylase immunoreactive neurons are induced
by L-dihydroxyphenylalanine and nerve growth factor treatment in 6hydroxydopamine lesioned rats. Neurosci Lett 362:79-82.
Kala K, Haugas M, Lillevali K, Guimera J, Wurst W, Salminen M, Partanen J
(2009) Gata2 is a tissue-specific post-mitotic selector gene for midbrain
GABAergic neurons. Development 136:253-262.
Kawano H, Ohyama K, Kawamura K, Nagatsu I (1995) Migration of dopaminergic
neurons in the embryonic mesencephalon of mice. Brain Res Dev Brain
Res 86:101-113.
Keohane A, Ryan S, Maloney E, Sullivan AM, Nolan YM (2010) Tumour necrosis
factor-alpha impairs neuronal differentiation but not proliferation of
hippocampal neural precursor cells: Role of Hes1. Mol Cell Neurosci
43:127-135.

194

Keshet GI, Tolwani RJ, Trejo A, Kraft P, Doyonnas R, Clayberger C, Weimann
JM, Blau HM (2007) Increased host neuronal survival and motor function
in BMT Parkinsonian mice: involvement of immunosuppression. J Comp
Neurol 504:690-701.
Kim J, Su SC, Wang H, Cheng AW, Cassady JP, Lodato MA, Lengner CJ,
Chung CY, Dawlaty MM, Tsai LH, Jaenisch R (2011) Functional
integration of dopaminergic neurons directly converted from mouse
fibroblasts. Cell stem cell 9:413-419.
Kim SM, Yang JW, Park MJ, Lee JK, Kim SU, Lee YS, Lee MA (2006)
Regulation of human tyrosine hydroxylase gene by neuron-restrictive
silencer factor. Biochem Biophys Res Commun 346:426-435.
Kim YK, Na KS, Myint AM, Leonard BE (2015) The role of pro-inflammatory
cytokines in neuroinflammation, neurogenesis and the neuroendocrine
system in major depression. Prog Neuropsychopharmacol Bol Psychiatry.
Kono T, Nishimura F, Sugimoto H, Sikata K, Makino H, Murayama Y (2001)
Human fibroblasts ubiquitously express glutamic acid decarboxylase 65
(GAD 65): possible effects of connective tissue inflammation on GAD
antibody titer. J Periodontol 72:598-604.
Koprich JB, Reske-Nielsen C, Mithal P, Isacson O (2008) Neuroinflammation
mediated by IL-1beta increases susceptibility of dopamine neurons to
degeneration in an animal model of Parkinson's disease. Journal of
neuroinflammation 5:8.

195

Kosaka K, Hama K, Nagatsu I, Wu JY, Kosaka T (1988) Possible coexistence of
amino acid (gamma-aminobutyric acid), amine (dopamine) and peptide
(substance P); neurons containing immunoreactivities for glutamic acid
decarboxylase, tyrosine hydroxylase and substance P in the hamster main
olfactory bulb. Exp Brain Res 71:633-642.
Kosaka K, Hama K, Nagatsu I, Wu JY, Ottersen OP, Storm-Mathisen J, Kosaka
T

(1987a)

Postnatal

development

of

neurons

containing

both

catecholaminergic and GABAergic traits in the rat main olfactory bulb.
Brain Res 403:355-360.
Kosaka T, Kosaka K, Nagatsu I (1991) Tyrosine hydroxylase-like immunoreactive
neurons in the olfactory bulb of the snake, Elaphe quadrivirgata, with
special reference to the colocalization of tyrosine hydroxylase- and GABAlike immunoreactivities. Exp Brain Res 87:353-362.
Kosaka T, Kosaka K, Hataguchi Y, Nagatsu I, Wu JY, Ottersen OP, StormMathisen J, Hama K (1987b) Catecholaminergic neurons containing
GABA-like and/or glutamic acid decarboxylase-like immunoreactivities in
various brain regions of the rat. Exp Brain Res 66:191-210.
Kosloski LM, Kosmacek EA, Olson KE, Mosley RL, Gendelman HE (2013) GMCSF induces neuroprotective and anti-inflammatory responses in 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Neuroimmunol 265:1-10.

intoxicated

mice.

J

196

Kumar GK, Kim DK, Lee MS, Ramachandran R, Prabhakar NR (2003) Activation
of tyrosine hydroxylase by intermittent hypoxia: involvement of serine
phosphorylation. J Appl Physiol (1985) 95:536-544.
Kumer SC, Vrana KE (1996) Intricate regulation of tyrosine hydroxylase activity
and gene expression. J Neurochem 67:443-462.
Kurkowska-Jastrzebska

I,

Wronska

A,

Kohutnicka

M,

Czlonkowski

A,

Czlonkowska A (1999) The inflammatory reaction following 1-methyl-4phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol
156:50-61.
Lahti L, Achim K, Partanen J (2013) Molecular regulation of GABAergic neuron
differentiation and diversity in the developing midbrain. Acta Physiol (Oxf)
207:616-627.
Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD,
McClanahan T, Kastelein RA, Cua DJ (2005) IL-23 drives a pathogenic T
cell population that induces autoimmune inflammation. J Exp Med
201:233-240.
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in
humans due to a product of meperidine-analog synthesis. Science
219:979-980.
Langston JWaP, J. (2014) The case of the frozen addicts: how the solution of a
medical mystery revolutionized the understanding of Parkinson's disease:
IOS Press.

197

Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D,
Fulop T (2009) Dramatic shifts in circulating CD4 but not CD8 T cell
subsets in mild Alzheimer's disease. Journal of Alzheimer's disease : JAD
17:91-103.
Lazar MA, Truscott RJ, Raese JD, Barchas JD (1981) Thermal denaturation of
native striatal tyrosine hydroxylase: increased thermolability of the
phosphorylated form of the enzyme. J Neurochem 36:677-682.
Levy R, Lang AE, Dostrovsky JO, Pahapill P, Romas J, Saint-Cyr J, Hutchison
WD, Lozano AM (2001) Lidocaine and muscimol microinjections in
subthalamic nucleus reverse Parkinsonian symptoms. Brain 124:21052118.
Li S, Joshee S, Vasudevan A (2014) Mesencephalic GABA neuronal
development: no more on the other side of oblivion. Biomolecular
concepts 5:371-382.
Lindvall O, Bjorklund A (2004) Cell replacement therapy: helping the brain to
repair itself. NeuroRx 1:379-381.
Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson's
disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195:453-464.
Lopez-Real A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL (2003)
Localization and functional significance of striatal neurons immunoreactive
to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat
Parkinsonian models. Brain Res 969:135-146.

198

Luchtman DW, Ellwardt E, Larochelle C, Zipp F (2014) IL-17 and related
cytokines involved in the pathology and immunotherapy of multiple
sclerosis: Current and future developments. Cytokine Growth Factor Rev
25:403-413.
Mao L, Lau YS, Petroske E, Wang JQ (2001) Profound astrogenesis in the
striatum of adult mice following nigrostriatal dopaminergic lesion by
repeated MPTP administration. Brain Res Dev Brain Res 131:57-65.
Masuda M, Miura M, Inoue R, Imanishi M, Saino-Saito S, Takada M, Kobayashi
K, Aosaki T (2011) Postnatal development of tyrosine hydroxylase mRNAexpressing neurons in mouse neostriatum. Eur J Neurosci 34:1355-1367.
Matsushita N, Okada H, Yasoshima Y, Takahashi K, Kiuchi K, Kobayashi K
(2002) Dynamics of tyrosine hydroxylase promoter activity during midbrain
dopaminergic neuron development. J Neurochem 82:295-304.
Matsuura S, Suzuki K (1997) Immunohistochemical analysis of DNA synthesis
during chronic stimulation with isoproterenol in mouse submandibular
gland. J Histochem Cytochem 45:1137-1145.
Mazloom M, Smith Y (2006) Synaptic microcircuitry of tyrosine hydroxylasecontaining neurons and terminals in the striatum of 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine-treated monkeys. J Comp Neurol 495:453-469.
McCormack AL, Mak SK, Di Monte DA (2012) Increased alpha-synuclein
phosphorylation and nitration in the aging primate substantia nigra. Cell
death & disease 3:e315.

199

Mehler MF, Kessler JA (1998) Cytokines in brain development and function. Adv
Protein Chem 52:223-251.
Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, Brinkmann V (2010)
Th17 central memory T cells are reduced by FTY720 in patients with
multiple sclerosis. Neurology 75:403-410.
Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C,
Kuhle J, Lindberg RL, Kappos L (2008) FTY720 therapy exerts differential
effects on T cell subsets in multiple sclerosis. Neurology 71:1261-1267.
Mehta A, Chesselet MF (2005) Effect of GABA(A) receptor stimulation in the
subthalamic nucleus on motor deficits induced by nigrostriatal lesions in
the rat. Exp Neurol 193:110-117.
Ming GL, Song H (2005) Adult neurogenesis in the mammalian central nervous
system. Annu Rev Neurosci 28:223-250.
Monje P, Marinissen MJ, Gutkind JS (2003) Phosphorylation of the carboxylterminal transactivation domain of c-Fos by extracellular signal-regulated
kinase mediates the transcriptional activation of AP-1 and cellular
transformation induced by platelet-derived growth factor. Mol Cell Biol
23:7030-7043.
Morales M, Root DH (2014) Glutamate neurons within the midbrain dopamine
regions. Neuroscience 282C:60-68.
Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation
and adaptive immunity in Parkinson's disease. Cold Spring Harbor
perspectives in medicine 2:a009381.

200

Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein
RA, Sedgwick JD, Cua DJ (2003) Divergent pro- and antiinflammatory
roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med
198:1951-1957.
Murrin LC (2012) Neurochemistry of Parkinson's disease. In: Parkinson's
Disease, Second Edition (Pfeiffer RF, Zbigniew, K.W., Manuchair, E., ed),
pp 521 - 528: CRC Press.
Nair-Roberts RG, Chatelain-Badie SD, Benson E, White-Cooper H, Bolam JP,
Ungless MA (2008) Stereological estimates of dopaminergic, GABAergic
and glutamatergic neurons in the ventral tegmental area, substantia nigra
and retrorubral field in the rat. Neuroscience 152:1024-1031.
Nakashima A, Ota A, Kaneko YS, Mori K, Nagasaki H, Nagatsu T (2013a) A
possible pathophysiological role of tyrosine hydroxylase in Parkinson's
disease suggested by postmortem brain biochemistry: a contribution for
the special 70th birthday symposium in honor of Prof. Peter Riederer. J
Neural Transm 120:49-54.
Nakashima A, Kaneko YS, Kodani Y, Mori K, Nagasaki H, Nagatsu T, Ota A
(2013b) Intracellular stability of tyrosine hydroxylase: phosphorylation and
proteasomal digestion of the enzyme. Adv Pharmacol 68:3-11.
Nakatani T, Minaki Y, Kumai M, Ono Y (2007) Helt determines GABAergic over
glutamatergic neuronal fate by repressing Ngn genes in the developing
mesencephalon. Development 134:2783-2793.

201

Notter MF, Irwin I, Langston JW, Gash DM (1988) Neurotoxicity of MPTP and
MPP+ in vitro: characterization using specific cell lines. Brain Res
456:254-262.
Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the
treatment of Parkinson disease (2009). Neurology 72:S1-136.
Omelchenko N, Sesack SR (2009) Ultrastructural analysis of local collaterals of
rat ventral tegmental area neurons: GABA phenotype and synapses onto
dopamine and GABA cells. Synapse 63:895-906.
Ong LK, Sominsky L, Dickson PW, Hodgson DM, Dunkley PR (2012) The
sustained phase of tyrosine hydroxylase activation in vivo. Neurochem
Res 37:1938-1943.
Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ (2000) Cloning of a type
I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl
Acad Sci U S A 97:11439-11444.
Pahapill PA, Levy R, Dostrovsky JO, Davis KD, Rezai AR, Tasker RR, Lozano
AM (1999) Tremor arrest with thalamic microinjections of muscimol in
patients with essential tremor. Ann Neurol 46:249-252.
Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H (1991)
The absolute number of nerve cells in substantia nigra in normal subjects
and in patients with Parkinson's disease estimated with an unbiased
stereological method. J Neurol Neurosurg Psychiatry 54:30-33.
Parkison SA, Carlson JD, Chaudoin TR, Hoke TA, Schenk AK, Goulding EH,
Perez LC, Bonasera SJ (2012) A low-cost, reliable, high-throughput

202

system for rodent behavioral phenotyping in a home cage environment.
Conference proceedings : Annual International Conference of the IEEE
Engineering in Medicine and Biology Society IEEE Engineering in
Medicine and Biology Society Annual Conference 2012:2392-2395.
Peghini M, Barabe P, Touze JE, Morcillo R, Veillard JM, Diagne L, Eynard JP,
Diallo A, Gueye PM, Mbaye PS, et al. (1990) [Epidemiology of cancer of
the digestive tract in Senegal. Review of 18,000 endoscopies performed at
the Principal Hospital of Dakar]. Med Trop (Mars) 50:205-208.
Pfisterer U, Kirkeby A, Torper O, Wood J, Nelander J, Dufour A, Bjorklund A,
Lindvall O, Jakobsson J, Parmar M (2011) Direct conversion of human
fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A 108:1034310348.
Pinal CS, Cortessis V, Tobin AJ (1997) Multiple elements regulate GAD65
transcription. Dev Neurosci 19:465-475.
Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R,
Akram M (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP): a technical review of its utility and safety. J
Neurochem 76:1265-1274.
Quik M (2004) Smoking, nicotine and Parkinson's disease. Trends in
neurosciences 27:561-568.
Radad KS, Al-Shraim MM, Moustafa MF, Rausch WD (2015) Neuroprotective
role

of

thymoquinone

against

1-methyl-4-phenylpyridinium-induced

203

dopaminergic

cell

death

in

primary

mesencephalic

cell

culture.

Neurosciences (Riyadh) 20:10-16.
Radcliffe PM, Sterling CR, Tank AW (2009) Induction of tyrosine hydroxylase
mRNA by nicotine in rat midbrain is inhibited by mifepristone. J
Neurochem 109:1272-1284.
Reynolds AD, Stone DK, Mosley RL, Gendelman HE (2009) Nitrated {alpha}synuclein-induced alterations in microglial immunity are regulated by
CD4+ T cell subsets. J Immunol 182:4137-4149.
Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL (2007)
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal
model of Parkinson's disease. J Leukoc Biol 82:1083-1094.
Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE
(2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal
dopaminergic neurodegeneration in a model of Parkinson's disease. J
Immunol 184:2261-2271.
Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, Ciborowski
P, Cerny R, Gelman B, Thomas MP, Mosley RL, Gendelman HE (2008)
Nitrated alpha-synuclein-activated microglial profiling for Parkinson's
disease. J Neurochem 104:1504-1525.
Richartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, Bartels M,
Buchkremer G, Schott K (2007) Altered lymphocyte distribution in
Alzheimer's disease. J Psychiatr Res 41:174-178.

204

Robinson AP, Harp CT, Noronha A, Miller SD (2014) The experimental
autoimmune

encephalomyelitis

(EAE)

model

of

MS:

utility

for

understanding disease pathophysiology and treatment. Handbook of
clinical neurology 122:173-189.
Rosenblad C, Martinez-Serrano A, Bjorklund A (1998) Intrastriatal glial cell linederived neurotrophic factor promotes sprouting of spared nigrostriatal
dopaminergic afferents and induces recovery of function in a rat model of
Parkinson's disease. Neuroscience 82:129-137.
Rostami A, Ciric B (2013) Role of Th17 cells in the pathogenesis of CNS
inflammatory demyelination. J Neurol Sci 333:76-87.
Rubin RP (2007) A brief history of great discoveries in pharmacology: in
celebration of the centennial anniversary of the founding of the American
Society of Pharmacology and Experimental Therapeutics. Pharmacol Rev
59:289-359.
Salazar P, del Carmen Sanchez-Soto M, Hiriart M, Tapia R (2001) Biochemical
characteristics of the gamma-aminobutyric acid system in the insulinoma
cell lines HIT-T15, RIN-m5F, betaTC3, and comparison with rat brain.
Arch Med Res 32:419-428.
Salvatore MF (2014) ser31 Tyrosine hydroxylase phosphorylation parallels
differences in dopamine recovery in nigrostriatal pathway following 6OHDA lesion. J Neurochem 129:548-558.
Sanchez JF, Crooks DR, Lee CT, Schoen CJ, Amable R, Zeng X, Florival-Victor
T, Morales N, Truckenmiller ME, Smith DR, Freed WJ (2006) GABAergic

205

lineage differentiation of AF5 neural progenitor cells in vitro. Cell Tissue
Res 324:1-8.
Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Alberoni M, Nemni
R, Clerici M (2011) Increased activity of Th-17 and Th-9 lymphocytes and
a skewing of the post-thymic differentiation pathway are seen in
Alzheimer's disease. Brain Behav Immun 25:539-547.
Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto
DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, Ali HH, Standaert
DG,

Mosley

RL,

Gendelman

HE

(2012)

CD4+

regulatory

and

effector/memory T cell subsets profile motor dysfunction in Parkinson's
disease. Journal of neuroimmune pharmacology : the official journal of the
Society on NeuroImmune Pharmacology 7:927-938.
Sawamoto K, Nakao N, Kobayashi K, Matsushita N, Takahashi H, Kakishita K,
Yamamoto A, Yoshizaki T, Terashima T, Murakami F, Itakura T, Okano H
(2001) Visualization, direct isolation, and transplantation of midbrain
dopaminergic neurons. Proc Natl Acad Sci U S A 98:6423-6428.
Schimmel JJ, Crews L, Roffler-Tarlov S, Chikaraishi DM (1999) 4.5 kb of the rat
tyrosine hydroxylase 5' flanking sequence directs tissue specific
expression during development and contains consensus sites for multiple
transcription factors. Brain Res Mol Brain Res 74:1-14.
Schneider JS, Anderson, D.W., Decamp, E. (2008) 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine-induced mammalian models of Parkinson's disease:
potential usues and misuses of acute, sub-acute, and chronic models. In:

206

Parkinson's disease: Molecular and therapeutic insignts form model
systems (Richard Nass SP, ed), pp 87-103: Elsevier.
Segovia J, Meloni R, Gale K (1989) Effect of dopaminergic denervation and
transplant-derived reinnervation on a marker of striatal GABAergic
function. Brain Res 493:185-189.
Segovia J, Tillakaratne NJ, Whelan K, Tobin AJ, Gale K (1990) Parallel increases
in striatal glutamic acid decarboxylase activity and mRNA levels in rats
with lesions of the nigrostriatal pathway. Brain Res 529:345-348.
Sesak SR (2002) Synaptology of dopamine neurons. In: Dopamine in the CNS I
(Chara GD, ed), pp 63-120: Springer.
Shafrir E (1994) Julius Axelrod, Bernard Katz and Ulf von Euler--Nobel Prize
winners for the discovery of mechanisms of nerve signal transmission. Isr
J Med Sci 30:869.
Shalit F, Sredni B, Brodie C, Kott E, Huberman M (1995) T lymphocyte
subpopulations and activation markers correlate with severity of
Alzheimer's disease. Clin Immunol Immunopathol 75:246-250.
Sheridan GK, Dev KK (2014) Targeting S1P receptors in experimental
autoimmune encephalomyelitis in mice improves early deficits in
locomotor activity and increases ultrasonic vocalisations. Scientific reports
4:5051.
Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman
DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD,
Kastelein RA, Pierce RH, Laface DM, Cua DJ (2012) IL-23 induces

207

spondyloarthropathy

by

acting

on

ROR-gammat+

CD3+CD4-CD8-

entheseal resident T cells. Nat Med 18:1069-1076.
Siderowf A, Stern M (2003) Update on Parkinson disease. Ann Intern Med
138:651-658.
Sie C, Korn T, Mitsdoerffer M (2014) Th17 cells in central nervous system
autoimmunity. Exp Neurol 262 Pt A:18-27.
Singh C, Ahmad I, Kumar A (2007) Pesticides and metals induced Parkinson's
disease: involvement of free radicals and oxidative stress. Cell Mol Biol
(Noisy-le-grand) 53:19-28.
Slavin AJ, Zamvil SS (2010) FTY720 and central memory: out of sight, out of
mind. Neurology 75:388-389.
Soghomonian JJ, Chesselet MF (1992) Effects of nigrostriatal lesions on the
levels of messenger RNAs encoding two isoforms of glutamate
decarboxylase in the globus pallidus and entopeduncular nucleus of the
rat. Synapse 11:124-133.
Soghomonian JJ, Gonzales C, Chesselet MF (1992) Messenger RNAs encoding
glutamate-decarboxylases are differentially affected by nigrostriatal
lesions in subpopulations of striatal neurons. Brain Res 576:68-79.
Specht

LA,

Pickel

VM,

Joh

TH,

Reis

DJ

(1981a)

Light-microscopic

immunocytochemical localization of tyrosine hydroxylase in prenatal rat
brain. I. Early ontogeny. J Comp Neurol 199:233-253.

208

Specht

LA,

Pickel

VM,

Joh

TH,

Reis

DJ

(1981b)

Light-microscopic

immunocytochemical localization of tyrosine hydroxylase in prenatal rat
brain. II. Late ontogeny. J Comp Neurol 199:255-276.
Speciale L, Calabrese E, Saresella M, Tinelli C, Mariani C, Sanvito L, Longhi R,
Ferrante P (2007) Lymphocyte subset patterns and cytokine production in
Alzheimer's disease patients. Neurobiol Aging 28:1163-1169.
Stein G, Nudelman, A., Rephaeli, A., Gil-Ad, I., Weizman, A. (2012) Conjugates
for treating neurodegenerative diseases and disorders. In. United States:
Ramot at Tel-Aviv Univeristy Ltd., Bar-Ilan University.
Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW, Bell
JE, Kilford L, Kingsbury AE, Daniel SE, Ingham CA (2005) Evidence of a
breakdown

of

corticostriatal

connections

in

Parkinson's

disease.

Neuroscience 132:741-754.
Suen MF, Chan WS, Hung KW, Chen YF, Mo ZX, Yung KK (2013) Assessments
of the effects of nicotine and ketamine using tyrosine hydroxylase-green
fluorescent

protein

transgenic

zebrafish

as

biosensors.

Biosens

Bioelectron 42:177-185.
Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC (2006) A crucial role for
interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate
autoimmune encephalomyelitis. J Exp Med 203:1685-1691.
Tamamaki N, Fujimori KE, Takauji R (1997) Origin and route of tangentially
migrating neurons in the developing neocortical intermediate zone. J
Neurosci 17:8313-8323.

209

Tande D, Hoglinger G, Debeir T, Freundlieb N, Hirsch EC, Francois C (2006)
New striatal dopamine neurons in MPTP-treated macaques result from a
phenotypic shift and not neurogenesis. Brain 129:1194-1200.
Tank AW, Xu L, Chen X, Radcliffe P, Sterling CR (2008) Post-transcriptional
regulation of tyrosine hydroxylase expression in adrenal medulla and
brain. Ann N Y Acad Sci 1148:238-248.
Taylor JL, Rajbhandari AK, Berridge KC, Aldridge JW (2010) Dopamine receptor
modulation of repetitive grooming actions in the rat: potential relevance for
Tourette syndrome. Brain Res 1322:92-101.
Tecott LH, Nestler EJ (2004) Neurobehavioral assessment in the information
age. Nat Neurosci 7:462-466.
Tepper JM (2010) GABAergic Interneurons of the Striatum. In: Handbook of
Basal Ganglia Structure and Function (Tseng HSaKY, ed), pp 151-166.
Tepper JM, Tecuapetla F, Koos T, Ibanez-Sandoval O (2010) Heterogeneity and
diversity of striatal GABAergic interneurons. Front Neuroanat 4:150.
Thomas B (2009) Parkinson's disease: from molecular pathways in disease to
therapeutic approaches. Antioxid Redox Signal 11:2077-2082.
Thomas MP, Chartrand K, Reynolds A, Vitvitsky V, Banerjee R, Gendelman HE
(2007) Ion channel blockade attenuates aggregated alpha synuclein
induction of microglial reactive oxygen species: relevance for the
pathogenesis of Parkinson's disease. J Neurochem 100:503-519.
Thomsen GM, Gowing G, Svendsen S, Svendsen CN (2014) The past, present
and future of stem cell clinical trials for ALS. Exp Neurol 262 Pt B:127-137.

210

Tremblay L, Worbe Y, Thobois S, Sgambato-Faure V, Feger J (2015) Selective
dysfunction of basal ganglia subterritories: From movement to behavioral
disorders. Mov Disord.
Trojanowski JQ, Kleppner SR, Hartley RS, Miyazono M, Fraser NW, Kesari S,
Lee VM (1997) Transfectable and transplantable postmitotic human
neurons: a potential "platform" for gene therapy of nervous system
diseases. Exp Neurol 144:92-97.
Truckenmiller ME, Tornatore C, Wright RD, Dillon-Carter O, Meiners S, Geller
HM, Freed WJ (1998) A truncated SV40 large T antigen lacking the p53
binding domain overcomes p53-induced growth arrest and immortalizes
primary mesencephalic cells. Cell Tissue Res 291:175-189.
Turjanski N, Lees AJ, Brooks DJ (1997) In vivo studies on striatal dopamine D1
and D2 site binding in L-dopa-treated Parkinson's disease patients with
and without dyskinesias. Neurology 49:717-723.
Varju P, Katarova Z, Madarasz E, Szabo G (2002) Sequential induction of
embryonic and adult forms of glutamic acid decarboxylase during in vitroinduced neurogenesis in cloned neuroectodermal cell-line, NE-7C2. J
Neurochem 80:605-615.
Vasudevan A, Won C, Li S, Erdelyi F, Szabo G, Kim KS (2012) Dopaminergic
neurons modulate GABA neuron migration in the embryonic midbrain.
Development 139:3136-3141.
Von Euler US (1946a) The presence of a sympathomimetic substance in extracts
of mammalian heart. J Physiol 105:38-44.

211

Von Euler US (1946b) Sympathin in adrenergic nerve fibres. J Physiol 105:26.
Vrana KE, Roskoski R, Jr. (1983) Tyrosine hydroxylase inactivation following
cAMP-dependent phosphorylation activation. J Neurochem 40:1692-1700.
Vrana KE, Allhiser CL, Roskoski R, Jr. (1981) Tyrosine hydroxylase activation
and inactivation by protein phosphorylation conditions. J Neurochem
36:92-100.
Wallen A, Perlmann T (2003) Transcriptional control of dopamine neuron
development. Ann N Y Acad Sci 991:48-60.
Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC (2009) Inflammation
mediates varying effects in neurogenesis: relevance to the pathogenesis
of brain injury and neurodegenerative disorders. J Neurochem 108:13431359.
Wulle

I,

Wagner

HJ

(1990)

GABA

and

tyrosine

hydroxylase

immunocytochemistry reveal different patterns of colocalization in retinal
neurons of various vertebrates. J Comp Neurol 296:173-178.
Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhou Y, Hong
JS, Zhang J (2005) Aggregated alpha-synuclein activates microglia: a
process leading to disease progression in Parkinson's disease. FASEB J
19:533-542.
Zhao S, Maxwell S, Jimenez-Beristain A, Vives J, Kuehner E, Zhao J, O'Brien C,
de Felipe C, Semina E, Li M (2004) Generation of embryonic stem cells
and transgenic mice expressing green fluorescence protein in midbrain
dopaminergic neurons. Eur J Neurosci 19:1133-1140.

212

Zhou FM, Lee CR (2011) Intrinsic and integrative properties of substantia nigra
pars reticulata neurons. Neuroscience 198:69-94.
Zhou Y, Wang Y, Kovacs M, Jin J, Zhang J (2005) Microglial activation induced
by neurodegeneration: a proteomic analysis. Molecular & cellular
proteomics : MCP 4:1471-1479.
Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM (1984) Neurochemical
compensation after nigrostriatal bundle injury in an animal model of
preclinical parkinsonism. Arch Neurol 41:856-861.
Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990)
Compensations after lesions of central dopaminergic neurons: some
clinical and basic implications. Trends in neurosciences 13:290-296.

